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Chronic pain, considered here to be pain lasting 3 months or longer, imparts 
significant socioeconomic and public health burden around the globe. Chronic 
pain is associated with a wide range of conditions, illnesses, or injuries, and is 
categorised and investigated in many ways. Treatment and management of 
chronic pain is complicated by this heterogeneity, and by lack of full 
understanding of factors (including genetic) that influence vulnerability to 
developing chronic pain and biological mechanisms of chronic pain development. 
Major depression is commonly comorbid with chronic pain, and results of studies 
into potential causal direction between the two conditions are mixed. Due to 
symptom overlap and common comorbidity, it may be that cases of chronic pain 
are misclassified as major depression and vice versa. Understanding genetic 
factors that contribute to chronic pain vulnerability and development has the 
potential to improve treatment of both conditions, in addition to allowing for 
investigation of potential causal relationships and clinical heterogeneity. 
Recently, the International Association for the Study of Pain released an updated 
definition of chronic pain and advocated for the study of chronic pain as a 
disease entity. Studying the genetics of chronic pain through genome wide 
association study of broad chronic pain traits, in line with this updated pain 
definition, may present a more tractable way to uncover common genetic 
variation associated with vulnerability to and mechanisms of development of 
chronic pain. This mode of study can also provide genome wide association study 
summary statistics for use in analyses that aim to investigate causality, genetic 
correlation and pleiotropy, and clinical heterogeneity in chronic pain and major 
depression.  
The overall aim of this PhD project is therefore to explore causal relationships 
between chronic pain and MDD in large UK general-population cohorts with 
whole-genome genotyping data using a wide range of statistical genetic methods. 
Data were obtained from two large UK cohorts with whole-genome genotyping. 
One, UK Biobank, is a cohort of 0.5 million participants recruited in middle age 
(40-79) with information on an extensive list of physical, behavioural and health 
related traits. Generation Scotland is a smaller (N ~ 22,000) Scottish cohort of 
participants recruited mainly through general practitioners in a family-based 
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manner, again with information of physical, health, and behavioural traits. 
Summary statistic data were also obtained from a 23andMe-Pfizer genome wide 
association study of chronic pain grade.  
As part of this PhD the largest genome wide association study of any chronic pain 
trait to date was carried out in UK Biobank. Validation of the trait (multisite 
chronic pain) was carried out through polygenic risk score analysis in Generation 
Scotland, examining the relationship between this novel chronic pain trait and 
chronic pain grade. Genetic correlation analyses were used to explore the 
genetic overlap of multisite chronic pain and a range of traits of interest, 
including other chronic pain phenotypes such as chronic widespread pain and 
chronic pain grade, in addition to major depression. Gene-level analyses were 
carried out to investigate genes of interest associated with chronic pain and 
potentially relevant to mechanisms of chronic pain development. BUHMBOX 
analyses were performed to test for clinical heterogeneity in chronic pain with 
respect to major depression and vice versa in UK Biobank. Conditional false 
discovery rate analyses using 23andMe-Pfizer data were also used to explore 
pleiotropy in chronic pain grade and major depression and to highlight 
pleiotropic loci of interest. Mendelian randomisation analyses, including recent 
mendelian randomisation methods explicitly designed to account for extensive 
horizontal pleiotropy, were carried out to assess potential causal relationships 
between major depression and chronic pain grade, and between major 
depression and multisite chronic pain. 
Results indicated multisite chronic pain was a polygenic, moderately heritable 
trait. Associated genes of interest implicated a strong central nervous system 
component, in addition to immune related genes. Conditional false discovery 
rate analysis highlighted loci of interest mapped to LRFN5, a gene involved in 
neuroinflammation, and that were associated with regulation of gene expression 
at this locus. Polygenic risk scoring analysis showed multisite chronic pain to be 
significantly associated with both chronic pain grade and chronic widespread 
pain, in addition to a multisite chronic pain-like trait in Generation Scotland, 
validating multisite chronic pain as a trait and indicating strong genetic overlap 
between widespread and non-widespread pain. Genetic correlation analysis 
showed significant genetic overlap between multisite chronic pain and mental 
health traits, markedly major depressive disorder, and depressive symptoms, but 
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a lower degree of genetic correlation with conditions associated with significant 
chronic pain such as rheumatoid arthritis, and no significant genetic correlation 
with inflammatory bowel diseases. BUHMBOX analyses showed no evidence of 
clinical heterogeneity in chronic pain with respect to major depression in UK 
Biobank or vice versa. Mendelian randomisation analyses showed no causal 
relationship between chronic pain grade and major depressive disorder, but a 
significant causal effect of multisite chronic pain on major depressive disorder.  
In conclusion, I have shown that broad chronic pain traits such as multisite 
chronic pain present a powerful and tractable way to study mechanisms of, and 
factors contributing to vulnerability to, chronic pain development. Output from 
well-powered genome wide association studies can also be used to validate 
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Chapter 1: Introduction 
This chapter introduces chronic pain and major depression, discussing defining 
and diagnosing chronic pain and depression, the epidemiology of both conditions, 
comorbidity of the two conditions, and introduces key concepts in complex trait 
genetics. 
1.1 What is chronic pain? 
1.1.1 Definitions 
Chronic pain was defined by the International Association for the Study of Pain 
(IASP) (Treede et al., 2019) until recently as pain persisting beyond the normal 
healing time, agreed to be 3 months. ‘Normal healing time’ can vary widely 
depending on the condition causing the pain and is hard to accurately ascertain, 
with no standard length of time agreed, e.g., between clinicians and researchers. 
Another problem with this definition is the fact that many disorders where 
chronic pain is a main symptom effectively never involve complete healing or 
are associated with continued tissue damage or degeneration; a good example of 
this is rheumatoid arthritis. Chronic pain can also be involved where there is no 
known pathology or damaged tissue, either existing or detectable from the 
outset of the chronic pain condition (e.g., fibromyalgia). These issues led to a 
somewhat arbitrary agreed window of 12 weeks as the standard cut off point, 
beyond which a pain is considered chronic or persistent. Recently, an IASP Task 
Force was instrumental in adding a code for chronic pain to the ICD-11 (the WHO 
International Classification of Diseases 11th edition), and for advocating that 
chronic pain is a disease entity in its own right (Nicholasa et al., 2019; Treede et 
al., 2019). The IASP definition of pain itself was also recently updated (July 2020) 
(Raja et al., 2020), to state that pain is defined as: 
“An unpleasant sensory and emotional experience associated with, or 
resembling that associated with, actual or potential tissue damage” 
Six key notes accompany this definition: 
• Pain is always a personal experience that is influenced to varying degrees 
by biological, psychological, and social factors. 
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• Pain and nociception are different phenomena. Pain cannot be inferred 
solely from activity in sensory neurons. 
• Through their life experiences, individuals learn the concept of pain. 
• A person’s report of an experience as pain should be respected. 
• Although pain usually serves an adaptive role, it may have adverse effects 
on function and social and psychological well-being. 
• Verbal description is only one of several behaviours to express pain; 
inability to communicate does not negate the possibility that a human or 
a nonhuman animal experiences pain. 
This definition and accompanying notes emphasise that nociception refers to the 
neural process by which noxious stimuli are encoded, whereas pain refers to the 
unpleasant emotional, sensory perception that is linked to actually or 
potentially-occurring tissue damage (Jaracz et al., 2016), that pain and 
nociception do not necessarily occur together (Baliki & Apkarian, 2015), and that 
pain is thought to be a “complex, perceptual” experience with a large affective 
component (Asmundson & Katz, 2009).  
IASP terminology also includes mechanistic descriptors of pain, defining pain as 
nociceptive, neuropathic, or nociplastic (IASP, 2017a). Nociceptive pain is 
defined as that which “arises from actual or threatened damage to non-neural 
tissue and is due to the activation of nociceptors”, neuropathic pain as “caused 
by a lesion or disease of the somatosensory nervous system”, and nociplastic as 
“pain that arises from altered nociception despite no clear evidence of actual or 
threatened tissue damage causing the activation of peripheral nociceptors or 
evidence for disease or lesion of the somatosensory system causing the pain”. 
Additionally, though not included in the IASP terminology, mixed pain states 
(presence of pain types fitting multiple mechanistic descriptors in a single 
individual or patient) are receiving increased attention (Freynhagen et al., 2019, 
2020). 
1.1.2 Measurement (Phenotyping) 
Pain is a subjective experience, and chronic pain falls under the umbrella of 
symptom-based disorders: there are no scans or biological tests that can be used 
to decisively diagnose chronic pain. At present there are also no objective 
biomarkers available for use in diagnosing chronic pain (Mouraux & Iannetti, 
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2018; Reckziegel et al., 2019), presenting a significant barrier both in clinical 
treatment of pain and in pain research. There are quantitative methods for 
clinical assessment of pain including chronic pain, such as Quantitative Sensory 
Testing (QST), originally developed to assess somatosensory changes associated 
with neuropathic pain and involving application of various stimuli by a clinician 
(Backonja et al., 2009; G. Cruccu et al., 2010; Giorgio Cruccu & Truini, 2009; 
Geber et al., 2011; Peripheral Neuropathy Association., 1993). Somatosensory 
changes in non-neuropathic pain conditions can also be assessed using QST 
(Geber et al., 2011), and QST is often applied in the study of central 
sensitisation (see 1.1.4). Other experimental quantitative methods to assess pain 
and chronic pain include cutaneous biopsy, microneurography, functional and 
structural brain imaging, chemical neuroimaging, and pharmacological 
phenotyping (stratifying pain patients by drug response) (Fillingim et al., 2016; 
Martucci & Mackey, 2016) – these methods have varying utility and usage rates in 
a clinical setting, and may fail to capture subjective and psychological aspects 
of pain and chronic pain experience. 
In the context of patients or individuals reporting their pain, questionnaire 
assessments delivered in person by researchers or medical professionals, or 
remotely via survey, that ask the individual or patient about aspects of pain 
experience, such as severity, frequency, duration, and resultant disability, are 
widely used. Unsurprisingly, this generates a great deal of heterogeneity within 
the category ‘chronic pain’. Different questionnaire-based methods to assess 
chronic pain in patients are reviewed by Dansie and Turk and by Fillingim et al, 
and can be sorted into seven broad categories; unidimensional pain measures, 
measures of pain quality and location, pain interference and function (general 
measures), pain interference and function(specific diseases), HRQOL (Health-
Related Quality of Life) measures, psychosocial measures, and finally 
observational pain assessment measures (Dansie & Turk, 2013). In addition, tools 
such as the chronic pain grade (CPG) questionnaire, derived by Von Korff and 
colleagues and validated by Smith et al several years later, span across 
categories to assess pain intensity, duration, resultant disability and impact on 
quality of life (Smith et al., 1997; Von Korff et al., 1992).  
Several questionnaires for chronic pain assessment, such as the Brief Pain 
Inventory (Cleeland & Ryan, 1994), also include questions on site of chronic pain 
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on the body – most often assessed by asking the patient to shade areas on a pain 
drawing (Jensen & Karoly, 2001). Diagnosis of certain chronic pain conditions is 
also based on chronic pain location meeting requirements in terms of 
‘widespreadness’ or presence in a minimum number of body quadrants and 
tender points – these conditions include fibromyalgia and chronic widespread 
pain (CWP) itself (distinct from its role as a cardinal symptom of fibromyalgia) 
(Clauw, 2014; Wolfe et al., 1990, 2011). CWP is defined as constant axial (pain 
confined to a certain area/ ‘tender point’) pain, in addition to pain in both the 
upper and lower body quadrants, and left and right side of the body (Burri et al., 
2015; Wolfe et al., 1990).  
Chronic pain may also be characterised based on probable causal or related 
injury or illness – neuropathic pain is caused by damage to the somatosensory 
nervous system (Colloca et al., 2017), and may be chronic in nature. However, 
neuropathic and non-neuropathic types of chronic pain may ‘converge’ over time, 
in terms of changes in the dorsal horn and dorsal root ganglion (DRG) (Xu & 
Yaksh, 2011). In addition, individuals may be diagnosed with neuropathic pain in 
complete absence of definite or clear lesions or nervous system damage 
(Finnerup et al., 2016), and the extent or severity of pain experienced may not 
match observable nervous system damage (Weir et al., 2019). 
Cancer pain may also be chronic in nature, with causes of pain in individuals 
with cancer ranging widely. Cancer pain can be neuropathic (Mulvey et al., 2017; 
Stewart, 2014), pain classed as both neuropathic and non-neuropathic can co-
occur due directly to tumour growth and activity, to surgical and/or 
pharmacological cancer treatment, or due to comorbid chronic pain conditions 
(Caraceni & Shkodra, 2019). Pain may not be related directly to cancer, and 
distinguishing between acute and chronic pain in the context of cancer is 
difficult, further complicating classification and treatment (Caraceni & Shkodra, 
2019) 
Measuring and characterising chronic pain both clinically and in the context of 
research is challenging, resulting in extensive heterogeneity among and within 
chronic pain phenotypes, with many chronic pain conditions often occurring 
together (Maixner et al., 2016). Individuals with chronic pain often receive at 
least one misdiagnosis (Hendler, 2016), and may also be given an inappropriate 
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psychiatric diagnosis, such as somatic symptom disorder (Katz et al., 2015). One 
recent systematic review concluded that there are “hardly two research groups 
that assess chronic pain in exactly the same manner” (Steingrímsdóttir et al., 
2017). 
1.1.3 Epidemiology of chronic pain 
Chronic pain is estimated to affect approximately 20% of the adult population 
worldwide (Breivik et al., 2006; Goldberg & McGee, 2011; Gureje et al., 2008; 
Palmer et al., 2000; Santos-Eggimann et al., 2000; Von Korff et al., 2005), and 
prevalence can be much higher in certain population subgroups (e.g. amputees, 
where 85% are affected (Schug & Bruce, 2017)). Disorders involving chronic pain, 
including migraine, neck and back pain, low back pain and general 
musculoskeletal disorders, were amongst the top 10 global contributors to years 
lived with disability (YLDs) consistently from 1990-2017 (GBD 2015 Disease and 
Injury Incidence and Prevalence Collaborators, 2016; James et al., 2018). Low 
back pain represented the leading cause of disability worldwide until very 
recently (replaced by major depressive disorder (MDD) (WHO, 2017)).  
Chronic pain and chronic pain disorders are widely documented as being more 
prevalent in women than in men, often twice as common in women (Bartley & 
Fillingim, 2013; Fillingim, 2015; Fillingim et al., 2009; Hardt et al., 2008; Munce 
& Stewart, 2007; Rollman & Lautenbacher, 2001; Tsang et al., 2008). Low back 
pain also remains in the top three of YLD in both the highest and lowest SDI 
(sociodemographic index) quintiles (James et al., 2018). For example, there are 
stark contrasts between the rates of YLDs between high-SDI and low-SDI groups 
of individuals with low-back pain globally (a difference of approximately twice 
the level of YLDs per 100,000 higher for low-SDI compared to high SDI) (James et 
al., 2018). Overall, although chronic pain contributes to disability levels similarly 
across developed and developing countries, deprivation is associated with 
increased disability and less effective management for those with chronic pain 
(Bonathan et al., 2013; Dorner et al., 2011; Jackson et al., 2015; Mills et al., 
2019; Poleshuck & Green, 2008; Yu et al., 2020). 
Increased mortality may be associated with chronic pain phenotypes such as 
chronic widespread pain(both all-cause mortality and specific causes of death) 
(H. I. Andersson, 2009; Macfarlane et al., 2017). Chronic widespread pain is 
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defined as chronic pain in multiple sites of the body including both above and 
below the waist, on right and left body quadrants, and axially (Butler et al., 
2016; F. Wolfe et al., 1990, 2011). This is distinct from multisite chronic pain 
(2.3.3.1.2), where chronic pain can be present at a few sites and not necessarily 
fulfilling quadrant, axial or above/below waist location requirements. The 
relationship between chronic widespread pain and mortality may be mediated by 
lifestyle factors associated with pain such as poor diet, reduced physical activity 
levels, smoking and high BMI (Macfarlane et al., 2017). Psychosocial factors, 
including depression, may also be involved in the relationship between chronic 
widespread pain and excess mortality (Da Silva et al., 2018). 
1.1.4 From Acute to Chronic Pain 
The mechanisms of chronic pain development are not fully known, but likely 
involve both central and peripheral nervous-system processes, the immune 
system, and genetic and environmental risk factors, including previous injury 
and psychological stress (reviewed by (Denk & Mcmahon, 2017)). The 
relationship between acute and chronic pain also tends to vary greatly: not 
every person who experiences serious injury or undergoes surgery goes on to 
develop chronic pain, and conversely, chronic pain may develop after seemingly 
innocuous procedures (Denk et al., 2014). Additionally, across a variety of 
chronic conditions associated with chronic pain, the degree of tissue damage is 
not necessarily correlated with the severity of pain experienced. This has been 
observed with endometriosis, where disease severity in terms of lesion size and 
type is generally not associated with increasing severity of chronic pelvic pain 
experienced (Stratton & Berkley, 2011; Vercellini et al., 2007). This poor 
correlation between tissue damage or extent of disease and chronic pain 
experienced is also seen in both osteoarthritis (Dieppe & Lohmander, 2005; 
Neogi, 2013; Trouvin & Perrot, 2018; Valdes et al., 2012) and rheumatoid 
arthritis (Meeus et al., 2012).  
Significant peripheral neuropathy or central nervous system injury can also be 
present without subsequent development of chronic neuropathic pain (Colloca et 
al., 2017). In conditions involving widespread chronic pain such as fibromyalgia, 
complex regional pain syndrome (CRPS), and conditions such as irritable bowel 
syndrome and temporomandibular disorder (TMD), there may be an absence of 
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damaged or diseased tissue altogether, with the individual experiencing 
debilitating pain regardless (Cairns, 2010; C. Chang et al., 2019; Feng et al., 
2012; Goebel, 2011; Jahan et al., 2012; Kosek et al., 2016; Sluka & Clauw, 2016; 
Verne & Zhou, 2011). This further supports viewing chronic pain as a disease 
entity as outlined in 1.1.1. 
Central sensitisation is associated with the development and maintenance of 
chronic pain, with features of central sensitisation found across a range of 
chronic pain-associated conditions (Harte et al., 2018). Central sensitisation is 
defined by the IASP as increased responsiveness, to normal or sub-threshold 
afferent input, of nociceptor neurons in the CNS, resulting in hypersensitivity to 
stimuli and increased pain response (IASP, 2017; Ji et al., 2018). This 
phenomenon can only be observed directly when both input and output of the 
neural system are known e.g. through QST (see also 1.1.2), or indirectly through 
healthcare-professional administered assessment or questionnaire assessment of 
manifestations of central sensitisations i.e. allodynia (pain resulting from 
normally innocuous stimuli) or hyperalgesia (heightened sensitivity to pain). As 
well as being implicated in the transition from acute to chronic pain in general, 
central sensitisation has also been found to be a common occurrence across 
chronic pain diagnostic boundaries, from chronic pain at specific body sites such 
as the shoulder (Sanchis et al., 2015), or pelvis (Kaya et al., 2013), to a range of 
conditions associated with significant chronic pain, including endometriosis (P. 
Zheng et al., 2019), rheumatoid arthritis (Meeus et al., 2012), osteoarthritis 
(Lluch et al., 2014), temporomandibular disorders (La Touche et al., 2018) and 
fibromyalgia (Desmeules et al., 2003; Woolf, 2011). Although earlier definitions 
of central sensitisation state a requirement for initial noxious/ painful stimuli, 
recent study has highlighted that peripheral input (sustained or repeated 
application of noxious stimulus) may not be required – central sensitisation may 
result from changes in the CNS that are independent of peripheral input (Hains & 
Waxman, 2006; Latremoliere & Woolf, 2009; Yang et al., 2014), including 
dysfunction in endogenous pain control systems (Yarnitsky, 2015). 
In addition to central sensitisation specifically, a range of other functional 
(changes to activity) and structural (changes to composition or appearance) 
changes in the brain and spinal cord are associated with the development and 
maintenance of chronic pain (Baliki et al., 2014; Baliki & Apkarian, 2015; Bliss et 
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al., 2016; Hashmi et al., 2013; Khoutorsky & Price, 2018; Mansour et al., 2013; 
Sheng et al., 2017). Structural changes such as synaptic spine density, cellular 
changes (both loss and gain) involving microglia and multiple neuron types, and 
remodelling of neuronal circuits that results in separation or bringing together of 
nociceptive and non-nociceptive neurons, have been linked to chronic pain 
development (Kuner & Flor, 2016; Mansour et al., 2013). Functional changes 
associated with chronic pain include synaptic plasticity in multiple different 
brain regions linked to pain such as the anterior cingulate cortex, thalamus, and 
dorsal horn of the spinal cord (Bliss et al., 2016), the periaqueductal grey (Yu et 
al., 2014), and more recently in visual networks (Shen et al., 2019). 
Considering the above, the transition from acute to chronic pain may occur as 
follows: firstly, acute injury results in prolonged activation of peripheral 
nociceptors, namely Aδ- and C-fibres (Apkarian et al., 2005; Moehring et al., 
2018). This prolonged activation can lead to neuroplastic changes in central as 
well as peripheral somatosensory circuits (Cichon et al., 2017; Zhuo, 2008), and 
changes in higher brain regions associated with emotion. One of the specific 
kinds of synaptic plasticity that may constitute these neuroplastic changes in the 
case of chronic pain development include increased glutamate release and 
increase in the postsynaptic response to glutamate in the spinal cord in the 
ascending pain pathway (the route of signal transmission from the periphery 
towards the CNS) (Kuner & Flor, 2016; Latremoliere & Woolf, 2009). The 
descending pain pathway (the downward route of nerves from the CNS to the 
periphery via the spinal cord) is also thought to be involved in chronic pain 
development, through modulation of spinal responses to noxious stimuli (E. P. 
Mills et al., 2018; Ossipov et al., 2014). In cases without underlying injury or 
tissue damage, this central sensitisation through neuroplastic changes is still 
thought to occur – instead of persistent engagement of ascending/descending 
pain circuits driving persistent experience of pain, pain circuitry outside of these 
pathways is affected during acute injury and contributes to pain experienced 
after the healing period. One example of such circuitry is the nucelus accumbens, 
where studies in rodents showed neuroplasticity associated with development of 
chronic pain (Chang et al., 2014; Ferris et al., 2019; Goffer et al., 2013). 
Another example is, in humans, structural changes in corticolimbic circuits 
(encompassing the prefrontal cortices, hippocampus and amygdala) have also 
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been found to predict transition to chronic pain (Baliki et al., 2012; Vachon-
Presseau et al., 2016).  
A range of social and psychological factors are also likely to be involved in the 
transition from acute to chronic pain, and the role of non-medical/ non-
biological factors is increasingly recognised as important in chronic pain 
management. The biopsychosocial model (Bevers et al., 2016) of chronic pain 
outlines how psychological, social and biological factors interact to influence the 
development and course of chronic pain. Factors such as ethnicity, age and 
gender fall under the psychosocial label in addition to potentially being markers 
for biological factors linked to chronic pain development (Fillingim, 2017), and 
lifestyle or behavioural factors such as level of physical activity and cigarette 
smoking are also associated with risk of chronic pain development (Mills et al., 
2019). Previous studies found that factors related to social support such as 
spousal negative reinforcement of pain behaviours were involved in chronic pain-
related disability, and that an introverted personality and tendency towards 
catastrophizing were associated with increased chronic post-surgical pain 
(reviewed by (Katz & Seltzer, 2009)). Factors such as low mood and somatising 
tendency may also contribute to increased risk of developing chronic pain, and 
at the societal level psychosocial aspects of the workplace may also contribute 
to chronic pain development risk (Vargas-Prada & Coggon, 2015). A recent 
systematic review found that fear-avoidance beliefs and depression/ anxiety 
were both associated with transition from acute to chronic pain in a range of 
scenarios including post-surgical and non-specific widespread pain syndromes, 
but also that some studies found no link between psychosocial factors examined 
and pain chronicity (Hruschak & Cochran, 2018).  
The imprecision hypothesis (Moseley & Vlaeyen, 2015) outlines the method by 
which biopsychosocial factors influence chronic pain development suggesting 
that a lack of precision in integrating multisensory information (physical, 
nociceptive, psychological, emotional) leads to chronic pain development 
through the painful response then generalizing to non-painful events.  
Additionally, the functions of brain areas involved in nociception are not limited 
to pain processing: many are also involved in emotional regulation (Tracey, 2010; 
Tracey & Johns, 2010), including affective aspects of the pain experience (Peirs 
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& Seal, 2016; Schweinhardt & Bushnell, 2010). A recent systematic review found 
maladaptive emotional regulation in general to be linked to increased risk of 
chronic pain development (Koechlin et al., 2018).  
Overall, research across multiple fields suggests that chronic pain conforms to 
the biopsychosocial model of disease. A complex array of genetic, medical, 
lifestyle, social and psychological factors are associated with and likely 
contribute to risk of developing chronic pain, and to pathology or mechanisms of 
chronic pain development. However, unifying qualities among chronic pain 
conditions exist across all three (biological, psychological, social) domains, and 
these similarities could aid understanding of chronic pain development in 
general and do so more powerfully in comparison to study of chronic pain within 
disease or diagnostic boundaries. Such similarities include absence of 
identifiable injury or cause of pain for many individuals with chronic pain, likely 
extensive CNS involvement in a wide range of chronic pain states and overlap 
with brain areas involved in emotion and affect.  
1.1.5 Associations with Other Conditions 
Individuals with certain traits and conditions experience chronic pain at 
significantly higher rates compared to the general population, and for some 
conditions and disorders chronic pain is a hallmark symptom. Conditions 
associated with chronic pain include obesity (Okifuji & Hare, 2015; Paley & 
Johnson, 2016), and high BMI more generally, with chronic pain incidence 
estimated to be ~68-254% higher in individuals classed as obese compared to 
individuals with a BMI of less than 30 kg/m2 (Paley & Johnson, 2016). Higher BMI 
and increased body fat may influence chronic pain development through 
mechanical stress (Okifuji & Hare, 2015; Wearing et al., 2006), activity of 
molecules secreted from adipose tissue (Hauner, 2005; Urban & Little, 2018), 
and general inflammation (DeVon et al., 2014; Eichwald & Talbot, 2020).  
Autoimmune disorders are also associated with chronic pain (Mifflin & Kerr, 2017; 
Phillips & Clauw, 2013). The immune system in general is also implicated in 
chronic pain development, including inflammatory responses in the brain and 
spinal cord (neuroinflammation) (Ren & Dubner, 2010). The complement system, 
part of the innate immune system, has also been found to play a part in synaptic 
pruning and neuronal connectivity during both development and as part of 
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neurodegenerative disease progression (Stephan et al., 2012). There is also 
significant communication between the nervous and immune systems in 
nociception and in sensitisation processes that can lead to chronic pain 
(Kwiatkowski & Mika, 2018; Pinho-Ribeiro et al., 2017). Though not classed as an 
autoimmune disease, another disorder with immune involvement, asthma, may 
also be associated with increased chronic pain risk – this may be due to 
musculoskeletal damage involved with severe coughing during asthma attacks or 
with postural changes associated with asthma (Lunardi et al., 2011), with higher 
opioid use associated with having asthma (Naik et al., 2019). Additionally, 
autoimmune conditions that can involve significant and chronic pain such as 
lupus have been found to be more common in those with asthma (Krishna et al., 
2019), and pain has been found to be a significant comorbidity and generally 
more common in individuals with asthma compared to those without 
(Weatherburn et al., 2017).  
Insomnia and sleep disturbance are also commonly experienced by those with 
chronic pain, with ~65% of those with chronic pain conditions also having clinical 
insomnia (Alföldi et al., 2014), rates which are 2-20x higher than those 
estimated for the general population (Roth, 2007; Singareddy et al., 2012; Y. 
Zhang et al., 2019). Reduced sleep duration and poor sleep quality may be a 
significant risk factors in development of subsequent chronic pain, in addition to 
potentially being caused by pain (Broberg et al., 2021; Haack et al., 2020; Jank 
et al., 2017; Sun et al., 2020). Opioid treatment of chronic pain can also 
negatively impact sleep (Ferini-Strambi, 2017; Tentindo et al., 2018). Improving 
sleep duration and quality has the potential to improve treatment outcomes for 
comorbid chronic pain, with individuals with chronic pain likely to experience 
increased pain sensitivity, lower mood, and higher levels of disability in 
comparison to individuals with chronic pain but without comorbid sleep issues 
(reviewed by Cheatle et al., 2016).  
Neurological diseases, such as Parkinson’s disease, are also associated with 
chronic pain (Borsook, 2012), as are migraine (Minen et al., 2016) and multiple 
sclerosis (MS) (Marrie et al., 2012). 30-95% of individuals with Parkinson’s disease 
experience chronic pain (Broen et al., 2012; Buhmann et al., 2017; Valkovic et 
al., 2015), which can be related to rigidity, posture changes, reduced movement 
of the joints, and involuntary muscle contractions experienced as part of 
33 
 
Parkinson’s, or a central pain syndrome which could be due to Parkinson’s-
related brain changes (Blanchet & Brefel-Courbon, 2018). Pain can also be 
classified in terms of whether it is thought to be directly related, indirectly 
related, or not related to Parkinson’s disease in the individual, and further 
labelled in terms of whether this pain is experienced in the off or on-phase of 
the condition (Skogar & Lokk, 2016). Individuals with MS tend to experience pain 
and pain syndromes more often than the general population, with estimates of 
pain prevalence of ~30-80% (Drulovic et al., 2015; Foley et al., 2013; Heitmann 
et al., 2020; O’Connor et al., 2008; Solaro et al., 2013), and estimates of chronic 
pain prevalence more specifically ranging from ~40-50%  (Ehde et al., 2003; 
Ferraro et al., 2018) to as high as 86% (Urits et al., 2019). 
A wide range of psychiatric traits and disorders have been found to be associated 
with chronic pain. These include addiction and substance use disorders (Cheatle 
& Gallagher, 2006; Elman & Borsook, 2016; Speed et al., 2018), with 8-12% of 
those with chronic pain prescribed opioids going on to develop an opioid use 
disorder (reviewed by Speed et al., 2018), in contrast to 0.6% of the US 
population aged 12+ in general estimated to misuse analgesic medication 
(SAMHSA, 2018).  
PTSD in both veterans and civilian populations is associated with higher rates of 
chronic pain (Akhtar et al., 2019; Dunn et al., 2011; Outcalt et al., 2015; Phifer 
et al., 2011; Shipherd et al., 2007). For example, a non-veteran sample 
attending pain clinic for treatment of chronic pain was found to have rates of 
PTSD over four times as high as that of the general US population (28% vs. ~6%) 
(Akhtar et al., 2019), and other studies found between 46%-66% of combat 
veterans seeking chronic pain treatment had PTSD (Dunn et al., 2011; Shipherd 
et al., 2007). A systematic review found consistent evidence that PTSD was 
associated with chronic pain (Fishbain et al., 2017). 
In addition to PTSD, anxiety disorders in general are commonly comorbid with 
chronic pain (Asmundson & Katz, 2009; Gureje, 2008). 2012 Canadian Community 
Health Survey–Mental Health participants with chronic pain were  found to have 
generalised anxiety disorder (GAD) up to 2.6x more often than in comparison to 
the entire cohort (Csupak et al., 2018), and World Mental Health Survey results 
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indicated that participants reporting chronic pain showed increased odds from 
90-170% of having a comorbid anxiety disorder (Gureje, 2008).  
Individuals with schizophrenia commonly experience chronic pain, and often 
have comorbid conditions associated with significant chronic pain (De Hert et al., 
2011; Gabilondo et al., 2017; Smith, Langan, et al., 2013; Von Hausswolff-Juhlin 
et al., 2009). However systematic reviews found prevalence of pain with 
apparent medical cause to be lower amongst a sample of individuals with 
schizophrenia in comparison to the general population (Engels et al., 2014), or 
similar when compared to age and sex-matched controls (Stubbs et al., 2014). In 
contrast other studies, for example of cohorts of veterans, found schizophrenia 
to be associated with higher rates of chronic pain (in comparison to veterans 
without this psychiatric comorbidity) (Birgenheir et al., 2013). In addition, 
differences in pain perception and the integration and processing of sensory 
information (interoception) in those with schizophrenia, have been reported. 
One study showed participants with schizophrenia to have elevated sensitivity to 
acute pain and reduced sensitivity to prolonged pain in an experimental setting 
(Lévesque et al., 2012), though another study highlighted that such differences 
may be due to issues in expressing and reporting pain for individuals with 
schizophrenia, as opposed to nociception-related effects (Urban-Kowalczyk et 
al., 2015). Autism spectrum disorder and anorexia nervosa have also been 
associated with altered pain perception and interoception (Bär et al., 2015; 
Bischoff-Grethe et al., 2018; C. Clarke, 2015; Gu et al., 2018; Strigo et al., 2013), 
which may impact chronic pain prevalence and reporting in these specific 
populations. There is growing evidence that many autistic people also have 
significant joint hypermobility (Baeza-Velasco et al., 2018; Casanova et al., 2020; 
Csecs et al., 2020), often associated with chronic pain, and which may or may 
not be subthreshold to official Joint Hypermobility Syndrome (JHS) or Ehlers-
Danlos (Castori et al., 2017) diagnosis.  
Similarly to schizophrenia, living with bipolar disorder is associated with a range 
of serious and pain-associated chronic physical conditions (De Hert et al., 2011). 
In contrast to results from some studies of individuals with schizophrenia, those 
with bipolar disorder tend to experience chronic pain at rates higher than the 
general population (Nicholl et al., 2014; Stubbs et al., 2015), for example with a 
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relative risk for “clinically relevant pain” of 2.14 and of migraine specifically of 
3.3 (Stubbs et al., 2015).  
Chronic pain conditions are often commonly comorbid with one another (Maixner 
et al., 2016). Chronic pain syndromes involving specific body parts or areas (e.g. 
irritable bowel syndrome, low back pain) were  found to be associated with one 
another (Kato et al., 2009), and chronic pain, including both abdominal and joint 
pain, is a common symptom for those with inflammatory bowel disease and is 
often not resolved even in the absence of active disease (Docherty et al., 2011; 
Norton et al., 2017). Arthritis and fibromyalgia have also been found to be 
associated with one another (Haliloglu et al., 2014). Neuropathic ocular pain has 
also been found to be associated with other chronic pain syndromes (Galor et al., 
2016). Rheumatoid arthritis is associated with a wide variety of pain experiences, 
but pain is often the most significant and disabling symptom, even with well-
managed inflammation (Walsh & McWilliams, 2014).  
Explanatory factors connecting chronic pain and other disorders, including MDD, 
involve shared biological mechanisms, environmental factors, shared 
psychological aspects, or most likely a complex mixture of multiple genetic and 
non-genetic factors. There is extensive overlap not only between different 
chronic pain conditions, but also between chronic pain conditions, chronic pain 
experience in a general sense, and a diverse range of traits and conditions, many 
of which do not feature chronic pain as a core symptom. The focus of this thesis 
is aspects of the relationship between chronic pain and MDD specifically (see 
also 1.3.1).  
1.2 What is Major Depressive Disorder (MDD)? 
1.2.1 Screening and Diagnosis of MDD  
Diagnoses of depression and of MDD are based on the self-report of symptoms, 
often in a primary care setting using self-report inventories where the individual 
completes a survey or questionnaire. Most depression rating scales fall under this 
umbrella, although some are completed by researchers (e.g. Hamilton 
Depression Rating Scale (Hamilton, 1960; Williams, 1988)). The most commonly 
used screening tools in a primary care setting for adults is the Patient Health 
Questionnaire-9 (PHQ-9) (Kroenke et al., 2001; Spitzer et al., 2000). The PHQ-
36 
 
9can also be used in more specific populations such as post-partum and older 
adults, although more specialised screening tools such as the Edinburgh Post-
Natal Depression Scale and the Geriatric Depression Scale are also available 
(reviewed by (Maurer et al., 2018; Sharp & Lipsky, 2002)). The PHQ-9 is also one 
of three measures of depression severity recommended by the UK general 
practice contract Quality and Outcomes Framework (QOF) (Kendrick et al., 2009). 
If an individual is screened and scores positively for MDD, this diagnosis should 
then be confirmed using the Diagnostic and Statistical Manual of Mental 
Disorders (DSM), currently in its fifth edition (DSM-5). The DSM classification is 
used by researchers in mental health (Regier et al., 2013) and consists of lists of 
symptoms and threshold levels of endorsements of these symptoms for a positive 
diagnosis of a psychiatric disorder.  
In order to meet the criteria for a DSM-5 diagnosis of MDD, an individual must 
have five or more symptoms from two lists of criteria (A and B), at least one of 
which must come from the A list; A: depressed mood, markedly diminished 
interest or pleasure in almost all activities, B: significant weight loss/gain or 
decrease/increase in appetite, insomnia or excessive sleep, psychomotor 
agitation or retardation, fatigue or loss of energy, feelings of worthlessness or 
excessive/inappropriate guilt, diminished concentration or indecisiveness and 
finally recurrent thoughts of death, suicidal ideation, plans or an attempt. There 
is also an ICD-10 equivalent for DSM-5 MDD, ‘Major Depressive Episode’, again 
with two lists of criteria (reviewed in McIntosh et al., 2019). For both DSM-5 and 
ICD-10 diagnoses both sets of criteria also require that the symptoms have lasted 
at least two weeks, that there is significant functional impairment, and that the 
disorder is not better accounted for by another condition.  
Even use of the same ‘instrument’ to diagnose MDD (such as the DSM) can result 
in a wide range of symptom profiles being grouped into the same diagnostic 
category. The single diagnosis of MDD based on DSM-IV criteria can cover over 
100 different and in some cases non-overlapping symptom combinations (Fried & 
Nesse, 2015a; Olbert et al., 2014; Zimmerman et al., 2015). 
In addition, many large epidemiological studies of depression also use self-
reported depression phenotypes (e.g., answering survey or questionnaire items 
as to whether participant has ever been diagnosed with depression by a doctor, 
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seen a psychologist or psychiatrist). These are often very different to methods 
used in primary care or other clinical settings. However, self-reported 
phenotypes can share significant overlap with clinical diagnoses of MDD, and the 
two together (MDD and self-reported depression) have been used as a single 
diagnostic group in some studies of MDD (McIntosh et al., 2019).  
1.2.2 Epidemiology of MDD 
An extensive review found that lifetime prevalence estimates of MDD from 
population surveys worldwide ranged from 1-19%, with prevalence higher in 
high-income versus low-income countries, and with a worldwide average 
prevalence of 11.1% and age of onset at 24 years old (Kessler & Bromet, 2013). 
Another study, using the World Mental Health Survey, found a global estimate of 
MDD prevalence to be 5.5-5.9% (Ferrari et al., 2013). 
A study of US populations, using DSM-5 diagnoses, found the 12-month and 
lifetime prevalence of MDD to be 10.4% and 20.6% respectively (Hasin et al., 
2018). A European estimate of 12-month MDD prevalence was found to be 5% 
(Ferrari et al., 2013). Prevalence of 12.2% has been inferred for Scotland from 
work in the Generation Scotland: Scottish Family Health Study (Fernandez-Pujals 
et al., 2015). 
Similar to chronic pain, Kessler & Bromet also found that women were twice as 
likely to have MDD as men, and that this was consistent across different adult 
population samples around the world (Kessler & Bromet, 2013). Earlier work also 
found lifetime incidence of MDD to be almost twice as high in women compared 
to men (20% vs 12%) (Belmaker & Agam, 2008). Work involving the GS: SFHS also 
found higher prevalence in women than in men (15.8% versus 9.1%) (Fernandez-
Pujals et al., 2015). This 2:1 ratio appears to vary with age (WHO, 2017), first 
emerging in adolescence and early adulthood (Avenevoli et al., 2015; Patton et 
al., 2008). In contrast to some studies suggesting convergence of male and 
female prevalence rates of major depression in older age in some populations 
(Forlani et al., 2014; Kuehner, 2017; Patten et al., 2016), this ratio does appear 
to persist into old age (Byers et al., 2010; Girgus et al., 2017; Luppa et al., 2012). 
Additionally, in pre-puberty males may be at greater risk of depression than 
females of the same age (Douglas & Scott, 2014).  
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The prevalence of MDD for those with chronic comorbidities is between three 
and seven times higher compared to those without. Comorbidities here refers to 
other health, including mental health, conditions experienced by the same 
individual simultaneously with MDD. Earlier work across the 48 contiguous states 
of the USA found an MDD prevalence of 16.2%, and that most lifetime and 12 
month MDD cases (>70% in both categories) had comorbid psychiatric disorders 
(Kessler et al., 2003). Furthermore, the comorbidity of MDD with other 
psychiatric and substance use disorders was substantial in later work on a large 
US sample (Hasin et al., 2018). Risk of all-cause mortality was significantly 
increased in most common mental disorders, including in depression (Chesney et 
al., 2014). 
1.3 Overlap between MDD and Chronic Pain 
1.3.1 Comorbidity between MDD and Chronic Pain 
MDD and chronic pain are often comorbid: chronic pain is found at higher rates 
than expected in those with MDD and vice versa, and this is true across a diverse 
range of populations around the world. Estimates quantifying the degree of 
comorbidity between MDD and chronic pain vary widely: one review found 
chronic pain in people with depression to range from 15-100%, and prevalence of 
depression in people with chronic pain from 1.5-100% (Bair et al., 2003). Another 
study found 65.7% of those with MDD had chronic pain, compared to 43.5% of 
those without MDD, and that chronic pain was more likely to be disabling in 
those with MDD (Arnow et al., 2006). In people with chronic pain 10.4% also met 
the criteria for MDD, compared to 4.5% of people without chronic pain who met 
the criteria for MDD (Arnow et al., 2006).  
Analyses of the World Mental Health survey results found higher rates of mood 
disorders including MDD are found in those with chronic pain across a range of 
global populations, and these rates increase with number of pain sites (Gureje et 
al., 2008; Tsang et al., 2008). 66.3% of individuals with MDD reported chronic 
pain in a US study (compared to 49% of the whole sample) – if this was more 
stringently limited to chronic pain that led to medical consultation or 
medication use this resulted in 44.2% of MDD subjects with this level of pain 
(compared to 21.8% in the entire sample). 73.3% of individuals reporting a 
chronic painful physical condition also meet the criteria for MDD (Ohayon & 
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Schatzberg, 2010). An independent positive association was also found between 
depression/ anxiety and chronic pain in a study of a New Zealand population 
(Dominick et al., 2012). Chronic pain was more prevalent in individuals with MDD 
compared to those without a history of mood disorder (50.4% versus 38.2%) in a 
subset of UK Biobank (Nicholl et al., 2014), with a positive relationship seen 
between the number of sites of chronic pain and the risk of MDD. It was also 
found that unexplained painful physical symptoms, including chronic pain, are 
experienced by up to two thirds of patients with MDD (Jaracz et al., 2016). This 
comorbidity can negatively impact success in treatment and management for 
either disorder (Asmundson & Katz, 2009; Bair et al., 2003, 2008; Jaracz et al., 
2016; Ohayon & Schatzberg, 2010). 
1.3.2 Causal Relationships between MDD and Chronic Pain 
Although comorbidity between chronic pain and MDD is high, the temporal 
nature of the relationship is not fully clear. Causality in relationships between 
MDD and chronic pain has been previously explored in both pre-clinical (non-
human) and human samples, but with conflicting results. In mouse models of 
neuropathic pain, pain was found to have a causal effect on depressive 
behaviour in several studies, as was arthritis, IBS (in female mice and not males) 
(reviewed by (Li, 2015)). A general chronic-pain phenotype in Wistar-Kyoto mice 
was also found to exacerbate depression-like symptoms (reviewed by (Li, 2015)). 
Animal model studies investigating any potential causal effect of depression on 
pain, however, show less clear results, whereas studies assessing causal effects 
of pain on depression showed some consistency in results regardless of modality 
(the way pain/depression-like symptoms are measured) (reviewed by (Li, 2015)). 
A range of cross-sectional and longitudinal studies in human populations tend to 
suggest that chronic pain has a causal effect on depression. A longitudinal study 
found that chronic pain in rheumatoid arthritis patients seemed to have a causal 
effect on development of depression (Brown, 1990). A later extensive review 
showed several studies where results suggest that pain causes depression 
(demonstrated through depression severity increasing with number of sites of 
pain), and that depression was not antecedent to pain but was a consequence. 
Studies were of a range of pain types, including cancer pain. They also highlight 
three studies of intermittent pain and depression, which showed depression to 
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be consequent to pain episodes. (Fishbain et al., 1997). Later studies also 
showed pain at baseline to be predictive of depression onset (Gureje et al., 
2001), and that pain contributes to the risk of a first episode of depression 
(Gerrits et al., 2014). 
Other studies show mixed results, suggest depression precedes chronic pain 
development, or indicate that the depression-pain relationship is reciprocal. In a 
study of US participants where pain and MDD were surveyed, pain occurred prior 
to the first depressive episode in 57.1% of cases, concurrently with a depressive 
episode in 14.3% of cases, and following a depressive episode in 24.3% of cases 
(Ohayon & Schatzberg, 2010). Other work suggests the pain-depression 
relationship to be bidirectional (Bair et al., 2003; Kroenke et al., 2011; Von Korff 
& Simon, 1996). Studies also link both pain and depression to HPA axis 
dysfunction (Blackburn-Munro, 2001; Hasler, 2010), or indicate that the shared 
genetic and environmental factors influencing MDD and chronic pain may act 
independently on either condition (Pinheiro et al., 2015). A study in paediatric 
chronic pain indicated onset of psychiatric disorders preceded chronic pain 
development (Tegethoff et al., 2015), and a study of adults (free from chronic 
pain at baseline) followed up for 24 months found depression to triple the 
incidence of chronic pain in later waves (Currie & Wang, 2005). 
Studies investigating causal relationships between MDD and chronic pain in 
human populations vary widely in many respects, including the assessment of 
MDD and chronic pain, the kinds of chronic pain conditions and bodily sites 
investigated, in sample size and in other population characteristics. Cross-
sectional studies most often do not or cannot explicitly test causality. In 
addition, even longitudinal studies with data collection over multiple time points 
may be subject to extensive confounding (Streeter et al., 2017) which may 
influence results. The use of a large general-population sample with genotyping 
data, such as the UK Biobank, can address these outstanding issues in 
investigating causal direction between depression and chronic pain development.  
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1.3.3 Genetics of Complex Traits 
1.3.3.1 Common genetic variation and common traits and diseases 
Many human traits, which can include physical characteristics such as height and 
weight, disease status, or personality and mental health related characteristics, 
have a genetic component; they cluster within families and are hereditary, and 
this is observable and quantifiable through twin and pedigree studies. In some 
cases, variation in phenotypic or trait value is due to a single mutation or 
disruption in a single gene, and inheritance patterns clearly show the dominant 
or recessive nature of the mutation underlying the trait – termed Mendelian 
inheritance in reference to Mendelian traits, first outlined by Gregor Mendel in 
his work in plant genetics (Mendel, 1866). One example of a Mendelian disease 
trait, where phenotypic variation can be mapped back to a single gene, is 
Huntington’s disease. Here the causal variant is a CAG repeat expansion in the 
huntington gene inherited in an autosomal dominant fashion (Macdonald et al., 
1993) and protein-coding changes drive trait variation (Botstein & Risch, 2003). 
In other cases, traits show a genetic, heritable component, but patterns of 
inheritance are less clear. Rather than changes at a single gene resulting in 
corresponding changes to a single phenotype or trait, trait variation is 
influenced by many small-effect variants, the external environment, and 
interactions between these components. These complex disease traits also tend 
to be more common than traits or diseases that are associated with large 
detrimental effects at single genes – common genetic variation most likely 
contributes the largest proportion of variance to the phenotype, and this 
variation would not persist in the population at the frequency it does if it were 
extremely deleterious, due to natural selection. Genetic variants with large 
effects are virtually always rarer –these large-effect variants will have been 
subject to negative selection and therefore circulate at low frequency in the 
population.  
Rare variants do not provide a sample pool large enough to test for association 
across the genome with sufficient power. The finer resolution of common 
genetic variation contributing to most complex traits is not fully understood. 
Variation in complex traits also appears to be often influenced by variants in 
non-coding regions of the genome (Li et al., 2016; Pickrell, 2014; Welter et al., 
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2014), again in keeping with selective constraint ideas (i.e. most of the variation 
in the human genome that could potentially be associated with any trait is in 
non-coding regions (Hindorff et al., 2009)). Common genetic variation here 
refers to Single Nucleotide Polymorphisms (SNPs), single-base changes in DNA 
sequence, usually with minor allele frequency (MAF) of more than 5%, and not 
less than 1%. SNPs with an MAF of less than 1% are considered rare variants. 
One example of a complex trait is human height, where several hundred SNPs 
have been found to be associated with height (Wood et al., 2014) and 
environmental factors such as nutrition also contribute. Disease traits can also 
be complex – complex diseases include Parkinson’s disease, where both genetic 
and environmental factors are thought to contribute to the disease phenotype, 
and high blood pressure (hypertension), the pathological ‘upper end’ of a 
continuous complex trait phenotypic value spectrum (blood pressure), also 
influenced by many common genetic variants (Evangelou et al., 2018) and by 
environmental and lifestyle factors.  
These two types of traits, (single gene) Mendelian and complex (or quantitative), 
are not necessarily as distinct as previously thought. Instead, Fisher’s 
infinitesimal model of inheritance of quantitative traits, whereby an infinitely 
large number of genetic variants, in addition to environmental factors, 
contribute to phenotypic variation (Barton et al., 2017; Mather, 1964), and 
Mendelian trait inheritance can be thought of as opposite ends of a spectrum in 
terms of number of contributing genetic variants. Fisher’s infinitesimal model 
unified competing schools of thought at the turn of the 20th century 
(biometricians versus Mendelian geneticists) to establish quantitative genetics as 
a research field (Nelson et al., 2013).  
Another important model in considering complex traits, specifically disease 
traits, is the liability-threshold model. Generally speaking, a threshold model is 
any model where a threshold distinguishes ranges of values i.e. where behaviour 
predicted by the model (the outcome) varies in some way above or below a 
particular threshold. In genetics such models were first applied in studies of 
guinea pig polydactyly by Wright (Wright, 1934b, 1934a). In this work he outlined 
that although the trait in question was binary in nature (three-toed versus four-
toed), the underlying genetic factors contributing to this could not be a 
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“singular factor” (Wright, 1934a), and additionally that environmental factors 
contributed to whether the animal’s morphology was pushed over this 
“physiological threshold” (Wright, 1934a). He also theorised that particular 
guinea pig strains were much closer to the polydactyl threshold, due to 
increased genetic and/or environmental risk burden, despite appearing to be 
phenotypically identical to “normal” strains (Wright, 1934b). The modern 
disease liability-threshold model in complex trait genetics with regard to human 
disease is attributed to Falconer (Falconer, 1965, 1967), with disease traits as 
“threshold characters” and liability to developing disease described as a graded 
attribute which incorporates both innate and external contributors to increased 
risk of developing disease.  
Disease liability-threshold models represent a way to incorporate both genetic 
and environmental contributions to disease-trait phenotypic variance for binary 
traits, where above a certain threshold of accumulated genetic and 
environmental risk factors the outcome varies significantly (i.e. disease is 
present, versus below the threshold, disease is not).  
Common genetic variants can be tested for their association with traits of 
interest via Genome Wide Association Studies (GWASs) (Visscher et al., 2017), 
discussed in further detail in 2.2.1. MDD and chronic pain are both complex 
traits, with an inherited genetic component in addition to environmental factors, 
and interaction between genetic and environmental factors, contributing to 
phenotypic variance. Both traits can be examined within the disease liability-
threshold model framework, e.g., in chronic pain the “physiological threshold” 
for diagnosis when chronic pain is considered a binary or threshold character 
may be reached with increasing genetic risk burden in combination with 
environmental factors (e.g. injury, surgery, or disease).  
1.3.3.2 Pleiotropy and genetic correlation 
Many hundreds or even thousands of common genetic variants contribute to 
variation in each complex trait, and the number of human complex traits is large 
but still finite. This means that there is significant genetic ‘overlap’ in terms of 
the genetic architecture of complex traits. Common genetic variants often 
contribute to variation in more than a single trait. These contributions to 
variation in more than one trait may be made independent of one another, so-
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called ‘biological’ or ‘horizontal’ pleiotropy (Fig 1: a + b), or a variant may 
contribute to variation in a trait, which then itself contributes to variation in a 
second trait, termed ‘mediated’ or ‘vertical’ pleiotropy (Fig 1: c). Pleiotropy 
overall is extremely commonplace in human complex traits and diseases 
(Gratten & Visscher, 2016; Hackinger & Zeggini, 2017; Visscher & Yang, 2016; 
Watanabe et al., 2018), and complicates the investigation of causal relationships 
and mechanisms of disease development. Furthermore, ‘directional’ pleiotropy 
refers to when shared variants tend to be associated with the same direction of 
effect in both traits, making the average value across variants non-zero, and 
‘balanced’ pleiotropy to when there are opposing directions of effect associated 
with shared variants, effectively cancelling each other out.  
Genetic correlation and pleiotropy are closely linked. Two traits are genetically 
correlated when a significant proportion of associated genetic variation is shared 
between them, as can occur with a high enough degree of pleiotropy. Formally, 
genetic correlation rg is the additive genetic covariance between two traits 
scaled by the geometric mean of the trait variances. Genetic correlation can 
inform on shared genetic influences contributing to variation in two compared 
traits, as well as in applications such as validation of measurement of a 
phenotype in one cohort by assessing its genetic correlation with the same 
phenotype in a separate cohort (which should approach 1, if the measurement is 
examining sufficiently similar trait constructs). 
 
Figure 1. 1: Pleiotropy.  
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(a) and (b) show biological (horizontal) pleiotropy, with a single causal variant influencing more than 1 
trait, or two causal variants at a single locus affecting two traits (and so a single locus affecting two traits)  
due to linkage disequilibrium. (c) shows mediated a.k.a vertical pleiotropy – variant influences trait which 
then has an effect/ associated with an effect on a ‘subsequent’ trait. Note that this type of pleiotropy is 
the cornerstone of MR. (d) shows spurious pleiotropy where the causal variants/ associated variants are in 
independent loci but are tagged by (i.e. in LD with) a single variant in both trait 1 and 2. Diagram from 
(Hackinger & Zeggini, 2017).  
Heterogeneity, specifically clinical heterogeneity, is due to the misclassification 
of individuals into disease or phenotype categories. This misclassification can be 
due to shared risk factors, and overlap in symptom profiles, and error in 
measurement and assessment.  
In psychiatric disorders error in measurement is introduced as diagnoses may 
overlap and are based on questionnaire assessment (i.e., there are no laboratory, 
biomarker or imaging tests to decisively deliver a psychiatric diagnosis). 
Depression or MDD may therefore be several distinct disorders (Cai et al., 2020; 
Schwabe et al., 2019), and in our own assessment of this we introduce 
heterogeneity via the structure of the questionnaires. For example, considering 
all DSM-5 depression symptoms to be of equal importance and of more 
importance than non-DSM symptoms results in a large number of non-overlapping 
symptom profiles being categorised under the same diagnostic label (Fried et al., 
2016; Fried & Nesse, 2015b; Olbert et al., 2014). The situation for chronic pain is 
similar to that of major depression (see 1.1.2), again potentially leading to 
clinical heterogeneity because of error in measurement and assessment. 
Partially overlapping symptom profiles of chronic pain and depression may also 
contribute to potential clinical heterogeneity in depression with respect to 
chronic pain and vice versa. For example, those with chronic pain commonly 
report fatigue (Van Damme et al., 2018), and fatigue or loss of energy is 
included as a non-core symptom of MDD in DSM definitions, complicating the 
diagnosis of depression in chronic pain patients (Knaster et al., 2016). 
Additionally, manifestation of depression or depressive symptoms in certain 
groups could be misclassified as chronic pain altogether – men often view 
depression symptoms, particularly physical or somatic symptoms, as an indicator 
of physical illness (Seidler et al., 2016). In general many people with depression 
seek treatment in primary care for somatic symptoms, including aches, pains, 
and fatigue (reviewed (Kapfhammer, 2006)). Chronic pain and MDD also share 
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many risk factors, e.g., being female, or of lower socioeconomic status, and are 
commonly comorbid, further contributing to increased likelihood of clinical 
heterogeneity in the two conditions.  
Clinical heterogeneity can also be described as subgroup pleiotropy (Han et al., 
2016), and if the general case is that e.g. MDD is misclassified as chronic pain, 
then that may be a major contributor to the observation of shared genetic 
factors between the two conditions, as opposed to this sharing of genetic factors 
being an indicator of true pleiotropy. It is therefore important to distinguish 
clinical heterogeneity, or subgroup pleiotropy, from true or whole-group 
pleiotropy to further understand the genetic architecture of both MDD and 
chronic pain. Confirming that misdiagnosis of chronic pain as MDD and vice versa 
is not a significant issue also has implications for examining causal relationships 
between the two conditions.  
1.3.4 Genetics of Chronic Pain and Chronic Pain Disorders 
Twin studies have also shown several chronic pain disorders to have a heritable 
component – a systematic review of a range of twin studies of chronic pain 
phenotypes found heritability to range from ~25% (irritable bowel syndrome) to 
77% (in studies of headache including migraine) (Nielsen et al., 2012). Nielsen et 
al also note that heterogeneity and lack of pain intensity measurement, lack of 
assessing the pain itself, and use of dichotomous pain phenotyping may reduce 
power. This approach to measurement may also mean that genetics and 
resulting heritability estimates may be related to tissue pathology rather than 
pain processing or the chronic pain itself. Subsequent twin studies of chronic 
pain phenotypes have also indicated moderate heritability, including phenotypes 
such as low back pain, H2 = 21-67% (P. H. Ferreira et al., 2013; Junqueira et al., 
2014), and the number of sites (0-31) of chronic pain H2 = 55-63% (Burri et al., 
2018). 
Non-family genetic studies of chronic pain have, to date, commonly been 
investigated using candidate gene and animal model-based approaches (Zorina-
Lichtenwalter et al., 2016, 2017). Although not a focus of this thesis animal 
models of pain and chronic pain reviewed in greater detail by (Burma et al., 
2017; Mogil et al., 2010). In addition to chronic pain as described and 
investigated in this thesis (as a complex trait), rare autosomal recessive genetic 
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diseases such as congenital insensitivity to pain (CIP) have been previously 
described (Golshani et al., 2014; Nagasako et al., 2003). CIP inhibits the ability 
to perceive any physical pain, and this difference in perception is present from 
birth. CIP is heterogeneous both in terms of clinical presentation and genetic 
mutations causing the disease, and mutations in genes including NTRK1 
(neurotrophic tyrosine kinase receptor type 1) (Kilic et al., 2009), PRDM12 (PR 
domain zinc finger protein 12) (Chen et al., 2015) , and SCN9A (sodium channel 
voltage-gated type IX, alpha subunit) (Majeed et al., 2018; Peddareddygari et al., 
2014), among many others, have been implicated. CIP may also be more 
specifically classified according to symptoms, genetic cause, and/or 
comorbidities such as intellectual disability, into one of five kinds of hereditary 
sensory and autonomic neuropathy (HSAN) (Houlden et al., 2006; Lafrenière et 
al., 2004; Minde et al., 2004; F. Zhao et al., 2020). More recently, a novel 
pseudogene microdeletion (in FAAH, fatty acid amide hydrolase) was found in a 
66 year old British woman that conferred pain insensitivity, fast-healing wounds, 
and absence of anxiety, fear and depression (Habib et al., 2019). Two further 
rare genetic disease associated with mutations in SCN9A have also been 
described. One such condition is primary erythromelalgia, characterised by 
erythema (rashes), temperature changes (warmth) and episodes of burning pain 
in the extremities (Dabby, 2012; Fischer & Waxman, 2010; Mann et al., 2019; 
Tang et al., 2015). Disease inheritance in primary erythromelalgia is autosomal 
dominant, with gain-of-function mutations in the SCN9A gene (which encodes 
voltage-gated sodium channels) causing symptoms (Fischer & Waxman, 2010; 
Mann et al., 2019; Tang et al., 2015). Another autosomal dominant disease 
associated with extreme pain is paroxysmal extreme pain disorder (PEPD), 
caused by gain-of-function mutations in genes encoding voltage-gated sodium 
channels (Fertleman et al., 2006; Fischer & Waxman, 2010). PEPD manifests as 
episodic burning pain (of ocular, mandibular and rectal regions as opposed to 
extremities in erythromelalgia), which can be accompanied by non-epileptic 
seizures and slowed heart rate in addition to skin flushing (Fischer & Waxman, 
2010). 
Candidate gene studies, where variants within a gene region chosen a priori by 
researchers are tested for their association with a complex trait (Patnala et al., 
2013; Tabor et al., 2002) (in contrast to single-gene Mendelian pain disorders 
described above), have also been carried out for chronic pain phenotypes. 
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However, candidate gene studies in general may be more likely to yield false-
positive associations (Sullivan, 2007), and so candidate genes in the study of 
chronic pain, such as COMT, SLC6A4, GCH1, OPRM1 and ADRB2 (Mogil, 2012; 
Veluchamy et al., 2018), may not be associated with chronic pain in large-scale 
GWAS of chronic pain as a trait.  
Certain chronic pain phenotypes such as CPG, a graded classification of chronic 
pain assessing pain severity, duration, resultant disability and impact on quality 
of life first constructed by von Korff (Von Korff et al., 1992) and colleagues and 
later validated by Smith et al (Smith et al., 1997), pain at specific bodily sites 
(e.g. low back pain), and specific chronic pain related conditions (e.g. migraine, 
temporo-mandibular joint disorder), have been shown to be complex traits with 
moderate heritability, and common genetic variation (SNP variation) has been 
found to contribute to variation in these traits (Hocking et al., 2012; McIntosh et 
al., 2016; Nicholl et al., 2011; M. J. Peters et al., 2013; Suri et al., 2018; Zorina-
Lichtenwalter et al., 2016, 2017). However, as pain assessment and experience 
are so heterogeneous (Steingrímsdóttir et al., 2017; Vellucci, 2012), there are 
few large-scale genetic, particularly GWAS, studies of chronic pain as a 
phenotype in its own right (Nicholl et al., 2011; Tsepilov et al., 2020; Zorina-
Lichtenwalter et al., 2016, 2017). However, GWAS studies of chronic low back 
pain and chronic pain in particular body sites have been previously carried out 
(Meng et al., 2020; Suri et al., 2018).  
Due to the fact that common genetic variants across the genome are tested for 
their association with a complex trait in a GWAS, sufficient sample size is 
essential (Hong & Park, 2012). At an absolute minimum, this sufficient total 
sample size is estimated to be 2,000 individuals (Hong & Park, 2012), and in 
general number of variants discovered appears to reliably increase with 
increasing sample size (Visscher et al., 2017). GWAS of chronic pain likely 
requires extremely large sample sizes to find associated common genetic 
variants. For example, a genome-wide association study with a sample size of 
~23,000 found no SNPs to be significantly associated with CPG (McIntosh et al., 
2016), a GWAS meta-analysis of low-back pain in ~150,000 individuals showed 
only three trait-associated SNPs at genome-wide significance (Suri et al., 2018) 
and recent GWAS of a musculoskeletal pain phenotype with a sample size of 
~190,000 found nine trait-associated loci (Tsepilov et al., 2020). Required 
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sample sizes for discovery of a large number of chronic pain associated SNPs are 
likely to approach the magnitude (~ 0.5 – 1 million) of those in recent large 
GWAS meta-analyses of MDD (Howard et al., 2019; Wray et al., 2018).  
1.3.5 Genetics of MDD 
As previously discussed with respect to chronic pain, candidate gene analyses 
have been problematic generally, with replication of gene-trait associations 
often inconsistent in subsequent studies. Wray et al (2012) systematically tested 
180 previously highlighted potential candidate genes for MDD, and showed no 
significant findings (Wray et al., 2012). A more recent paper also investigated a 
range of historical MDD candidate genes, and again found “not much support” 
(Border et al., 2019). Linkage analysis findings are also non-overlapping with 
GWAS findings and likely assumptions of analyses were not robust (reviewed 
(McIntosh et al., 2019)). Twin studies indicate MDD has a significant genetic 
component, with heritability estimated at ~30-40% (Kendall et al., 2021; 
Polderman et al., 2015; Sullivan et al., 2000). Heritability estimates from other 
types of familial relationships including extended kinship constructs and varying 
familial-relationship dyads also produce results within a similar range 
(Fernandez-Pujals et al., 2015; also reviewed by Kendall et al., 2021).  
As recently as 6 years ago an extensive review of the genetics of major 
depression asserted that no GWAS up to that point had found loci significantly 
associated with MDD, depression or for any traits genetically related to MDD (e.g. 
neuroticism) (Flint & Kendler, 2014). This paper also emphasised that candidate 
gene work in MDD had, for the most part, only revealed false positives. 
As discussed above (1.3.3.1), MDD is a complex, quantitative trait, where the 
genetic architecture is highly polygenic, and many common variants of small 
effect contribute to variation in the trait. MDD is also more common and less 
heritable than e.g., schizophrenia, further complicating the search for trait-
associated common genetic variation. This is emphasised by the fact that sample 
sizes of over 0.3 million individuals were required before more than one or two 
variants were found significantly associated with MDD (Hyde et al., 2016; Wray 
et al., 2018), and a recent GWAS meta-analysis including broader depression 
phenotypes, the largest to date with a sample size over 1 million participants, 
found more than 100 SNPs significantly associated with depression (Howard et al., 
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2019). Additionally, a much more deeply phenotyped cohort of a more extreme 
depression phenotype of severe recurrent MDD (mean number of episodes being 
5.6) (where contrasts in trait-associated alleles are likely to be much larger 
between cases and controls and so there is more power to detect them) showed 
only two significantly-associated SNPs (Cai et al., 2015). 
Analysis of broader depression phenotypes (i.e., aside from clinician diagnosed 
MDD) has also been shown to be of value. In analyses of broad depression, ICD-9 
or ICD-10 coded MDD and probable MDD in UK Biobank, Howard et al showed all 
three phenotypes to be highly genetically correlated (rg = 0.85-0.87), genetically 
correlated with depression phenotypes from an independent study (rg = 0.63-
0.79), and that the broad depression phenotype was most highly genetically 
correlated (more so than either probable or ICD-coded MDD) with clinically 
defined MDD from an independent study (Howard, Adams, Shirali, et al., 2018; 
Howard et al., 2019). 
GWAS findings of MDD thus far highlight the importance of the immune system, 
synaptic plasticity and neurogenesis, prefrontal brain regions and multiple types 
of neurotransmission (calcium, glutamate), as well as genetic correlation with a 
wide range of psychiatric, behavioural and physical/health traits including 
schizophrenia, bipolar disorder, neuroticism and BMI (Howard et al., 2019; Wray 
et al., 2018).  
MDD has been found to be significantly genetically correlated with chronic pain. 
In family-based analyses of environmental and genetic risk for chronic pain, 
chronic pain grade (M Von Korff et al., 1992) was found to be genetically 
correlated with MDD at ρ = 0.53, indicating that just over half of the common 
genetic variation contributing to either disorder is shared. Positive genetic 
correlations were found between chronic pain at a range of body sites in UK 
Biobank, and between most of the different chronic pain-site phenotypes and 
MDD (rg = ~0.3 – 0.5) (Meng et al., 2019). 
1.4 Summary 
MDD and chronic pain are commonly comorbid, and represent significant global 
socioeconomic and health burdens, both individually and when considered 
together. Mechanisms of chronic pain development, and drivers of differing 
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vulnerability to developing chronic pain, are not currently fully understood, but 
likely include biological and medical, and psychosocial factors, and complex 
interactions between these factors.  
Both MDD and chronic pain as phenotypes represent very heterogeneous 
constructs, complicating the understanding of their aetiology. Chronic pain has 
recently been defined as a disease entity in its own right by an IASP taskforce 
and studying chronic pain as a complex trait may be a more tractable way to 
investigate chronic pain vulnerability and mechanisms in comparison to only 
studying conditions and disorders associated with significant chronic pain 
separately. This is comparable to recent large-scale analyses investigating MDD 
in terms of “broad depression” phenotypes. Common genetic variation 
associated with these two conditions, chronic pain as a disease and MDD, can be 
used to address outstanding questions on: 
• Common genetic variation associated with chronic pain 
• Pleiotropy – to investigate the degree to which common genetic variation 
is shared between chronic pain and MDD, and which genomic loci are 
involved  
• Clinical heterogeneity – is it possible that depression is mis-diagnosed as 
chronic pain, and vice versa? 
• Causal relationships between chronic pain and depression through 
Mendelian Randomisation analyses. 
Further understanding both chronic pain and MDD through use of common 
genetic variant data also has the potential to shed light on aetiology and 
highlight potential new treatment options for both conditions.  
1.5 Aims and Objectives 
1.5.1 Overall Aim 
The over-arching aim of this PhD project is to explore causal relationships 
between chronic pain and MDD in large UK general-population cohorts with 




The overall aim will be achieved through investigations that set out to address 3 
main objectives. 
1. To uncover common genetic variation associated with chronic pain 
phenotypes 
2. To investigate genetic correlation and pleiotropy between MDD and 
chronic pain 














Chapter 2: Methodologies and Technical Information 
2.1 Introduction 
This chapter introduces and outlines in detail different methods in statistical 
genetics used throughout this thesis. Certain key concepts involved in analyses, 
such as aspects of complex trait genetics, are also discussed in greater detail 
compared to their introduction in Chapter 1. Datasets, cohorts, and phenotypes 
which are used in multiple analyses and referred to in multiple results chapters 
are also described. 
2.2 Methodologies 
2.2.1 Genome-Wide Association Studies 
Genome-wide association studies (GWASs) are a search for common genetic 
variation that is associated with a complex trait of interest.  Methodologically, 
this involves many millions of regressions, where single-nucleotide polymorphism 
(SNP) genotype (i.e., allele complement) is a predictor or independent variable, 
and trait value (e.g., blood pressure, or case vs control status of a disease trait) 
is the outcome or dependent variable. Each regression tests whether genotype is 
associated with trait value. As outlined previously in Chapter 1: Genetics of 
Complex Traits, SNPs are single-base changes in the genomic DNA sequence, 
each making a very small contribution to the variation in a trait.  
This common variation may ‘tag’ (be physically nearby and in LD with) a causal 
variant, whilst having statistical properties that allow for the surveying of the 
genome, and the general population, in this manner. These properties include 
the genetic variation being common, which means the sample size of each of the 
three genotypes (e.g., AA, AT, TT) is more likely to be sufficiently large to give 
enough power to test association when effect sizes are low.  
GWASs were made possible by the advent of next generation sequencing 
methods (reviewed by Goodwin et al., 2016) and of SNP reference panels, with 
decades of work both sequencing point-mutation changes and mapping these 
genetic variants in the human genome involved. In the 1980s, Botstein and 
colleagues proposed restriction fragment length polymorphisms (RFLPs) be used 
as molecular markers in linkage studies, with the first RFLP map of the human 
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genome completed in 1987 (Botstein et al., 1980; also reviewed by Kruglyak, 
2007). However, linkage studies are underpowered for the discovery of common 
loci associated with complex traits, and the need for association studies in non-
family structured populations was increasingly recognised (reviewed by Kruglyak, 
2007). The SNP consortium (Thorisson & Stein, 2003) and HapMap project 
(Belmont et al., 2005; International HapMap Consortium, 2003) were formed 
with the initial goal of providing a dense genome-wide map of SNPs for use as 
molecular markers in association studies. In addition to highlighting the need for 
association studies of complex traits, it was suggested linkage disequilibrium 
(see also 2.2.5) mapping (Lander, 1996) would also be necessary: in line with 
these previous theories, studies showed SNPs chosen as markers could not be 
uniformly spaced across the genome, nor could they be randomly chosen – LD 
mapping would be necessary to obtain a set of optimally informative markers 
(Carlson et al., 2004; Gabriel et al., 2002). In addition to the HapMap project, 
more recent endeavours such as the 1000 Genomes project (Auton et al., 2015) 
and Haplotype Reference Consortium (McCarthy et al., 2016) provide reference 
panels for a range of human populations, and can also be used for obtaining 
informative SNP marker sets. For example, UK Biobank (see 2.3.2.1) phasing and 
imputation was carried out using 1000 Genomes and Haplotype Reference 
Consortium data (Bycroft et al., 2018; Marchini, 2015).  
It should also be noted that the contributions of non-common-SNP genetic 
variants to phenotypic variation in a trait are unmeasured in GWAS, and such 
genetic variants may also contribute to missing heritability (see next section, 
2.2.1.1). Rare SNP variants (MAF < 1%) are not assayed in GWAS, and non-point 
mutations (mutations where alterations involve more than a single nucleotide), 
such as larger (2 or more bases) insertions and deletions, chromosomal 
rearrangements such as inversion and translocations, and copy number variants 
(CNVs) (J. M. Kidd et al., 2008; Lodish et al., 2016; Scherer et al., 2007) are also 
not investigated (A. J. Clarke & Cooper, 2010; Maher, 2008; Manolio et al., 2009; 
McCarroll, 2008).   
2.2.1.1 The problem of missing heritability in GWASs of complex traits  
Heritability is generally defined as the proportion of phenotypic variation in a 
trait which is due to genetic differences between individuals in a population. 
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These genetic differences include the effects of alleles in an additive sense, but 
also include potential inter- and within-loci effects (dominance and epistasis, 
respectively) - this broad-sense heritability can be calculated using Equation 2.1.  
𝐻2 =






Equation 2. 1: Broad-sense heritability. 
In complex traits such as those measured using GWAS, many small-effect genetic 
variants likely contribute to this heritability. In a GWAS context, heritability in 
terms of the proportion of phenotypic variance explained by SNPs under an 
additive model of inheritance is usually calculated – a narrow-sense heritability 
(Equation 2.2). One method to do this is through linkage-disequilibrium score 
regression (LDSR, see 2.2.5), with rescaling of the regression slope to give the 





Equation 2. 2: Narrow-sense heritability. 
Prior to GWASs, heritability in complex traits was most often estimated through 
twin and pedigree studies, comparing the phenotypic correlations between 
relatives where the shared proportion of the genome between them is known 
(e.g., parent-offspring pairs or trios, full and half-sib pairs, monozygotic versus 
dizygotic twins). For example, narrow-sense heritability can be estimated from 
the slope of the regression line between mid-parent phenotypic value and 
offspring phenotypic value (Visscher et al., 2008), or broad-sense heritability 
through comparing phenotypic correlations between different sets of relatives 
(Griffiths et al., 2000). 
Missing heritability in GWAS is the heritability that cannot be explained by 
common SNPs assayed in the analyses (Timpson et al., 2018), or the much lower 
values of SNP-heritability from GWAS in comparison to estimates of heritability 
from twin and pedigree studies for the same traits (Maher, 2008; Manolio et al., 
2009). For example, estimates of heritability for major depression from twin 
studies range from 30-40% (Sullivan et al., 2000), but estimates of heritability 
from GWASs are less than 10% (Howard et al., 2019). 
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One possible reason for missing heritability in GWASs may be due to not 
detecting all contributing genetic variation. This can be due to low power to find 
trait-associated variants, and as power increases with increasing sample size, we 
may see more of the phenotypic variation in complex traits explained by 
common genetic variation. Another potential reason we may not be detecting all 
contributing variants is due to genotyping – only a certain proportion of all SNPs 
are genotyped, and the contribution of rare variants (MAF < 1%) or other non-SNP 
variation (e.g., Copy Number Variants, CNVs) is not usually examined (A. J. 
Clarke & Cooper, 2010; Manolio et al., 2009; Marjoram et al., 2014). 
Furthermore, the majority of GWASs are carried out using European-ancestry 
samples – isolated populations and African populations may be enriched for 
unique variants and contain more genetic variation in general, respectively, and 
GWASs carried out in these populations may reveal previously undiscovered trait-
associated variants (Manolio et al., 2009).  
Heritability estimates from twin studies capture non-additive genetic 
contributions to phenotypic variation (i.e., estimates are of broad-sense 
heritability), whereas estimates of heritability derived from GWAS assess only 
additive contributions to phenotypic variation (narrow-sense heritability). For 
example, estimates from twin studies could be inflated due to common-
environment effects (e.g., identical twins more likely to be similarly treated 
than non-identical twins and pairs of siblings) which generate a gene-by-
environment interaction and inflate heritability estimates. Therefore, another 
way heritability may go missing is in the comparison of narrow-sense (GWAS) and 
broad-sense (twin or certain pedigree analyses) heritability estimates.  
Broad-sense heritability can be higher than narrow sense due to both epistasis 
and dominance effects, but in addition to this ‘legitimate’ increase in 
phenotypic variation explained in comparison to narrow-sense heritability, 
broad-sense heritability in twin studies can be inflated due to confounding 
(Hemani et al., 2013). Specifically, variance is generated due to the confounding 
between common-environment effects and non-additive genetic effects (Evans 
et al., 2002). In a GWAS, the proportion of variation in phenotype explained can 
be formalised as the ratio of SNP-heritability (contribution of known variants to 
phenotypic variation) to total additive genetic contribution to variation in a trait 








Equation 2. 3: Proportion of variance explained. 
Rather than missing heritability being due to not discovering all possible trait-
associated variants (i.e. the numerator is underestimated), the denominator 
(total narrow-sense heritability) may instead be overestimated (Zuk et al., 2012). 
While the numerator is directly estimated from the GWAS data, the denominator 
is estimated indirectly from population parameters, in a way that does not 
account for the effects of gene x gene interactions on heritability attributable to 
additive variation.  
In contrast, it may be the case for most complex traits that non-additive genetic 
contribution to phenotypic variation is minimal (W. G. Hill et al., 2008). In this 
case, missing heritability cannot be explained solely by the comparison of 
narrow versus broad-sense estimates. It may never be possible to find this 
missing heritability: Barton argues that missing heritability is “to be expected” 
(Barton et al., 2017), as SNPs are not perfectly associated with causal alleles (J. 
Yang et al., 2010), so only the top tail of the distribution is obtainable even if all 
genomes in all people are assayed (Boyle et al., 2017). 
2.2.1.2 Population stratification  
Population stratification is the presence of systematic differences in allele 
frequencies between subpopulations in a population (e.g., human populations 
from different continents are subpopulations of the global population). This is 
due to non-random mating, which in turn can be caused by physical barriers to 
migration and admixture such as distance, or more subtle influences such as 
selective mating and related factors such as language and country boundaries. 
Genetic drift, a neutral process by which allele frequencies change with time, 
then occurs in this subpopulation, and stochasticity and the possible differences 
in the original ‘split’ subpopulations results in systematic allele frequency 
differences.  
Stratification in the sample population means that any association between 
genotype and trait of interest may not be due to a genetic variant’s association 
with the trait of interest (the fundamental question asked in GWAS), but instead 
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due to the variant segregating at higher or lower frequency in a certain 
subpopulation. These subpopulations may then be unequally represented 
between cases or controls, or distribution of quantitative trait values varies 
between subpopulations. 
GWASs are mostly carried out on samples of white Europeans (Chaichoompu et 
al., 2020). This gap in the field is due to early GWASs being performed almost 
entirely on unrelated, relatively small, European ancestry samples (Mills & Rahal, 
2019; Visscher et al., 2012, 2017): methodology and reference panels were 
developed with these populations in mind. There is comparatively vast genetic 
diversity and different haplotype block structures in non-European populations, 
particularly African populations (Ardlie et al., 2002; Calafell et al., 1998; 
Peterson et al., 2019; Richter et al., 2017; Rito et al., 2013, 2019; Rosenberg et 
al., 2002; Schlebusch et al., 2017; J. C. Stephens et al., 2001; Tishkoff et al., 
2009). This genetic diversity makes it more difficult to build usable reference 
panels for these populations relative to white Europeans. Reference panels are 
needed for genotype imputation, amongst other functions, as part of GWASs.  
Using large, admixed, and ancestrally diverse populations in general is also 
difficult in GWAS not only due to reference panel build issues, but due to 
population stratification on a larger scale in comparison to populations without 
admixture, and the issues this presents for standard GWAS analysis. Modelling 
the extent of fine-scale population structure in genetically diverse populations 
with a long evolutionary history, such as African populations, can be more 
computationally inefficient and complex in comparison to modelling population 
structure in white/ white-European populations. As previously mentioned, GWAS 
is a regression analysis – in standard regression data are assumed to have an 
identically and independently distributed property (i.e., all variables share the 
same underlying probability distribution and so are mutually independent of one 
another). As sample sizes increase and/or include participants of diverse and/or 
admixed ancestry, the chances of including related participants (either in terms 
of familial or ancestral relatedness) increases and this non-independence can 
generate spurious genetic association results (Peterson et al., 2019; Sul et al., 
2018). Analyses in this thesis are carried out on primarily white study 
participants, partly due to the above considerations and due to the demographic 
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composition of UK Biobank, Generation Scotland and 23andMe Pfizer datasets 
(2.3.2) – this limitation is further discussed in 7.5. 
Potential inflation of test statistic values, and associated false-positive results, 
due to population structure, can be mitigated via calculation of a genomic 
inflation factor, commonly λ (J. Yang, Weedon, et al., 2011). Lambda is largely 
a function of population stratification, which can be corrected for in a range of 
ways. Older methods include genomic control (Devlin et al., 2004; Devlin & 
Roeder, 1999), whereby every association test statistic (i.e. per-SNP) is adjusted 
by an overall genomic inflation factor – this may not be appropriate as some 
SNPs differ in terms of allele frequency across ancestral populations more than 
others – some results will be over-adjusted and others under-adjusted, resulting 
in loss of power overall. Another method is structured association, where 
samples are sorted into discrete subpopulation-based clusters, and evidence of 
association is then assessed on a by-cluster basis (Pritchard et al., 2002; Satten 
et al., 2002). This method is also flawed, this time due to issues with defining 
the number of clusters, and inability of the method to allow for membership of 
more than one cluster. The most widely-used approach for population 
stratification correction in GWAS is therefore genetic principal component (GPC) 
analysis-based methods such as EIGENSTRAT (Price et al., 2006), where no prior 
knowledge of population ancestry is required and underlying stratification is 
modelled empirically from the genetic data of the sample population. In 
addition, newer GWAS methods such as BOLT-LMM (Loh et al., 2015), take a 
Bayesian linear mixed-model approach in order to account for relatedness and 
cryptic population stratification in GWAS samples. 
2.2.1.3 Relatedness and Population Stratification– BOLT-LMM 
Linear mixed models allow for both fixed and random effects 
(https://stats.idre.ucla.edu/other/mult-pkg/introduction-to-linear-mixed-
models/; Dean & Nielsen, 2007), effectively allowing for hierarchical structure 
within sample data. Hierarchical structure in sample data means there are 
‘levels’ to the data e.g., individuals make up the sample, but an added level is 
that these individuals are related in family groups, or are students sampled from 
different classrooms, or individuals from different geographic locations. 
Observations per-individual are likely to be non-independent as these groupings 
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may make individuals more similar to one another within groups compared to 
between groups. To find a true estimate of the relationship between per-
individual observations and an outcome, groupings must be taken into account in 
any model. Non-independence and correlation can also occur in genetic data, 
due to individuals belonging to groups i.e., presence of population stratification 
and/or cryptic relatedness within a sample.  
One linear-mixed model approach used to account for population stratification 
and cryptic relatedness in GWAS samples is BOLT-LMM (Loh et al., 2015). In 
contrast to traditional GWAS where related individuals are removed from the 
sample and GPCs are added as covariates to the GWAS model, BOLT-LMM 
incorporates a genetic relatedness matrix (GRM) into the GWAS model, allowing 
related individuals to remain in the sample while still adjusting for stratification 
and relatedness.  
Mixed model approaches in general are gaining traction in association studies 
particularly in terms of investigating non-infinitesimal traits (Loh et al., 2015; 
Sul et al., 2018), but BOLT-LMM is one of the most computationally efficient, 
and additionally allows for modelling of both infinitesimal and non-infinitesimal 
trait architectures directly.   
2.2.2 Multiple-testing correction in a GWAS context 
As a GWAS is essentially the process of running millions of regressions of SNP 
genotype on trait value, correction for multiple comparisons is vital. Due to 
linkage disequilibrium some genotyped variants are inherited together more 
often than expected by chance, making the number of independent tests smaller 
than the number of genotyped SNPs tested in the GWAS. The standard practice 
for multiple comparison correction in GWAS is Bonferroni correction, giving a 
genome-wide significance alpha value of 5 x 10-8 i.e., the nominal alpha value of 
0.05 is divided by 1 million (an estimate of the number of independent tests).  
2.2.3 Conditional False Discovery Rate Analyses 
As explained in the previous section, multiple testing correction is of great 
importance in a GWAS context, with Bonferroni correction the standard practice. 
Bonferroni correction is generally considered very conservative, a quality which 
some argue may make it less than ideal in the context of a GWAS where the aim 
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is discovery of new trait-associated genetic variation rather than testing of a 
pre-set hypothesis, and the number of tests is extremely large. Bonferroni 
correction is a method for controlling the family-wise error rate – specifically, if 
we set a significance level according to this procedure, we specify the 
probability of concluding at least one false positive result out of the entire set of 
tests we are carrying out.  
An alternative set of multiple-testing corrections fall instead under the umbrella 
of false discovery rate (FDR)-controlling procedures. The false discovery rate is 
the rate or proportion of type 1 errors amongst a set of tests – in contrast to 
Bonferroni correction, FDR-controlling procedures do not control the family-wise 
error rate (chance of at least one type 1 error amongst a set of tests), providing 
a less stringent, but more powerful approach. The tail-end FDR procedure is 
concerned with controlling the FDR at a pre-defined level, and deciding the 
maximum test statistic value from a list of ordered test statistic values which 
allows for this (Benjamini & Hochberg, 1995), which then becomes the new cut-
off value for deciding significance. Local FDR reframes the FDR as a Bayesian 
posterior probability that the SNP in question is not associated with the disease 
or trait, given its association test statistic (usually a p value) (Benjamini & 
Hochberg, 1995; Storey, 2002). Conditional FDR then simply extends local FDR 
analysis and incorporates association data for a second, genetically correlated 
trait, to ask ‘what is the posterior probability that the SNP in question is not 
associated with trait 1 given its association test statistics for both trait 1 and 
trait 2’ (Equation 2.4). This is equivalent to adjusting each association test 
statistic (p value) for trait 1 by an empirical conditional probability value, which 
can be calculated by finding the proportion of instances where the two 
conditions pi ≤ Pi and pj ≤ Pj are true.  
 
 
𝑐𝐹𝐷𝑅 = Pr(𝐻0(𝑖)| 𝑝𝑖 ≤  𝑃𝑖 , 𝑝𝑗 ≤ 𝑃𝑗) =  
𝑝𝑖
Pr(𝑝𝑖 ≤ 𝑃𝑖 | 𝑝𝑗 ≤  𝑃𝑗)
 




cFDR analyses have been used to find novel variants associated with 
schizophrenia, type 2 diabetes, Alzheimer disease, bipolar disorder and systolic 
blood pressure (Andreassen et al., 2014; Andreassen, Djurovic, et al., 2013; 
Andreassen, Thompson, et al., 2013; Wang et al., 2016). This therefore 
represents a promising and potentially more cost-effective method for 
identifying new SNPs associated with complex traits by maximising the utility of 
existing GWAS outputs.  
2.2.4 BUHMBOX 
BUHMBOX (Breaking Up Heterogeneous Mixture Based on cross(X)-locus 
correlations) is based on the principle that if clinical heterogeneity were present 
(a subset of disease A cases are mis-diagnosed disease B cases), disease B risk 
variant (allele) frequencies will be higher only within a subset of disease A cases 
(Han et al., 2016), and under ‘true’ or whole-group pleiotropy, disease B risk 
alleles will be found at higher allele frequencies in all disease A cases in the 
sample. In addition, under true whole-group pleiotropy, the expected 
correlation between risk allele dosages at different loci should be “consistently 
positive” (Han et al., 2016). These between-loci pairwise correlations are 
combined into a single BUHMBOX statistic, which tests for excessive positive 
correlations. This test, and thus its statistic, will be significant in the case of 
heterogeneity, and non-significant in the cases of whole-group pleiotropy (lack 
of true heterogeneity) or insufficient power.  
The statistic itself is calculated in several steps. Genotype data in a sample of 
disease A cases and controls is assembled, along with information about SNPs 
associated with disease B (risk allele, risk allele frequency and effect size 
(measured as or converted to odds ratio)). A set of SNPs is compiled where all 
SNPs are associated with disease or trait A at p < 10-4 and are pruned in controls 
by excluding SNPs with r2 > 0.1. SNPs with an info score of < 0.8, MAF < 0.01 and 
HWE test p value of < 10-6 are also excluded. Genetic principal components are 
regressed out from risk allele dosages to give residual dosages for each 
individual locus. Individuals without complete information on SNP rsID, risk allele 
and dosage, risk allele frequency and effect size are excluded. A correlation 
matrix, R, of residual risk-allele dosages in N cases of disease A is constructed, 
along with a correlation matrix R’ of risk-allele dosages in N’ controls. These 
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matrices are then used to calculate Y (Equation 2.5), a matrix where non-
diagonal elements are z scores from delta correlations, where a delta 
correlation is the relative increase in correlation between risk allele dosages at 




(𝑅 − 𝑅′) 
Equation 2. 5: Y matrix for BUHMBOX calculations. 
 
The BUHMBOX statistic is then calculated according to Equation 2.6 using the 
matrix generated by Equation 2.5, where yij in Equation 2.6 is the element in Y 
row I column j. wij refers to a weighting function designed to maximise power, 
discussed in detail in the BUHMBOX method paper Supplementary Note (Han et 









Equation 2. 6: BUHMBOX test statistic. 
 
A p value is calculated using Equation 2.7, where ϕ is the cumulative density 
function of the standard normal distribution. 
 
𝑃𝐵𝑈𝐻𝑀𝐵𝑂𝑋 = 1 −  𝜑(𝑆𝐵𝑈𝐻𝑀𝐵𝑂𝑋) 
Equation 2. 7: P value for BUHMBOX test statistic.  
 
Population stratification and linkage disequilibrium could lead to a false positive 
result of the BUHMBOX test. Population stratification is addressed through 
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regressing out genetic principal components (GPCs), as part of the calculation of 
delta-correlations (Han et al., 2016). Linkage disequilibrium is adjusted for 
through LD pruning and examining delta-correlations (Han et al., 2016). 
Insufficient power may lead to potential false insignificance or false negative 
result from BUHMBOX analysis. Insufficient power can result when the number of 
disease A cases is too small, heterogeneity proportion is too low, and the 
number of known risk alleles and/or their effect sizes are low. Through 
simulation Han et al showed that high power (approaching 100%) at moderate 
suspected true heterogeneity proportions (0.2) can be achieved if the number of 
risk loci used in analyses is 100 or greater, and when the number of individuals 
with the disease (case individuals) is greater than 2,000 (Han et al., 2016). 
 
2.2.5 Linkage-Disequilibrium Score Regression 
Linkage disequilibrium (LD) is a property of genetic variants, namely alleles at 
different loci, whereby they are inherited together more often than is expected 
by chance (Pritchard & Przeworki, 2001).  
LD can be measured in a range of ways (Devlin & Risch, 1995), most commonly 
between pairs of genetic markers (and mostly using an r2 estimate; see Equation 
2.8 below which gives r. Note the numerator is equal to ‘D’, another common LD 
measure, and the denominator can be written (p1p2q1q2)1/2). p1 is the 
frequency of allele 1 at a biallelic locus SNP 1, q1 is the frequency of allele 2 at 
SNP1, q2 is the frequency of allele 2 at SNP 2, and p2 is the frequency of allele 1 
at SNP 2. r2 can then be used to prune out SNPs correlated (in LD) at an 
undesirable level e.g., SNPs at r2 > 0.1 (10%). Note that r2 is a preferred measure 
of LD rather than D, as r2 correctly accounts for differences in allele frequencies 
at loci being compared.    
 
𝑟 =  
𝜋11𝜋22 − 𝜋12𝜋21
(𝜋1 + 𝜋2 + 𝜋+1 𝜋+2)
1/2 




LD can be caused by a range of factors, including those in the evolutionary 
history of the population in which the variants segregate, as well as influences at 
the molecular level. Formally, r2 is a function of a scaled recombination rate 
parameter, or ρ (Equation 2.9) (Pritchard & Przeworki, 2001).  
𝜌 = 4𝑁𝑒𝑐 
Equation 2. 9: Recombination rate. 
 
Where c is the rate of recombination between the two markers and Ne is the 
effective population size. Genetic recombination refers to the rearrangement of 
DNA sequences and its consequences (Alberts, Johnson & Lewis, 2002; Carroll, 
2001; Heyer et al., 2010). Where effective population size and recombination 
rate are relatively large, r2 is inversely proportional to ρ i.e., LD between two 
markers decreases with increasing recombination. Recombination rate between 
markers tends to increase with increasing physical distance, and recombination 
rate in general varies across the human genome (Altshuler et al., 2010; Kong et 
al., 2002; Y. Liu et al., 2017; Myers et al., 2005; Stapley et al., 2017). Mutation 
rates also tend to vary across the human genome (Casane et al., 1997; Nachman 
& Crowell, 2000; Smith et al., 2002; K. H. Wolfe et al., 1989), and as high 
mutation rates break down LD between loci and nearby markers this also affects 
the degree of LD between markers. Also, at the molecular level, gene conversion 
can lead to decrease or breakdown in LD – gene conversion is the swapping of 
short sections of chromosomes between copies of a chromosome pair (i.e., is a 
form of non-reciprocal recombination), and effect on LD is equivalent to two 
recombination events in close proximity (and so acts on LD in similar fashion to 
recombination in general).  
Higher-order influences such as genetic drift can also influence levels of LD – 
genetic drift is the change in allele frequencies from one generation to the next 
due to random sampling without replacement in a finite population (Kimura, 
1954; Masel, 2011; S. Wright, 1937).  In small (finite) populations drift can lead 
to general loss of haplotypes over time and lead to an increase in LD 
(Charlesworth, 2009; Star & Spencer, 2013). Conversely, rapid population grown 
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can reduce genetic drift and so reduce levels of LD. Admixture, or migration, 
can generate LD in a population as gene flow temporarily results in long 
haplotype blocks (Darvasi & Shifman, 2005; Smith & O’Brien, 2005). Natural 
selection acting on linked variants can also lead to increase in LD through 
genetic hitchhiking (Smith & Haigh, 1974), as a haplotype flanking an 
advantageous variant is swept to high frequency or potentially to fixation in a 
population – negative selection can remove regions linked to deleterious variants, 
also inflating LD.  
Linkage disequilibrium score regression (LDSR) is a widely used method making 
use of linkage disequilibrium and its relationship with GWAS test statistics in 
order to quantify genetic correlation between traits, and to differentiate 
between population stratification and polygenicity in the inflation of association 
statistics in GWAS data estimated by the lambda value (Bulik-Sullivan et al., 
2015).  
The LD score is a measure of the amount of genetic variation tagged by variant j 
(Equation 2.10), calculated as the sum across k individuals included in the 
reference panel (see Supplementary Note in (Bulik-Sullivan et al., 2015) for full 
derivation).   




Equation 2. 10: Amount of genetic variation tagged by variant j.  
 
Variants in LD with a causal variant for a trait display an elevation in their test 
statistic in a GWAS, and this elevation is proportional to the degree of LD with 
the causal variant (Pritchard & Przeworki, 2001; J. Yang, Weedon, et al., 2011). 
Additionally, inflation in test statistics caused by population stratification does 
not correlate with LD (Devlin & Roeder, 1999; Lin & Sullivan, 2009; Voight & 
Pritchard, 2005). The expected value of the test statistic from GWAS for a 
variant j therefore depends on sample size (N), SNP-heritability (h2), number of 
markers included in the calculation (M), the contribution of confounding biases 
such as cryptic relatedness and population stratification (a), and the LD score of 







+ 𝑁𝑎 + 1 
Equation 2. 11: Expected value for GWAS test statistic associated with variant j.  
 
The intercept of the regression of the test statistic on LD score (Equation 2.11), 
minus one, provides a measure of test statistic inflation and an indication of 
whether this is due to stratification or polygenicity. Therefore, the closer the 
intercept value to 1, the lower the contribution of confounding bias (such as 
stratification) to inflation of GWAS test statistics, and an intercept value 
including 1 indicates no significant inflation in test statistics due to these 
influences. 
 
To obtain a genetic correlation value for two traits, LDSR can be extended 
(cross-trait LDSR), replacing the chi-squared test statistic of a single study with 
the product of two z scores calculated from GWAS effect sizes (beta values) for 
two separate traits (Bulik-sullivan et al., 2015) (Equation 2.12). N1 and N2 refer 
to the sample size for each of the two traits being compared, M to the number 
of markers included in the calculation, Ns to the number of overlapping samples 
(individuals included in GWAS for both trait 1 and 2), e.g., to genetic covariance 









Equation 2. 12: Expected value of cross-trait product of GWAS z scores. 
 
A genetic covariance value between the two traits can then be obtained by 
regression of this z score product on LD score, and normalisation of this 
covariance value by square root of the product of the SNP-heritabilities for the 
corresponding studies gives a genetic correlation value between the two traits of 
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interest (Bulik-sullivan et al., 2015). As any sample overlap inflates the z score 
product and then influences the intercept (term to the right-hand side of ‘+’ in 
Equation 2.12) rather than the slope value for the regression, genetic correlation 
as calculated by cross-trait LDSR is not biased by sample overlap.  
2.2.6 Polygenic Risk Scoring 
An individual’s burden of risk (trait-associated) alleles can be quantified by 
calculating their polygenic risk score (PRS). This can be calculated as a simple 
sum of independent trait-associated and trait-increasing alleles present in the 
individual, determined from GWAS output, or as a weighted sum where each 
trait-associated SNP included in the score is weighted by its effect size value 
(Chatterjee et al., 2016; Dudbridge, 2013). Independence of trait-associated 
SNPs contributing to a PRS is ensured via LD-based pruning, which can be carried 
out using tools such as PLINK (S. Purcell et al., 2007). To avoid over-fitting and 
over-estimation of the predictive accuracy of PRSs, the cohort from which the 
score is constructed (i.e. discovery cohort/ sample or training data) should be 
independent from the cohort in which PRSs are calculated and analyses are 
performed (target sample) (S. W. Choi et al., 2020; Wray et al., 2013).  
Significance thresholds to use in PRS construction have been contested – in the 
case of complex traits and considering the infinitesimal model (Barton et al., 
2017), it may in fact be more powerful to include variants associated with the 
trait at much lower than traditional genome-wide significance thresholds (Wray 
et al., 2013), and this approach (using all SNPs whether significantly associated 
or otherwise) is commonly used in animal and plant breeding applications (Erbe 
et al., 2012; Hayes et al., 2009; Meuwissen et al., 2001). Several purpose-built 
statistical tools have been constructed for PRS analyses, one of which, PRSice 
(Euesden et al., 2015), calculates the ‘optimum’ PRS from a range of PRSs with 
varying variant inclusion thresholds based on maximising Nagelkerke R2 value (a 
measure of predictive value of a model and a quantification of amount of 
variation explained).  
PRSs can be included in regression models and used to validate GWAS results, by 
testing whether a PRS for a trait is significantly associated with that trait in an 
independent cohort. In this case population stratification must be accounted for 
by covarying for genetic principal components (similarly to GWAS analyses), or 
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other measures of substructure (underlying stratification) in genetic data such as 
Multidimensional Scaling (MDS) components. PRS analysis can also be used to 
investigate shared genetic factors between traits in a similar fashion to genetic 
correlation – should a PRS for one trait be significantly associated with a 
different trait in an independent cohort, this suggests shared genetic factors 
underlie the two traits. PRSs have been valuable in a clinical setting in some 
cases and may inform treatment or allow stratification of patients by genetic 
risk for disease – examples of diseases where this is true include coronary heart 
disease and certain cancers (reviewed in (Chatterjee et al., 2016; Torkamani et 
al., 2018). In psychiatry, the clinical utility of PRSs is less clear, but there may 
be potential for PRS use in diagnosing of individuals whose symptoms meet 
multiple diagnostic criteria (Ruderfer et al., 2018), and perhaps eventually for 
prediction of illness and to inform treatment, as seen for some physical diseases, 
although this is in its infancy, particularly for psychiatric disorders with lower 
heritability in comparison to more highly heritable disorders such as 
schizophrenia, such as MDD (Binder, 2019).  
2.2.7 Mendelian Randomisation 
The first outlining of the principles of Mendelian randomisation, the “natural 
randomised control trial” (Smith & Ebrahim, 2005; Smith & Hemani, 2014) (Fig 
2.1) framework, is attributed to Katan (Katan, 1986). The basic premise of MR is 
that the causal effect of an exposure on an outcome can be estimated through 
division of the regression coefficients from the regression of the outcome on the 





Figure 2. 1: MR as a natural randomised control trial.  
Adapted from: https://www.researchgate.net/figure/Principles-and-assumptions-behind-Mendelian-
randomization-A-Diagram-illustrating-the_fig1_325460102 
In the early 2000s MR gained traction in the context of genetic and observational 
epidemiology (Brown, 2003; Keavney et al., 2006; Smith & Ebrahim, 2003). Even 
during these early stages, the potential problems with Mendelian Randomisation 
such as pleiotropy, gene-environment interactions, gene-gene interactions and 
population stratification were recognised (Thomas & Conti, 2001a). Also 
recognised was the potential insight MR could provide into causal relationships 
when only observational/ cross-sectional data were available. Use of aspects of 
the genotype as instrumental variables meant that reverse causation issues are 
avoided, as the genotype is generated prior to experience of both the exposure 
and the outcome, and germline genotype is unaltered by exposures and 
outcomes. Regression dilution bias, whereby errors in measurement of the 
independent variable cause the regression slope to be biased towards zero 
(Hutcheon et al., 2010), is also avoided as the genetic variants associated with 
the exposure tend to remain associated to the same degree throughout the life 
course (Smith & Ebrahim, 2004), mitigating random measurement error in 
measurement of the exposure variable. To a degree, issues with confounding can 
also be avoided if genetic variants used as instruments are unrelated to factors 
that confound exposure and outcome such as socioeconomic status (Lawlor et al., 
2008) (see below for further discussion of this in the context of increasingly 
complex exposures).  
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However, this is only true if the instrument-outcome-exposure relationship 
adheres to a list of specific assumptions. This allows for investigation of the 
exposure-outcome relationship in a way that is analogous to a randomised 
control trial (RCT), as the ‘participants’ are ‘dosed’ with the exposure 
(measured via instrumental variable(s)) at conception, and this dosage is 
randomised according to Mendel’s second law (the law of independent 
assortment) (Mendel, 1866). The assumptions that allow causal effect estimation 
are as follows (Lawlor et al., 2008) (Fig 2.2); 
 
Figure 2. 2: MR assumptions.  
IV1 = instrumental variable assumption 1, IV2 = instrumental variable assumption 2, IV3 = instrumental 
variable assumption 3. Adapted from: https://www.researchgate.net/figure/Principles-and-assumptions-
behind-Mendelian-randomization-A-Diagram-illustrating-the_fig1_325460102  
1. the instrument is associated with the exposure (IV1) 
2. the instrument affects the outcome only via the exposure (IV2) 
3. the instrument is not associated with any confounders of the exposure-
outcome relationship. (IV3) 
 
If there is only one IV, the simple ratio of regression coefficients described 
above can be used as-is, and this is the Wald ratio method. However, in most 
cases, there will be more than one IV. This is because in the cases of MR analysis 
of complex traits, instruments are genetic variants and are commonly chosen 
from GWAS (Burgess et al., 2017). Here is where the problems of population 
stratification, pleiotropy, gene-gene and gene-environment interactions, as 
envisioned in the early 2000s (Thomas & Conti, 2001b) become apparent. As the 
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number of IVs increases so does the chance that one or more will be associated 
with a second trait other than the exposure (pleiotropy). It also becomes more 
likely that an IV will be associated with another genetic factor (G) in addition to 
an environmental factor (E) – if G and E are independently distributed and the 
relationship between exposure and outcome is linear, this G x E interaction may 
not be a problem, but with non-independent distribution of G and E (where G is 
associated with likelihood of exposure to E) and non-linear relationships 
between exposure and outcome, this can result in both false positive and false 
negative results in MR analyses. If an IV is involved in a gene-gene interaction, 
this would produce similar results to G x E in MR analyses. Population 
stratification in GWAS introduces “distortion” of estimates of association 
between genetic variants and traits, which can then bias results of MR analyses 
through introduction of confounding between genetic variants and trait values.  
There are two main branches of MR analysis, depending on whether the 
researcher has access to individual-level genetic information, or just to genome-
wide association study (GWAS) summary statistics. In the former, associations 
between genetic variants (instruments) and exposures are measured in the same 
dataset as the measurement of instrument-outcome associations. In the latter, 
two independent GWAS summary statistic datasets are used, one for instrument-
outcome association measurement, and one for instrument-exposure 
measurement. Discussion below will focus on two-sample MR (where two 
independent GWAS summary statistic datasets are used) which is used in 
analyses in this thesis, but one-sample MR (and the relative merits of one versus 
two-sample MR) is summarised in detail elsewhere (Haycock et al., 2016; Lawlor, 
2016; Smith & Ebrahim, 2003). 
In the context of MR, the derivation of instruments from GWAS can be 
problematic for three main reasons. Firstly, since associated variants are likely 
to have small effects on the variation of the exposure, they may be weak as 
instruments (and so may not meet assumption 1). This can result in weak 
instrument bias, which is when the causal estimate tends towards the 
confounded observed estimate between exposure and outcome. In some 
situations, inclusion of a greater number of instruments can increase power – 
this is not true if many, or all, of the instruments are weak, and is known as 
‘many weak instruments’ bias (Bound et al., 1995).  
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The decision as to what constitutes robust association in an instrument is less 
straightforward for complex, heterogeneous exposures. APOE genotype and 
serum cholesterol have a clear relationship, and intuitively genotype makes a 
good ‘stand-in’ (instrument) for serum cholesterol level (Katan, 1986). For 
exposures such as BMI, employment status or MDD the genetic variants found to 
be associated with the traits through GWAS will have negligible effect sizes, and 
the ‘threshold’ for choosing certain variants rather than others is tricky to define. 
Genome-wide significance may be chosen as a threshold, but in the case of MDD 
this provides potentially over a hundred variants as the starting pool of 
instruments – and again each will only contribute to a tiny proportion of the 
variance in the exposure. Many algorithms exist to prioritise and rank GWAS SNP 
associations according to predicted functional consequence (de Leeuw et al., 
2015; McLaren et al., 2010, 2016), but again the relationship between predicted 
functional consequence of a SNP-change and the end-point of variation in the 
exposure trait value is not clear and many variants may have relevant functional 
annotation (or conversely, it may be that none of the trait-associated variants 
have relevant functional annotation).  
Secondly, pleiotropy is of great concern. Biological a.k.a. horizontal pleiotropy 
could mean that assumptions 2 and 3 are violated, as the variant may be 
associated indirectly with confounders and/or directly with the outcome 
(reviewed by Hemani, Bowden, & Smith, 2018). Furthermore, chances of 
pleiotropy are increased with increasing number of associated variants. Many 
hundreds of SNPs are associated with many complex traits at genome-wide 
significance, as sample sizes and variant-discovery power of GWASs increase. For 
example in a recent analysis of ~0.8 million individuals over 100 variants were 
found to be associated with MDD at genome-wide significance (Howard, Adams, 
Clarke, et al., 2018). It is impossible to empirically test MR assumptions 2 and 3 – 
not all possible confounders are known, and their possible association with 
instrument(s) is not assessed – it is likely, due to pleiotropy, that each 
instrument is associated with at least one confounder or the outcome.  
Thirdly, there may be extensive measurement error in a GWAS, depending on 
factors such as sample size. Both the SNP-exposure association and the SNP-
outcome association may be measured with considerable error, depending on 
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study size and design (particularly case-control versus continuous/ quantitative-
trait association analyses) (Liao et al., 2014).  
2.2.7.1 Pleiotropy in Mendelian Randomisation Analyses 
As discussed directly above, pleiotropy may render an instrument invalid. In 
complex traits this is an issue because pleiotropy is widespread and likely to be 
unavoidable when choosing instruments (Sivakumaran et al., 2011; Solovieff et 
al., 2013; Timpson et al., 2018; Visscher & Yang, 2016). Considering this, MR 
methodology has been developed to account and correct for pleiotropy amongst 
instruments. Two methods for dealing with pleiotropic instruments in MR, 
Inverse-Variance Weighted MR and MR-Egger, are conceptually based upon 
dealing with heterogeneity in estimates derived from meta-analyses, and small-
study bias in meta-analysis respectively. In contrast MR-RAPS is based on errors-
in-variables regression models.  
2.2.7.2 Inverse-variance weighted (IVW) MR 
In IVW analyses the Wald ratio estimates of the causal effect of the exposure on 
the outcome, obtained for each individual instrument, are essentially weighted 
and combined in a fixed-effect meta-analysis model to obtain an overall 
estimate of causal effect of exposure on outcome. This can be visualised as a 
line of best-fit passing through causal estimates plotted on an instrument-
outcome versus instrument-exposure coefficient plot: in IVW, this line is 
constrained to pass through the origin (Bowden et al., 2015). It is assumed that 
heterogeneity in causal estimate values across instruments is due to horizontal 
pleiotropy in at least one or more instruments, but could be due to a range of 
issues that lead to model assumptions not being met (Hemani et al., 2018). 
An adaptation of Cochran’s Q statistic can be used to quantify and statistically 
test the significance of this heterogeneity-indicated horizontal pleiotropy 
(Bowden et al., 2017, 2019; Burgess et al., 2013). Q, derived from the IVW 
estimate, should follow a chi-squared distribution with degrees of freedom equal 
to the number of SNP instruments minus 1, and significant departure indicates 
heterogeneity (and so potential horizontal pleiotropy). Additionally, a measure 
of instrument strength in IVW MR analyses is the F-statistic (Bowden et al., 2016, 




MR-Egger is another MR method, and is based on the fact that small-study bias in 
meta-analysis can be visualised by plotting the precision associated with study 
estimate against estimates themselves in a funnel plot (Egger et al., 1997). 
Unlike IVW MR analyses which indicates presence of general horizontal 
pleiotropy whether balanced or directional, MR-Egger detects directional 
horizontal pleiotropy specifically. Directional pleiotropy is when pleiotropic 
effects of genetic variants are not balanced around the null (zero), but tend to 
be in the same direction (trait increasing or trait decreasing) across different 
traits (Bowden et al., 2015). 
In MR analysis, directional pleiotropy can be considered a kind of small-study 
bias, with each SNP instrument representing a ‘study’, with asymmetry in a plot 
of ‘precision’ (size of the association between instrument and exposure) against 
the causal estimate for that instrument indicating directional pleiotropy. If the 
intercept in MR-Egger is significantly different from zero, this indicates 
directional pleiotropy is present amongst instruments. Note that balanced 
horizontal pleiotropy (i.e., where effect direction is heterogeneous amongst 
individual estimates, effectively cancelling out overall) would not be detected. 
Analogous to the F-statistic in IVW analysis, a version of the I2 statistic (Higgins 
et al., 2003) termed I2GX (Bowden et al., 2016) can be calculated in MR-Egger 
analysis to give an estimate of instrument strength. I2GX can range from 0 to 1 
and quantifies the degree of bias (or dilution) of the causal estimate obtained 
from MR-Egger due to measurement error in SNP-exposure association values.  
Overall, MR-Egger and/or IVW, or other MR analyses, can be done in tandem to 
further interrogate causal estimates obtained via MR, and attempt to identify 
and adjust for the presence of horizontal pleiotropy amongst instruments. 
Multiple approaches can be used to further understand the most prominent type 
of horizontal pleiotropy present e.g., IVW and MR-Egger to assess for presence of 
horizontal pleiotropy generally and directional pleiotropy, respectively.  
2.2.7.4 MR-RAPS 
An alternative methodology treats potential violations of IV assumptions an 
‘errors in variables regression’ problem framework, in contrast to meta-
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analysing effect estimates from individual instruments. Errors-in-variables 
models account for error in measurement of the independent variables (R. J. 
Carroll, 2006)– in standard regression (and so in IVW, MR-Egger and similar 
methods) it is assumed that independent variables are measured without error 
and these models therefore only account for errors in dependent (outcome) 
variables, and measurement error in SNP-exposure association is assessed 
separately through measuring e.g. I2GX and F. MR-RAPS (Robust Adjusted Profile 
Score) adjusts the profile likelihood of the summary data (Zhao et al., 2020).  
The effect of an exposure on an outcome is modelled as an errors-in-variables 
regression (Equation 2.13). 
𝛤𝑗 ≈ 𝛽0𝛾𝑗 
Equation 2. 13: Errors-in-variables regression. 
 
Where 𝛤𝑗  is the association between instrument j and the outcome, and 𝛾𝑗 is the 
association between instrument j and the exposure, and 𝛽0 gives an estimate of 
the causal effect of exposure on outcome. For MR-RAPS analysis, first a log-
likelihood function of the summary data is obtained (Equation 2.14). This is the 
natural log transformation of the likelihood function of the summary data, where 
the likelihood function measures goodness-of-fit of the errors-in-variables 
regression model given the values of model parameters.  



























Equation 2. 14: Log-likelihood function of the summary data. 
 
‘Profiling out’ of nuisance parameters (𝛾𝑗) from the log-likelihood function gives 















Equation 2. 15: Profile score. 
 
A maximum likelihood estimator of 𝛽 is given by ?̂? = argmax𝛽𝑙(𝛽). Briefly, 
maximum likelihood estimation is the estimation of model parameters of a 
function (here, regression of exposure on outcome) via maximizing the likelihood 
function (of 𝛽 ) given the data x so the data are most probable under the 
assumed statistical model.  
Zhao et al showed the relationship between exposure and outcome deviates 
from the linear relationship described above due to systematic pleiotropy 
(almost all instruments show horizontal pleiotropy), and this can be modelled 
under a random-effects model. 
When a profile score is calculated according to this model, it is biased (does not 
have mean zero at the true value). Inflation in the variance of 𝛤 (due to 
systematic horizontal pleiotropy in instruments) is described by the unknown 
additive constant 𝜏0
2, and as a result the profile log-likelihood and one of the 
associated profile scores has a corresponding maximum likelihood estimator that 
is not statistically consistent. In order to correct for this bias (and so effectively 
model systematic pleiotropy), the profile score is modified (‘adjusted’) 
((McCullagh & Tibshirani, 1990), see also Zhao et al., 2020 section 4.2).    
In addition to systematic pleiotropy, idiosyncratic pleiotropy (horizontal 
pleiotropy of a single instrument or small subset of instruments) can mean even 
an adjusted profile score will not be able to deliver the best causal estimate – 
this idiosyncratic pleiotropy is indicated by outliers on diagnostic plots of the 
adjusted profile score estimator (QQ plots and leave-one-out versus instruments 
strength plots). To mitigate the effects of idiosyncratic pleiotropy on the 
adjusted profile score estimator of the causal estimate, the adjusted profile 
score can be made robust, through robust regression techniques first developed 
by Huber (Huber, 1964). This involves changing the l2-loss in the profile 
78 
 
likelihood to a robust loss function, either the Huber or the Tukey biweight loss 
function.  
Overall, using a robust adjusted profile score to estimate the causal effect is 
based on a model that is most likely to match underlying instrument (SNP) 
biology i.e., widespread pleiotropy in variants associated with in complex traits. 
MR-RAPS allows estimation of a causal estimate in scenarios where both 
systematic pleiotropy (most or all instruments are pleiotropic) and idiosyncratic 
pleiotropy (a small subset or single instrument(s) are/ is pleiotropic) are present, 
and this can be explicitly modelled. Additional added benefits of MR-RAPS 
include the fact that inclusion of additional weak instruments (e.g., associated 
SNPs at less than genome-wide significance) can improve accuracy of the causal 
estimate, and that this type of in-depth statistical correction is usually only 
possible with access to individual-level data (and through MR-RAPS is possible 
with summary statistics).  
In addition to IVW, MR-Egger and MR-RAPS described above and used in analyses 
described in later chapters of this thesis, a wide range of other MR approaches 
are also in common usage (Bowden et al., 2017; Burgess et al., 2017; Evans & 
Smith, 2015; Smith & Hemani, 2014; Zheng, Baird, et al., 2017), many also 
developed with respect to specific challenges of two-sample MR with multiple 
instruments derived from GWASs.  
2.2.7.5 Summary Statistics & Methodological Issues in Two-Sample MR 
If harmonisation of GWAS summary statistics for two-sample MR approaches is 
not carried out correctly, causal estimates can be wrong (reviewed by Hartwig, 
Davies, Hemani, & Smith, 2016). Harmonisation can be summarised as 4 main 
steps; 
1. merging of the GWAS datasets (one for exposure, one for outcome) 
2. choosing a subset of SNPs from the merged dataset 
3. matching the effect alleles in exposure and outcome GWAS datasets 
4. linkage-disequilibrium pruning  
In step 1, SNPs must be present in both GWAS datasets and have no missing 
allele information. SNPs must also be reported on the same strand of DNA in 
both GWAS datasets. For example, a SNP may be read as A/G if reported on the 
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forward strand, and T/C if reported on the reverse strand. If there are strand 
discrepancies between GWAS datasets, labelling can be easily converted (e.g., 
A/G ➔ T/C).  
In step 2 a subset is chosen via a significance threshold of the researcher’s 
choosing – this may be genome-wide significance, nominal significance, or 
another threshold (in relation to the SNP-exposure p-value). It is also ensured 
that the effect allele (allele for which the association beta or OR is reported) is 
exposure-increasing. If the effect (beta) value is less than zero (not exposure 
increasing), effect allele is swapped with non-effect in the exposure GWAS 
dataset, and the beta value is multiplied by -1. Effect alleles are then matched 
between exposure and outcome datasets, ‘flipping’ alleles in the outcome 
dataset where necessary & possible (step 3).  
Finally, LD pruning is carried out, r2 threshold depending on the type of MR 
analysis to follow (e.g., a PLINK default r2 threshold of 0.2 is acceptable for MR-
Egger, but r2 < 0.01 is required for MR-RAPS). This results in a set of independent 
instruments, ready for two-sample MR analyses. 
Selection bias can be avoided by selecting instruments (based on, for example, 
p-value of association with the exposure) in a third, independent dataset. 
Selection bias occurs if genetic instruments influence the likelihood of taking 
part in a study or participating fully in follow-up. As an example, to mitigate this, 
if the MR analysis was to be carried out with BMI as an exposure and MDD as an 
outcome, two independent GWAS summary statistic datasets would be used, one 
for BMI and one for MDD, with a third independent dataset of an entirely 
separate GWAS of BMI used for instrument selection initially – if SNPs are 
associated with BMI in two independent GWASs, this suggests the association is 
true rather than driven by an association between SNP and likelihood of 
participating in a particular study. However, selection bias may be of less 
concern in large, general-population cohorts such as UK Biobank in comparison 
to cohorts where participants are recruited from hospital or general practice 
settings, or specifically based upon a condition of interest.  
These methodological stumbling blocks relating to harmonisation errors can 
result in discordant results between two-sample MR analyses even when using 
the same GWAS datasets (Hartwig et al., 2016). In two independent MR analyses 
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of C-reactive protein and schizophrenia, Prins et al found a protective (negative) 
causal effect of CRP on schizophrenia (Prins et al., 2016), whereas Inoshita et al 
found a positive causal effect of CRP on schizophrenia, with the latter analysis 
since retracted as the results were likely biased due to harmonisation issues 
(Hartwig et al., 2016).  
2.3 Resources and Materials 
2.3.1 FUMA and analyses therein (MAGMA, GTEx) 
FUMA is an integrative, open-access web platform used for the annotation, 
prioritisation, visualisation and interpretation of GWAS results , with GWAS 
summary statistics as input (Watanabe et al., 2017). A range of the available 
tools within FUMA have been utilised in analyses in this thesis; MAGMA and GTEx 
are of importance and summarised below.   
2.3.1.1 MAGMA 
In a GWAS, association between SNPs and a trait of interest is tested for. GWAS 
output (summary statistics) can be further characterised at the gene level, to 
investigate genes and gene ‘sets’ (functional groupings of genes) which are 
significantly associated with the trait of interest. In gene a.k.a. gene-based or 
gene-level testing, effects of variants are aggregated at the gene level – SNPs 
within the same gene have their test statistics combined to give a single p value 
for the test of the association of the trait with that gene. This method was 
inspired by pathway analyses in microarray data (Wang et al., 2007), and some 
of the first implementations involved adapting the GSEA (Gene Set Enrichment 
Analysis) algorithm (Subramanian et al., 2005), and adjustment for multiple 
testing is achieved through a permutation-based procedure (Subramanian et al., 
2005; Wang et al., 2007).  
Combining the test statistics of each SNP in a gene into a single gene-level test 
statistic (p value), was done by calculating a maximum statistic by Wang et al 
(Wang et al., 2007) (summing p values or the logarithms of p values), followed 
by permutation-based adjustment. Permutation testing approaches are used to 
adjust for multiple comparisons, and in contrast to Bonferroni or Benjamini-
Hochberg where a family-wise or false discovery rate is controlled at a desired 
value, the underlying null distribution of the sample data is simulated by 
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resampling test statistics under the null hypothesis (Camargo et al., 2008; 
Conneely & Boehnke, 2007). 
There may be issues with this overall approach if multiple LD blocks in a gene 
contain a SNP contributing significantly to variation in the trait (i.e. putatively 
causal), and although a permutation-based approach to multiple testing 
corrections keeps the Type 1 error rate effectively the same across genes of 
different size, there may be a loss of power for larger genes, and there is some 
evidence that a permutation-based approach is not accurate with increasing LD 
as “undue weight” is given to highly correlated markers (Moskvina et al., 2012). 
There are a range of methods for gene-level association testing (gene-based 
testing) and gene-set analyses (De Leeuw et al., 2016; Holmans et al., 2009; P. H. 
Lee et al., 2012; Lips et al., 2012) which aim to address these issues related to 
linkage disequilibrium and gene size, and one of the best-performing of such 
methods is MAGMA (Multi-marker Analysis of GenoMic Annotation) (de Leeuw et 
al., 2015; De Leeuw et al., 2016). 
MAGMA gene-based testing or gene analysis uses a multiple linear principal 
components regression model to test for association between each gene and the 
trait of interest, and an F test is used to compute the gene-level p value. The 
SNP matrix for a gene, consisting of rows of participants and columns of SNP 
genotypes (i.e. each element in the matrix is a 0, 1 or 2) is projected onto that 
gene’s genetic principal components (PCs), PCs with very small eigenvalues are 
removed, and then remaining PCs are used as predictors of the trait of interest 
in the linear regression model (de Leeuw et al., 2015) (Equation 2.16), where Y 
phenotype or trait value, 𝛼0𝑔 is the intercept, 𝑋𝑔
∗ is the matrix of PCs, 𝛼𝑔 is the 
vector of genetic effects for gene g, W an optional matrix of additional 
covariates and 𝛽𝑔 the vector of covariate effects. 
𝑌 = 𝛼0𝑔𝐼 + 𝑋𝑔
∗𝛼𝑔 + 𝑊𝛽𝑔 + 𝜀𝑔 





An F test then tests the null hypothesis of no association between the gene and 
the trait (all values in the vector 𝛼𝑔 being zero for a gene). This method means 
that LD is fully accounted for, the model is flexible (allows for extra covariates 
and interaction terms without change to the underlying model), and 
computation time is much faster in comparison to permutation-based test 
methods.   
There is some discussion in the literature as to defining gene boundaries in the 
context of gene-level association testing (reviewed (Wang et al., 2007), see also 
(Portin & Wilkins, 2017)), which can be done according to SNPs locations in 
relation to expression boundaries, coding regions and varying length of 
up/downstream sequence, and may or may not include SNPs correlated with 
SNPs mapped to gene locations. In MAGMA analyses, genes are defined by their 
transcription start and stop sites, as given by human genome reference builds & 
Entrez gene IDs, and SNPs are mapped to the gene if they are located within 
that interval (between start and stop site) – options also exist to add upstream 
and downstream extensions of this interval (de Leeuw et al., 2015).  
As an extension of gene-based or gene-level association testing using MAGMA, 
trait-associated genes can be tested for membership of functional pathways 
(gene-set analysis). This is achieved by transforming the p value for each gene 
𝑝𝑔 (calculated during the gene-level analyses) into a Z value using Equation 2.17 
below. 
𝑧𝑔 = 𝜙
−1(1 − 𝑝𝑔) 
Equation 2. 17: Transformation of gene p values to Z values for gene set 
analysis. 
 
Where 𝜙−1 is the probit function. This gives a variable Z containing all values of 
𝑧𝑔. To ask whether all genes in a set s are associated with the trait (self-
contained gene-set analysis), an intercept-only regression is carried out 
(Equation 2.18).  
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𝑧𝑠 = 𝛽01⃗⃗ + 𝜀𝑠 
Equation 2. 18: Intercept-only regression (MAGMA gene set analysis, self-
contained)  
 
Competitive gene-set analysis tests whether genes in a set are more strongly 
associated with the trait than genes in another set. The regression used in self-
contained gene-set analyses is expanded through use of a binary indicator 
variable Ss with elements sg (with sg = 1 for genes present in a set, and = 0 for 
those outside the set) (Equation 2.19).  
𝑍 = 𝛽0𝑠 1⃗⃗ + 𝑆𝑠𝛽𝑠 + 𝜀 
Equation 2. 19: MAGMA gene set analysis (competitive) 
 
The parameter 𝛽𝑠 shows the difference in association between genes in the set 
and those not in the set and testing the null hypothesis 𝛽𝑠 = 0 against the one-
sided alternative 𝛽𝑠 > 0 is equivalent to performing a one-sided two-sample t-
test that compares mean association of genes in the set with the mean 
association of genes not in the set. Similarly, self-contained gene-set analyses is 
the same as carrying out a one-sided one-sample t-test, comparing the mean 
association value of genes in the gene set to 0. 
Aggregating SNP-level statistics to the gene and gene-set level allows for an 
increase in power as fewer tests are performed overall. These types of analyses 
can also inform on potential functional impact of trait-associated SNP variation, 
by indicating loci for further investigation.  
2.3.1.2 GTEx 
The Genotype-Tissue Expression (GTEx) project is  resource that enables study of 
relationships between genetic variation, gene expression, and other molecular 
phenotypes in a range of human tissues (Aguet et al., 2017; Ardlie et al., 2015). 
As of the GTEx v6 data freeze used within FUMA, the resource consists of data 
from over 7,000 cell and tissue samples from 449 donors (the most recent GTEx 
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release (v8) is made up of over 1,000 individuals). One of the key goals for the 
GTEx project was to identify eQTLs for all genes for a range of human tissue 
types, and over 150,000 cis-eQTLs have also been mapped using these data. This 
was done by calculating significance correlations between genotypes and gene 
expression levels by performing linear regression of genotype on quantile 
normalized gene-level expression values (following correction for technical 
covariates) using Matrix eQTL (Shabalin, 2012) – see also Ardlie et al 
Supplementary Information including Figure S8 (Ardlie et al., 2015). Gene-
specific p values with correction for multiple testing (of multiple SNPs per gene) 
were calculated using a permutation-based approach. SNPs were mapped to 
genes if they were located within 1Mb of the transcription start site.  
Normalized gene expression data (reads per kilobase per million) for 56, 320 
genes in 53 tissues were taken from GTEx v6 for use in FUMA (Watanabe et al., 
2017). These 56, 320 genes were filtered to include genes with an average RPKM 
per tissue greater than or equal to 1, in at least one tissue type, giving a set of 
28, 520 genes, of which 22, 146 were mapped to entrez ID identifiers. Gene 
expression analysis using GTEx in FUMA is an extension of MAGMA gene-level 
analyses: “gene-property” analysis is performed using the average expression of 
genes per tissue type as a gene covariate, in order to test the (positive) 
relationship between genes highly expressed in a certain tissue, and genetic 
associations. Gene expression values are log2 transformed average RPKM per 
tissue type, after winsorized at 50 (based on GTEx RNA-seq data). FUMA tissue 
expression analysis is performed separately for 30 general tissue types and 53 
specific tissue types. 
The full GTEx data are accessible via dbGap, and certain subsets can be 
explored and visualised using the online GTEx portal 
[https://www.gtexportal.org/home/].  
2.3.2 Cohort Profiles 
2.3.2.1 UK Biobank 
UK Biobank is a UK general-population cohort of 0.5 million individuals recruited 
in middle age (40-79 years) from 2006-2010, with ongoing follow-up assessments 
including imaging, repeated measures of baseline phenotypic measures and 
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linkage to health records and death registers (Sudlow et al., 2015). Many 
thousands of phenotypic measures, such as blood pressure, height and weight 
were recorded, along with whole-genome genotyping (Bycroft et al., 2018). A 
subset of the cohort also completed an online follow-up Thoughts and Feelings 
questionnaire, from which DSM-5-approximating psychiatric disorder phenotypes 
can be derived (Davis et al., 2020). In addition, and importantly for this PhD 
project, all 0.5 million UKB participants were also asked through touchscreen 
questionnaire about pain and duration of any pain, at a range of bodily sites, at 
baseline assessment. (Pain phenotyping is discussed in detail below and in 
relevant results chapters). Approved UKB projects with datasets used for 
analyses described in this thesis were 6553 and 7155.  
A large proportion of the information collected during the UKB assessment 
centre visits or as part of online follow up, including questions on pain, is based 
on self-report, which may also represent a limitation in comparison to use of 
data collected during interview by a healthcare professional or with testing or 
sample collection. In general, information collected by self-selected participants 
in a self-report format can be subject to a range of biases such as confounding 
(the risk factor(s) being studied is correlated with an unmeasured risk factor), 
information bias (systematic measuring errors during data collection), and 
selection bias (the studied population is non-representative of the general 
population) (Janssens & Kraft, 2012).  
More specific limitations include the fact that UKB participants tend to be 
wealthier and healthier than the general UK population, and are likely to be 
older, less likely to be obese, less likely to be physically inactive, and less likely 
to smoke and drink on a daily basis: the participation rate for UK Biobank was 
also 5.45% (Fry et al., 2017).This is in line with findings showing that research 
participants and those who purchase direct-to-consumer genetic tests tend to be 
non-representative of target or general populations (Klijs et al., 2015; Leitsalu 
et al., 2015; Prictor et al., 2018; Stamatakis et al., 2021). This ‘healthy 
volunteer effect’ can have adverse effects when estimating relative risk of 
lifestyle and environment exposures in the study of chronic disease (reviewed by 
Stamatakis et al., 2021). Additionally, UKB participants are also ethnically 
homogenous, with the majority being white (94.6%), again affecting the extent 
to which results of studies using UKB can be generalised to other populations. 
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Issues can also arise if the trait of interest is correlated with study participation 
– for example, in the study of chronic pain in non-clinical cohorts, results could 
be biased if participation is less likely for individuals with the most severe 
and/or disabling chronic pain or chronic pain conditions.  
Despite the unrepresentativeness of UKB with respect to the UK general 
population, some analyses found that results of studies using the UKB resource 
are still largely generalisable to the UK population (Fry et al., 2017). 
Furthermore, lack of representation in general is not necessarily problematic, if 
this is considered during interpretation of study results (Rothman et al., 2013).  
2.3.2.2 23andMe 
23andMe is a private direct-to-consumer genetic testing company. Consumers in 
50 countries worldwide including the US, UK and Canada may purchase saliva 
testing kits and receive information on ancestry and genetic predisposition to 
disease. Data is also used in research – 80% of 23andMe customers ‘opt-in’ for 
this, with each consumer contributing on average to 200 different studies. One 
such study was a GWAS of chronic pain grade carried out using 23andMe 
consumer genotyping data in collaboration with Pfizer. As discussed in the 
previous section research participants may be non-representative of wider target 
populations, and individuals purchasing direct-to-consumer genetic testing kits 
in particular tend to be white, have higher educational attainment, and have 
higher income (Gollust et al., 2017; J. S. Roberts et al., 2017).  
The sample characteristics of the collaborative chronic pain grade GWAS carried 
out by 23andMe and Pfizer have been summarised by McIntosh et al (McIntosh et 
al., 2016). Validated pain questionnaires identical to those used in Generation 
Scotland: Scottish Family Health Study (GS: SFHS) were completed by more than 
32,000 research participants, from which a sample of 23,332 unrelated white 
European ancestry participants was derived, consisting of 10, 780 pain cases (i.e., 
those with any chronic pain grade that was not zero) and 12, 552 controls. This 
GWAS was carried out with adjustment for age, sex, BMI, current and previous 
manual labour and the first five genetic principal components.  
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2.3.2.3 Generation Scotland: Scottish Family Health Study 
The GS: SFHS is a genetic epidemiology study with a family-based recruitment 
process and structure, comprised of sociodemographic, clinical and DNA data 
from ~ 24,000 participants recruited across Scotland, aged 18-98 years old (B. H. 
Smith et al., 2006, 2013). Recruitment was carried out from 2006-2011 through 
identifying suitable potential participants registered at participating general 
medical practices, and the final cohort was 59% female. As in UK Biobank, the 
sample is in general healthier and wealthier than the general Scottish population, 
but nevertheless contains participants from a wide range of socioeconomic 
backgrounds and with a wide range of clinical features (Smith et al., 2013). The 
family-based structure and depth and breadth of phenotyping information allows 
for family-based genetic studies, for example into parent-of-origin effects, and 
for different forms of genetic studies such as investigating the role of rare 
alleles in health and disease.  
2.3.3 Chronic Pain Phenotyping in Key Cohorts 
2.3.3.1 Chronic Pain in UK Biobank 
At baseline all UKB participants were asked about ‘Pain type(s) experienced in 
the last month’ (data field 6159). Participants could choose from seven non 
mutually exclusive body sites or ‘pain all over the body’ or could answer ‘none 
of the above’ or ‘prefer not to answer’. If participants selected ‘pain all over 
the body’ they could not then select a specific site. Each body site, and the ‘all 
over the body’ option, had a corresponding question item where participants 
could answer if this pain had lasted for 3+ months or not – to which participants 
could respond ‘yes’, ‘no’, ‘do not know’ or ‘prefer not to answer’.  
As discussed in 1.1.2, those defined as having ‘chronic pain’ can be extremely 
heterogeneous groups of people, and chronic pain is measured and defined in a 
wide range of ways. It may be more powerful to consider chronic pain as a 
disease in its own right, as recently outlined in IASP taskforce discussions and 
recent ICD-11 coding additions of “chronic primary pain”. Multisite chronic pain 
(MCP) is a derived quasi-quantitative trait, constructed in order to investigate 
chronic pain as a phenotype in its own right, and with consideration of the fact 
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that there are unlikely to be legitimate cut-off points between localised and 
widespread chronic pain (Kamaleri et al., 2008). 
The trait value for MCP was derived from the number of sites at which the 
participant had experienced chronic pain for 3+ months (0-7). Those answering 
‘prefer not to answer’ with regards to pain types experienced in the past month 
were removed from analyses. Those answering that they ‘did not know’ the 
duration of any pain were not labelled as having chronic pain at that site but 
were not excluded from analyses. In the GWAS analyses discussed in Chapter 4, 
those answering that they experienced pain all over the body, which lasted for 
3+ months, were excluded from initial GWAS. Rationale behind this is further 
discussed in Chapter 4, but briefly: pain all over the body may represent an 
extreme phenotype presentation of MCP, but this may also represent a distinct 
phenotype in comparison to having a number of individual chronic pain sites 
(Gerhardt et al., 2016a; Viniol et al., 2013; Zadro et al., 2020), or even in 
comparison to participants selecting 7 individual sites of chronic pain (Nicholl et 
al., 2014). In addition, ‘all over the body’ does not necessarily follow linearly 
from an MCP trait value of 7, potentially representing an experience of pain 
without distinct sites that can be quantified and therefore complicating GWAS 
analyses (which are regression-based). The relationship between chronic pain all 
over the body and MCP is investigated in downstream analyses in Chapter 4 in 
order to address these issues. 
A phenotype approximating chronic widespread pain can also be derived in UK 
Biobank, and consists of those labelled as having chronic pain all over the body 
i.e., those who answer ‘All over the body’ to pain types experienced in the past 
month, and answer that this pain has lasted for 3+ months.  
2.3.3.2 Chronic Pain in Generation Scotland and 23andMe-Pfizer Sample 
Chronic pain grade a validated chronic pain phenotype (B. H. Smith et al., 1997; 
M Von Korff et al., 1992) derived from questionnaire participation, was 
ascertained in both GS: SFHS and 23andMe-Pfizer sample. Chronic pain grade 
incorporates scores on both disability and pain severity, and trait value ranges 
from 0 (no chronic pain) to 4 (most severe and most disabling chronic pain) 
depending on both disability due to pain and pain intensity. These scores are 
calculated from the answers to seven questions, all of which besides question 4 
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(“About how many days in the last six months have you been kept from your 
usual activities (work, school or housework) because of this pain?”) are answered 
by giving a rating from 0-10. A rating of 0 represents ‘no pain’ for questions 1-3, 
‘no change’ for questions 6-7, or ‘no interference’ for question 5, and ratings of 
10 represent ‘pain as bad as it could be’ for questions 1-3, ‘unable to carry on 
activities’ for question 5 and ‘extreme change’ for questions 6-7. Pain intensity 
is then calculated as the mean of question 1 + question 2 + question3 multiplied 
by 10, and disability score as the mean of the sum of rating values for questions 
5-7, multiplied by 10. Disability points are then calculated from the recoded 
disability score (0-29 = 0, 30-49 = 1, 50 – 69 = 2, >70 = 3) added to the recoded 
number of days value from question 4 (0-6 days = 0, 7-14 days = 1, 15-30 days = 
2, >31 days = 3).  
Chronic pain grade is then assigned based on both pain intensity and disability 
due to pain, as measured using disability points and pain intensity score. Chronic 
pain grade classification of 0 corresponds to disability points of 0 and pain 
intensity of 0, grade 1 to pain intensity of < 50 and disability points < 3, 2 to 
pain intensity greater than or equal to 50 and disability points < 3, grade 3 to 
disability points of 3 or 4, regardless of pain intensity, and grade 4 to disability 
points of 5+, again regardless of pain intensity.  
Such a phenotype may be potentially problematic when trying to understand the 
mechanisms of chronic pain development, as increasing trait value is not only 
correlated with increased chronic pain severity but with how that pain affects 
interaction with the environment (disability due to pain). Disability due to pain 
is likely also influenced by a range of factors, some of which may constitute 
confounders of the relationship between pain and pain-related disability. For 
instance, low socioeconomic status is associated with both chronic pain and can 
contribute to disability related to chronic pain ( reviewed by Mills et al., 2019), 
a relationship which can complicate a study to find genetic variation associated 
specifically with chronic pain. Furthermore, extremes in chronic pain grade trait 
value do not necessarily represent the most severe chronic pain, only the pain 
associated with greatest disability – although these factors would be expected to 
correlate with one another (Chiarotto et al., 2019), again higher disability points 
could be related to other, non-pain-severity factors that increase pain-related 
disability (i.e. theoretically individuals with the ‘same’ chronic pain but who 
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experience environments that are disabling to different extent can have 
differing chronic pain grade classifications). For example, an individual living in 
smaller, less accessible housing may be more likely to find pain has a greater 
impact on daily tasks compared to an individual with similarly severe pain who 
has access to resources that allow them to modify their living environment. A 
phenotype closely matching that of MCP in UK Biobank was also derived using GS: 
SFHS data. GS: SFHS participants were asked “are you currently troubled by any 
pain or discomfort?” as part of a chronic pain identification questionnaire – if 
answering ‘yes’, they could then choose from six specific bodily sites and ‘other’. 
In contrast to UK Biobank there was no option to note whether pain at specific 
sites had lasted longer than 3 months, but participants were asked the single 
question “have you had this pain or discomfort for more than 3 months?” which 
could refer to one of, several of, or all their sites of pain and is not discernible 
from the data. Body site options also differ slightly between cohorts. Therefore, 
MCP in GS: SFHS can take a value from 0-6 sites of chronic pain. This assumes 
that answering yes to the question “Have you had this pain or discomfort more 
than 3 months” indicates that pain at every site indicated by the participant is 
chronic.  
2.3.4 Major Depression Phenotyping in UK Biobank 
A subset of UKB participants (N = 157, 366) fully completed the online follow-up 
‘thoughts and feelings’ mental health questionnaire (Davis et al., 2020). This 
mental health questionnaire was designed by an expert working group and 
involved consultation with a patient group, and aims to make use of existing, 
validated measures. Though case classifications aim to replicate a psychiatric 
diagnosis, their delivery and reliance upon self-report means they can only be 
thought of as “likely” psychiatric diagnoses (Davis et al., 2020). Despite this, 
prevalence and patterns of association between demographic factors and other 
disorders were found to match expectations based on previous research and the 
expectations of the Health and Safety Executive (HSE) (Davis et al., 2020). 






9dkp0gVCvOSuaV1CZcm1nu0p0qYII (UKB application 7155) and associated with 
(Smith et al., 2013). These MDD phenotypes are also discussed by Davis et al 
(Davis et al., 2020). Derived UKB MDD phenotypes are “single probable major 
depressive episode”, “probable recurrent major depression (moderate)” and 
“probable recurrent major depression (severe)”, and the latter two can be 
combined into “probable recurrent major depression”. A ‘ranked mood’ variable 
can then be constructed, where each participant has a value from 0-4, 0 
indicating they did not meet criteria for any derived major depression or bipolar 
disorder phenotype, 1 indicating meeting criteria for single episode major 
depression, 2 for probable recurrent major depression, and 3 or 4 indicating 






Chapter 3: Further Understanding Overlap of Chronic Pain 
and Depression: Pleiotropy and Clinical Heterogeneity  
3.1 Introduction 
Analyses undertaken in this chapter address objectives 1, 2 and 3: to investigate 
genetic correlation and pleiotropy between MDD and chronic pain, to uncover 
common genetic variation associated with chronic pain phenotypes, and to test 
for clinical heterogeneity between MDD and chronic pain. Some of the analyses 
described in this chapter have been published as part of an article in 
Translational Psychiatry (Johnston et al., 2019).  
As previously described (2.2.3), cFDR analyses provide an alternative route to 
SNP discovery, making use of existing GWAS datasets and leveraging association 
with related conditions to boost discovery power. In the case of chronic pain, 
the association with mood disorders (commonly comorbid with chronic pain and 
chronic pain conditions) is of substantial interest, as improved understanding of 
the biological underpinnings of this overlap may provide ideas for the 
development of novel treatment strategies. cFDR analyses have been used to 
find novel variants and pleiotropic loci associated with schizophrenia, type 2 
diabetes, Alzheimer disease, bipolar disorder and systolic blood pressure 
(Andreassen et al., 2014; Andreassen, Djurovic, et al., 2013; Andreassen, 
Thompson, et al., 2013; Wang et al., 2016). 
Additionally, to date there is a relative lack of large, well-powered GWASs of 
chronic pain as a phenotype in its own right (1.3.4), and in those which have 
been carried out few variants have been found to be significantly associated 
with chronic pain. One such GWAS is the 23andMe-Pfizer GWAS of CPG (2.3.2.2), 
N = 23, 332 (McIntosh et al., 2016), where no SNPs were found significantly 
associated with CPG. cFDR therefore represents a promising and potentially 
more cost-effective method for identifying new SNPs associated with complex 
traits such as chronic pain, by repurposing existing GWAS outputs. Genetic 
correlation between traits can be driven by pleiotropy (1.3.3.2), and MDD and 
chronic pain grade have been previously found be genetically correlated at ρ ~ 
0.5 (McIntosh et al., 2016). However, even if pleiotropy is detected it is unclear 
whether this is whole-group (so-called ‘true’ pleiotropy) or subgroup-driven 
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(clinical) heterogeneity (see also 2.2.4). Additionally, other types of analyses to 
check for clinical heterogeneity (e.g., polygenic risk scoring) are not robust in 
the face of pleiotropy. In order to test for presence of clinical heterogeneity and 
to distinguish this from whole-group pleiotropy in MDD and chronic pain in UK 
Biobank, BUHMBOX (Han et al., 2016) analysis was carried out. 
3.2 Methods 
3.2.1 Conditional False-Discovery Analysis of Chronic Pain Grade and Major 
Depressive Disorder 
3.2.1.1 Phenotype Definition and Source Data 
cFDR analyses require two independent GWAS summary statistic datasets. For 
chronic pain, summary statistics from a GWAS carried out collaboratively with 
Pfizer-23andMe Inc of CPG (McIntosh et al., 2016)) were used. This GWAS sample 
consisted of 23,332 unrelated white European ancestry participants was derived, 
consisting of 10, 780 pain cases (i.e., those with any chronic pain grade that was 
not zero) and 12, 552 controls. 
For MDD, summary statistics from a recent case-control GWAS meta-analysis 
(Wray et al., 2018) were provided by the Psychiatric Genomics Consortium (PGC). 
After removal of data from 23andMe and UK Biobank participants, this gave a 
dataset originating from an analysis using 43 028 cases and 87 522 controls. 
Phenotype definitions, study population demographics and meta-analysis 
procedures for the MDD GWAS have been described previously (Wray et al., 
2018). 
3.2.1.2 Data Preparation and Linkage Disequilibrium Pruning & cFDR 
Analysis 
A dataset of SNPs for which a p-value for association, chromosome position data 
and rsID were available in both MDD and CPG datasets was constructed. This was 
then LD pruned. Firstly, PLINK-format genotype data, for each SNP in the newly 
compiled CPG-MDD summary-statistic dataset, was extracted from the UK 
Biobank genotype data (approved application 6553). Pruning was carried out 
using command line PLINK (version 1.9) --indep-pairwise function. These 
parameters are as recommended for cFDR analyses (Andreassen, Djurovic, et al., 
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2013; Liley & Wallace, 2015). This resulted in an LD-pruned dataset of 774 292 
SNPs with association data available for both MDD and CPG. These SNPs were 
then taken forward and cFDR were calculated using equation X in 2.2.3, 
repeated below (Equation 1), following detailed formulae and derivations from 
Liley & Wallace (Liley & Wallace, 2015) using R (version 3.5.2). Conjunctional 
cFDR (ccFDR) values are then the highest cFDR value between the two cFDR 
analyses. 
𝑐𝐹𝐷𝑅 = Pr(𝐻0(𝑖)| 𝑝𝑖 ≤  𝑃𝑖 , 𝑝𝑗 ≤ 𝑃𝑗) =  
𝑝𝑖
Pr(𝑝𝑖 ≤ 𝑃𝑖 | 𝑝𝑗 ≤  𝑃𝑗)
 
Equation 3. 1: Conditional false discovery rate. 
 
3.2.2 Further understanding the overlap of MDD and Chronic Pain 
The genomic context for SNPs significantly associated with MDD, CPG or both 
was examined. The R package ‘rsnps’ was used to extract data from records in 
NCBI dbSNP (https://www.ncbi.nlm.nih.gov/snp). Genomic context for each SNP 
was examined in the UCSC Genome Browser (build GRCh38/hg38) (Kent et al., 
2002), using a window of 0.5Mbp around each SNP and data from the GENCODE 
v24 track, validated or reviewed by either Refseq or SwissProt staff. Genes 
partially or fully contained within this window were noted. The presence of cis-
eQTLs close to the significant SNPs was investigated using the IGV eQTL Browser 
(Aguet et al., 2017) web interface. 
3.2.3 Clinical Heterogeneity in MDD and Chronic Pain 
Briefly, BUHMBOX requires GWAS summary statistics for disease A obtained in a 
sample that is independent from the sample where disease B is measured (and 
vice versa). First, clinical heterogeneity in MDD cases was tested for, using CPG 
as the independent GWAS dataset, and secondly clinical heterogeneity in chronic 
pain cases was tested for using MDD as the independent GWAS dataset. 
BUHMBOX is fully described in 2.2.4.  
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3.2.3.1 Phenotypes & Data 
Chronic pain is widely defined as pain persisting beyond the healing period (with 
the threshold duration of 3 months taken to be the healing period) (Greene, 
2010; Merskey & Bogduk, 1994), and can be assessed using the CPG questionnaire 
(M Von Korff et al., 1992). On this scale 0 = no chronic pain (no pain that has 
persisted beyond 3 months), 4 = most severe chronic pain (pain persisting 
beyond 3 months which also fulfils specific criteria relating to impact on daily 
functioning, mood, and ability to work). In contrast to MCP, questions on pain 
duration and impact on quality of life are also incorporated into this chronic pain 
phenotype. A GWAS of CPG (0-4) using a linear regression model was carried out 
by 23andMe in collaboration with Pfizer (McIntosh et al., 2016), these summary 
data are used here. 
Wray et al carried out a GWAS meta-analysis of MDD (Wray et al., 2018). 
Summary statistic data with UK Biobank and 23andMe participants removed were 
used in this analysis. Effect allele frequencies were obtained from the GWAS 
summary statistic dataset where UK Biobank individuals were not removed, 
downloadable from the PGC website– this is unlikely to bias results significantly 
and is acceptable for BUHMBOX analysis (Han et al., 2016), despite EAF 
calculations involving UK Biobank participant data. 
With respect to phenotyping in UK Biobank for these analyses, being classed as 
having MDD approximates a DSM-5 diagnosis of MDD (see 2.3.4). Controls consist 
of those with no mood disorder, and those with bipolar type 1 or 2 are removed 
from the analyses, along with those answering ‘Prefer not to say’ or ‘Don’t know’ 
in components of the MDD phenotype. The number of MDD cases and controls 
prior to BUHMBOX quality control were 34,025 and 93,819, respectively.  
During the baseline investigations, UK Biobank participants were asked via a 
touchscreen questionnaire about “pain types experienced in the last month” 
(field ID 6159), with possible answers: ‘None of the above’; ‘Prefer not to 
answer’; pain at seven different body sites (head, face, neck/shoulder, back, 
stomach/abdomen, hip, knee); or ‘all over the body’ (see Chapter 2 section: 
Chronic pain phenotyping in key cohorts). Those who answered that they had 
chronic pain at any site were classed as cases, and chronic pain at none of the 
sites as controls – those who answered ‘don’t know’ or ‘prefer not to answer’ 
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were removed from analyses. The number of chronic pain cases prior to 
BUHMBOX quality control was N = 215, 383 and controls N = 279, 641.  
3.2.3.2 Genotype Data  
UK Biobank phenotyping, genotyping and quality control has been described in 
detail elsewhere (Bycroft et al., 2018; Sudlow et al., 2015). The first eight 
genetic principal components (pre-calculated and included as part of UK Biobank 
data) were used in BUHMBOX calculations. 
3.2.3.3 BUHMBOX Procedure 
SNPs associated with CPG at a p value of 10-4 or less, their effect allele 
frequencies and effect sizes (odds ratios, ORs) were compiled from the UKB 
genotyping data, as were MDD cases/controls UKB-IDs and genetic principal 
components. ORs as a measure of effect size for SNPs associated with CPG were 
obtained by taking the exponent of beta values for each SNP (in personal 
communication between Dr Nicholas Graham and Dr Buhm Han this 
transformation was deemed acceptable in BUHMBOX analysis, despite the CPG 
GWAS being non case-control). 
BUHMBOX quality control steps (Han et al., 2016), other exclusions (see 
‘Phenotyping’) and linkage-disequilibrium (LD) pruning using command-line 
PLINK ‘indep-pairwise’ function with recommended parameter settings of 50 
kilobase window size, a step size of 5 SNPs and r2 threshold of 0.1 (Han et al., 
2016) was carried out. The resulting number of MDD cases = 3,455 and controls = 
9,681, and the number of independent CPG-associated SNPs used in calculations 
was 156. 147 of these SNPs were imputed with mean average call rate (the 
imputation quality metric provided with the 23andMe GWAS data) of 0.99. 
BUHMBOX was carried out to obtain a BUHMBOX test statistic value. If the test 
statistic-associated z value is negative, the resultant P value is transformed via 1 
– P value (BUHMBOX analysis performs a one-sided test only). 
SNPs associated with MDD at a p value <= 10-4, effect allele frequencies and 
effect sizes were compiled, along with chronic pain case and control UKB IDs and 
genetic principal components. BUHMBOX-specific quality control steps, 
phenotypic exclusions and LD pruning were carried out at previously described. 
The resulting number of chronic pain cases was 51, 494 and controls was 67, 857, 
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with 120 SNPs also taken forward for use in BUHMBOX calculations. 110 of these 
SNPs were imputed with mean imputation score of 0.96. BUHMBOX test-statistic 
z values were converted as needed as previously described.  
3.3 Results 
3.3.1 cFDR: SNPs Associated with CPG and MDD 
cFDR analyses were carried out to investigate pleiotropic loci associated with 
both MDD and CPG. Eleven SNPs in total were found at cFDR ≤ 0.01 (Table 3.1), 
six of which, located on chromosomes 12 and 14, were associated with CPG and 
nine of which, located on chromosomes 1 and 14, were associated with MDD. 
Four of these 11 SNPs, all located within a 131 kilobase-pair region on 
chromosome 14, were found to be pleiotropic (ccFDR ≤0.01). 
 
rsID Position Alleles  β (CPG)  p (CPG) OR (MDD)  p (MDD) cFDR (CPG) cFDR (MDD) ccFDR 
rs4904790 14:42242623 C/T -0.03 1.44 x 10-3 1.042 1.37 x 10-5 0.02 3.58E-03 0.02 
rs1584317 14:42213816 C/G 0.028 4.48 x 10-3 0.96 4.59 x 10-6 0.029 3.57E-03 0.03 
rs11846556 14:42183025 A/G -0.037 1.11 x 10-4 1.05 2.98 x 10-7 5.57 x 10-4 3.76E-05 5.57E-04 
rs10131184 14:42166111 A/G 0.035 2.82 x 10-4 0.95 2.53 x 10-8 8.46 x 10-4 7.10E-06 8.46E-04 
rs8015100 14:42095232 A/T -0.033 6.67 x 10-4 1.06 1.50 x 10-9 6.67 x 10-4 9.27E-07 6.67E-04 
rs11157241 14:42051771 C/T 0.035 2.91 x 10-4 0.94 4.44 x 10-9 5.83 x 10-4 1.28E-06 5.83E-04 
rs10138559 14:41975989 C/T -0.02 0.03 1.042 1.04 x 10-6 0.1 5.25E-03 0.1 
rs10872954 14:41948768  A/G -0.026 6.45 x 10-3 1.04 7.68 x 10-6 0.053 7.02E-03 0.053 
rs149981001 12:60264802 C/T 0.2 6.24 x 10-8 1.087 0.0181  1.06 x 10-3 0.018 0.018 
rs147573737 12:60231575 C/T -0.2 2.09 x 10-7 0.917 0.023 2.21 x 10-3 0.023 0.023 
rs35641559 1:73760104 C/T  0.02  0.03 0.961 2.08 x 10-6 0.1 8.83E-03 0.11 
Table 3. 1: Loci identified from cFDR analysis.  
Position = position given as chromosome: base pair location. cFDR (CPG) = cFDR for CPG conditioning on 
MDD; β (CPG)/p (CPG) = effect size and p value from the CPG GWAS; cFDR (MDD) = cFDR for MDD 
conditioning on CPG; OR (MDD)/p (MDD) = effect size (odds ratio for the effect allele) and p value from 
the MDD GWAS. Alleles are given as effect allele/other; effect allele is defined as the allele for which 
association with the trait was tested in the original (CPG or MDD) GWAS. rsIDs for SNPs associated with 
both MDD and CPG (pleiotropic SNPs) (ccFDR < 0.01) are shown in bold. 
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3.3.2 cFDR: Genomic Context of Trait-Associated SNPs 
The R package ‘rsnps’ and the UCSC Genome Browser were used to investigate 
genomic context of SNPs found to be of interest through cFDR analyses, 





Gene(s) Alleles Major Minor MAF AA 
rs35641559 1 MDD LOC105378800 C/T T C 0.4641 T 
rs149981001 12 CPG NA C/T C T 0.0022 C 
rs147573737 12 CPG NA C/T T C 0.0024 T 
rs4904790 14 MDD LRFN5 C/T C T 0.3175 C 
rs1584317 14 MDD LRFN5 C/G G C 0.2993 G 
rs11846556 14 Both LRFN5 A/G A G 0.3676 G 
rs10131184 14 Both LRFN5 A/G G A 0.239 G 
rs8015100 14 Both LRFN5 A/T A T 0.2546 A 
rs11157241 14 Both NA C/T T C 0.2508 T 
rs10138559 14 MDD NA C/T C T 0.4399 T 
rs10872954 14 MDD NA A/G A G 0.4343 A 
Table 3. 2: Output of ‘rsnps’ query 
SNP ID (rsID), location, cFDR-associated trait, associated genes (Gene(s)), minor allele frequency (MAF) and 




rsID Chromosome cFDR-Associated Trait Gene(s) 
rs35641559 1 MDD LINC01360, LRRIQ3, FPGT, FPGT-TNNI3K 
rs149981001 12 CPG SLC16A7 
rs147573737 12 CPG SLC16A7 
rs4904790 14 MDD LRFN5 
rs1584317 14 MDD LRFN5 
rs11846556 14 Both LRFN5 
rs10131184 14 Both LRFN5 
rs8015100 14 Both LRFN5 
rs11157241 14 Both LRFN5 
rs10138559 14 MDD LRFN5 
rs10872954 14 MDD LRFN5 
Table 3. 3: UCSC Genome Browser Results. 
3.3.2.1 CPG-Associated SNPs  
No genes were found through an ‘rsnps’ query for cFDR-associated SNPs 
associated solely with CPG (Table 3.2). SLC16A7, which encodes 
monocarboxylate transporter 2 (MCT2), is located within 1Mbp of SNPs which 
were solely associated with CPG (Table 3.3). In the central nervous system, 
MCT2 is involved in high affinity, proton-coupled transport of metabolites 
(particularly lactate) into neurons and may play a role in neuronal uptake of 
energy substrates released by glia (Y. Itoh et al., 2003; Pellerin, 2003). MCT2 is 
localised to the post-synaptic compartment in many human neurons and may 
have a specialised role in synaptic functioning (Chiry et al., 2008; Pierre et al., 
2002). Regulation of SLC16A7 has also been linked to disorders of the brain: loss 
or under-expression has been associated with temporal-lobe epilepsy (Lauritzen 
et al., 2012) and it may be expressed and methylated at different levels in 
patients with psychosis versus controls (C. Chen et al., 2014).  
3.3.2.2 MDD-Associated SNPs 
A single SNP on chromosome 1 was solely associated with MDD and located 
within 1Mbp of LRRIQ3 and FPGT (Table 3.3). LRRIQ3 encodes leucine-rich repeat 
(LRR) and IQ motif containing protein 3, a calcium-channel component. LRR-
domain containing proteins in general are involved in cell-cell communication, 
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including processes involved in innate immunity and neuronal development 
(Bella et al., 2008; Ng et al., 2011). FPGT encodes fucose-1-phosphate 
guanylyltransferase, a protein involved in the alternative (salvage) pathways of 
fucose metabolism (Becker & Lowe, 2003). Fucose metabolism is important in a 
variety of cell-cell communication and host-microbe interaction situations, but is 
also important during neuronal development (Becker & Lowe, 2003). Previous 
studies have found associations between variants in the LRRIQ3 region, 
schizophrenia (Ripke et al., 2014), neurodevelopmental disorders (Reuter et al., 
2017) and migraine (Gormley et al., 2016).  
The pleiotropic LRFN5 SNPs were all located just upstream of the 5’-most 
promoter, or within a large intron close to the 5’-end of the gene. The SNPs 
solely associated with MDD were also located within this intron or were located a 
little further upstream of the gene. The CPG-only SNPs were all located 
downstream of SLC16A7.  
GTEx eQTL results revealed that some of these phenotype-associated SNPs were 
also associated with expression levels of nearby genes. A SNP associated only 
with MDD, on chromosome 1 (rs35641559), was found to be significantly 
associated with expression of a long non-coding RNA gene LINC01360 in the testis 
(FDR < 0.05, Table 3.4). The MDD-associated and pleiotropic SNPs on 
chromosome 14 are all significantly associated with expression of LRFN5 in a 
range of tissues, including brain, heart, adipose tissue and spleen. The CPG-
associated SNPs on chromosome 12 were not significantly associated with 




rsID Chrom cFDR-Associated Trait cis-eQTL Tissue Location(s) 
rs35641559 1 MDD testis  
rs149981001 12 CPG NA 
rs147573737 12 CPG NA 
rs4904790 14 MDD cerebellar hemisphere, cerebellum, transformed fibroblasts 
rs1584317 14 MDD transformed fibroblasts 
rs11846556 14 Both aorta, tibial artery, cerebellar hemisphere, cerebellum, transformed 
fibroblasts, spleen 
rs10131184 14 Both subcutaneous adipose, aorta, tibial artery, cerebellar hemisphere, 
cerebellum, thyroid, transformed fibroblasts, oesophagus muscularis, 
ovary, skin (lower leg, not sun-exposed), spleen 
rs8015100 14 Both omentum, aorta, coronary artery, cerebellum, cerebellar 
hemisphere, transformed fibroblasts, oesophagus muscularis, ovary, 
spleen, thyroid 
rs11157241 14 Both subcutaneous adipose, aorta, tibial artery, cerebellar hemisphere, 
cerebellum, transformed fibroblasts, oesophagus muscularis, skin 
(lower leg, not sun-exposed), spleen, thyroid 
rs10138559 14 MDD coronary artery, aorta, tibial artery, cerebellum, cerebellar 
hemisphere, transformed fibroblasts, oesophagus muscularis, spleen, 
thyroid 
rs10872954 14 MDD aorta, transformed fibroblasts, spleen  
Table 3. 4: IGV eQTL Browser results. 
The tissue location(s) of cis-eQTLs where a gene is significantly regulated by the queried SNP (rsID column) 
(FDR < 0.05) are listed, along with SNP ID (rsID), chromosomal location (Chrom) and cFDR-associated trait. 
Single tissue eQTL lookups of rs11846556 (Figure 3.1) showed different trends in 
expression pattern of LRFN5 with 0, 1 and 2 A alleles, with a trend towards 
increased expression in the cerebellum and cerebellar hemisphere associated 
with homozygosity for the A allele (Figure 3.1 A & B respectively), and decreased 
expression in tibial artery and transformed fibroblasts associated with increasing 




Figure 3. 1. Single tissue eQTL lookups of rs11846556  
A = Cerebellum, B = cerebellar hemisphere, C = tibial artery, D = transformed fibroblasts. Homo Ref = 
homozygous for the reference allele (GG), Het = heterozygote (AG), Homo Alt = homozygous for the 
alternative allele (AA). Boxplots display minimum, maximum, median, 1st and 3rd quartile rank normalised 
gene expression values. 
3.3.3 BUHMBOX: Whole-Group Pleiotropy in MDD and Chronic Pain in UK 
Biobank 
BUHMBOX analyses were carried out to test for clinical heterogeneity in chronic 
pain, using chronic pain grade data, with respect to MDD and vice versa in UK 
Biobank. No evidence for clinically heterogeneity was found in either MDD or 
chronic pain cases. The BUHMBOX test statistic was insignificant at p = 0.277 
(Table 3.5), indicating no clinical heterogeneity in terms of CPG-like MDD cases 
within MDD in UK Biobank. 
p p (adj) log(p) N N cases N controls Z N loci 
0.723 0.277 -0.141 13,136 3,455 9,681 -0.592 156 
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Table 3. 5: BUHMBOX results for test of clinical heterogeneity in MDD cases in UK Biobank.  
p = BUHMBOX p value, p (adj) = 1 – BUHMBOX p value, log(p) = log-transformed p value (base 10), N = total 
number of individuals included in analysis, N cases = number of case participants included in analysis, N 
controls = number of control participants included in analysis, Z = BUHMBOX test statistic Z score value, N 
loci = number of SNPs included in analysis. 
The BUHMBOX test statistic was also non-significant at p = 0.29 (Table 3.6) in 
analyses of chronic pain, showing no clinical heterogeneity, or in other words no 
MDD-like chronic pain cases.  
p p (adj) log(p) N N cases N controls Z N loci 
0.706 0.29 -0.151 119,351 51,494 67,857 -0.541 120 
Table 3. 6: BUHMBOX results for test of clinical heterogeneity in chronic pain cases in UK Biobank.  
p = BUHMBOX p value, p (adj) = 1 – BUHMBOX p value, log(p) = log-transformed p value (base 10), N = total 
number of individuals included in analysis, N cases = number of case individuals included in analysis, N 
controls = number of control individuals included in analysis, Z = BUHMBOX test statistic Z score value, N 
loci = number of SNPs included in analysis. 
3.3.5 Pleiotropic SNPs in LRFN5 
Conditional false discovery rate analyses, in addition to showing SNPs associated 
with chronic pain grade, indicated significant pleiotropy at the LRFN5 locus. 
3.4 Discussion 
3.4.1 Pleiotropic Loci 
LRFN5 encodes leucine-rich repeat (LRR) and fibronectin type 3 domain-
containing protein 5. Proteins in the LRFN family span the plasma membrane, 
with extracellular domains thought to participate in cell-cell interactions 
necessary for both neuronal development (Morimura et al., 2006; Nam et al., 
2011) and synapse formation (Choi et al., 2016). Lrfn5, along with another 
member of the Lrfn protein family, Lrfn2, may induce both inhibitory and 
excitatory presynaptic differentiation in nearby neuronal cells (Lin et al., 2018), 
a process that may play a critical role general brain development and function 
(Córdova-Palomera et al., 2016). This gene family is expressed primarily in the 
CNS. Polymorphic markers linked to LRFN5 have been associated with 
progressive autism and familial schizophrenia (De Bruijn et al., 2010; Xu et al., 
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2009). Neuroinflammation has also been linked to reduced expression of Lrfn5 
protein (Y. Zhu et al., 2016).  
Each of the four pleiotropic SNPs is associated with opposing directions of effect 
in MDD and CPG. This may be due to underlying differences in development of 
MDD and CPG related to brain structure and connectivity – e.g. the maintenance 
of CP has been theorised to involve neurogenesis and synaptic plasticity 
(Apkarian et al., 2011; Baliki et al., 2014; Vasic & Schmidt, 2017), and in 
contrast impaired neurogenesis has been associated with depression (Fang et al., 
2018; Jacobs et al., 2000).  
However, effect sizes compared are those in the original MDD and CPG GWASs – 
in this case the confidence intervals include zero (in CPG no SNPs were found to 
be significantly associated in the original GWAS). cFDR analyses using p values 
indicate pleiotropy in terms of significant cFDR-derived association, and new 
effect sizes are not estimated.  
3.4.2 Whole-group pleiotropy in MDD and chronic pain 
There was not significant evidence for misclassification of individuals with MDD 
as having chronic pain or vice versa, suggesting that genetic correlation and 
pleiotropy between MDD and chronic pain in this cohort is driven by whole-group 
pleiotropy. BUHMBOX is unable to distinguish between horizontal and vertical 
pleiotropy, so even though ‘true’ pleiotropy is indicated by these analyses, 
causal relationships cannot be explored. However, in analyses of rs11846556 
genotype (a pleiotropic SNP) carried out in attempts to distinguish mediated 
from horizontal pleiotropy, it was found that pleiotropy between the two 
phenotypes may be mediated (i.e., vertical), at least in relation to the LRFN5 
locus.  
 
3.4.2.1 BUHMBOX Power 
Non-significant BUHMBOX results may have been due to insufficient power. 
Power to detect moderate heterogeneity (proportion of cohort who actually are 
genetically distinct), i.e. a true underlying heterogeneity proportion of π = 0.2, 
approaches 100% when the number of cases is greater than ~1,500, or when the 
number of risk SNPs is greater than 50 (see (Han et al., 2016) Figure 3.). 
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In these analyses the minimum number of cases is 3, 455, and minimum number 
of trait-associated SNPs (risk SNPs) is 120. However, the true subgroup 
heterogeneity proportion is unknown, though it may be acceptable to assume 
moderate heterogeneity in MDD, as clinical heterogeneity in MDD can be 
estimated at 25-30% as based on the typical/ atypical symptom profile 
framework (Penninx et al., 2013). Clinical heterogeneity in chronic pain is less 
easy to estimate, as unlike in MDD there is no agreed ‘single’ clinical diagnosis of 
chronic pain and a lot of study is on chronic pain disorders rather than of chronic 
pain as a disease in itself (see 1.1.2 and 1.3.3.2.1).   
Therefore, these analyses may be underpowered due to low proportion of ‘true’ 
underlying heterogeneity, as heterogeneity proportion is unknown but estimated 
as moderate. In GWAS of CPG no SNPs were found to be associated with the trait 
at genome-wide significance, which may also mean BUHMBOX analyses are 
underpowered.  
Future steps may include use of larger, more well-powered independent chronic 
pain and MDD GWASs. Repetition of BUHMBOX analyses using depressive 
symptoms as opposed to GWASs of MDD itself may also be of interest – it may be 
more likely that chronic pain is misclassified as a depressive symptom as 
opposed chronic pain being misdiagnosed as MDD.  
Previous analyses using BUHMBOX use phenotypes such as serotypes of 
rheumatoid arthritis, which are distinct disorders with clear clinical differences, 
where participants or patients can be logically classified as a case or control. In 
contrast it may not be ideal to consider chronic pain as a case-control phenotype, 
and in addition to this, chronic pain phenotyping varies widely (see 1.1.2). 
Additionally, BUHMBOX is not agnostic: this analysis only tests for clinical 
heterogeneity with respect to a second phenotype chosen a priori. In other 
words, it is not possible to test for presence of any clinical heterogeneity in 










Chapter 4 Common Genetic Variation Associated with 
Chronic Pain and Shared with Phenotypes of Interest 
4.1 Introduction 
This chapter specifically addresses objectives 1: To uncover common genetic 
variation associated with chronic pain phenotypes, and 2: To investigate genetic 
correlation and pleiotropy between MDD and chronic pain. Analyses carried out 
in this chapter have been published as part of an article in PLOS Genetics 
(Johnston, Adams, Nicholl, Ward, Strawbridge, Ferguson, et al., 2019). 
As previously discussed, (1.1, 1.3.3, 1.3.4), chronic pain is a complex trait, and 
few large-scale genetic studies of chronic pain exist. Chapter 3 made use of one 
of these few large-scale GWAS studies of chronic pain (defined as chronic pain 
grade) along with existing MDD GWAS summary statistics to investigate 
pleiotropy, and to identify SNPs associated with Chronic Pain Grade. In contrast, 
in this chapter a new chronic pain phenotype, MCP, was defined in UK Biobank 
(see 2.3.2.1), and a GWAS was carried out to find common genetic variation 
(SNPs) associated with MCP. The summary statistics generated from this GWAS 
were then used to conduct linkage disequilibrium score regression analyses 
(LDSR) (2.2.5) examining genetic correlation between MCP and a range of other 
traits, including MDD. 
It can be argued that to understand genetic variation that contributes to 
vulnerability to, development and maintenance of chronic pain it is more 
powerful to examine measures of chronic pain as complex neuropathological 
traits in themselves. This contrasts with GWAS of chronic pain in specific body 
sites, or of disorders and diseases where chronic pain is a major component such 
as fibromyalgia and migraine. This view of chronic pain as a disease entity is also 
in line with recent IASP definitions of Chronic Primary Pain for the ICD-11 
(Nicholasa et al., 2019; Treede et al., 2019), and an IASP update on the 
definition of pain in general (see also 1.1.1). MCP represents a quasi-
quantitative chronic pain phenotype, with the aim of examining underlying 
chronic pain on a continuous scale rather than by threshold, specific body site, 
or associated specific chronic pain disorder. In keeping with recent IASP 
publications and previous research on chronic pain cut off points, derivation of 
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the phenotype MCP aims to capture underlying vulnerability to the development 
of chronic pain and potential genetic factors associated with maintenance of 
chronic pain. 
The range of phenotypes chosen for genetic correlation analyses was based on 
previous association evidence (see 1.1.5) and represents a small fraction of all 
possible correlations that could be calculated. Exploring the full constellation of 
genetic correlations between this new chronic pain phenotype and other traits 
and disorders is of interest, but somewhat beyond the scope of this thesis where 
the main genetic correlation-addressing objective is in relation to major 
depression.  
4.2 Methods 
4.2.1 Chronic Pain Phenotyping in UK Biobank 
UK Biobank participants were asked via a touchscreen questionnaire at baseline 
about “pain types experienced in the last month” (field ID 6159), with possible 
answers: ‘None of the above’; ‘Prefer not to answer’; pain at seven different 
body sites (head, face, neck/shoulder, back, stomach/abdomen, hip, knee); or 
‘all over the body’.  
MCP was defined as the sum of body sites at which chronic pain (at least 3 
months duration) was recorded: 0 to 7 sites. Chronic pain phenotyping in UK 
Biobank is discussed further in 2.3.3.1. Those who answered that they had 
chronic pain ‘all over the body’ were excluded from the MCP GWAS, as were 
10,000 randomly selected individuals reporting no chronic pain. These 
participants were used in a secondary GWAS of chronic widespread pain in this 
chapter, and as cases and controls, respectively, in subsequent polygenic risk 
score (PRS) analyses (see Chapter 5).   
4.2.2 Genome-Wide Association Study of Multisite Chronic Pain 
SNPs with an imputation quality score of less than 0.3, Minor Allele Frequency 
(MAF) < 0.01 and Hardy-Weinberg equilibrium (HWE) test p < 10-6 were removed 
from the analyses. Participants whose self-reported sex did not match their 
genetically determined sex, those who had putative sex-chromosome aneuploidy, 
those considered outliers due to missing heterozygosity, those with more than 10% 
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missing genetic data and those who were not of self-reported white British 
ancestry were excluded from analyses. A list of such “poor quality” samples (due 
to these reasons) was derived by Bycroft et al (Bycroft et al., 2018) and was 
used here as part of genetic quality control. Briefly, putative sex chromosome 
aneuploidy was defined by visual inspection of scatterplots of mean log2 ratio 
(L2R) on X and Y chromosomes, and 652 UKB participants meet these criteria for 
putative sex-chromosome aneuploidy (Supplemental Information S 3.6 (Bycroft 
et al., 2018)). Samples with a population-structure-adjusted heterozygosity 
value above the mean heterozygosity value (0.1903) and missing rate greater 
than 0.05 as computed using PLINK ‘—miss’ command were also flagged as 
potentially poor quality ((Bycroft et al., 2018); 968 such samples are listed in 
this paper’s Supplemental Information S 3.5.3). 
These exclusions are a standard part of GWAS analysis (Coleman et al., 2016; 
Marees et al., 2018), and represent indications of sample contaminations, 
genotyping error, inbreeding, markers under significant selection, or markers 
which are rare variants – these conditions would mean the statistical 
assumptions necessary for GWAS would be violated. These genetic quality 
control measures left a subset of “hard-called” PLINK-format genotypes (SNPs) 
of 615, 839 (see BOLT-LMM manual 5.1.2) on which the mixed model was built. 
GWAS was then carried out using BOLT-LMM under an infinitesimal model (see 
2.2.1.3), adjusting for age, sex and chip (genotyping array). Relatedness and 
population stratification were adjusted for within the BOLT-LMM model via use 
of a Genetic Relatedness Matrix (GRM), and age was found to have a relationship 
with MCP conforming to linearity. Genomic risk loci were identified via the 
definition employed by FUMA (Watanabe et al., 2017).  
4.2.3 Linkage-Disequilibrium Score Regression 
Genetic correlations between MCP and 22 complex traits selected on the basis of 
epidemiological evidence or suspected relationship with chronic pain (1.1.5) 
were calculated using LDSR (Bulik-Sullivan et al., 2015), implemented either 
using the ‘ldsc’ package (Bulik-Sullivan et al., 2015) and downloaded publicly-
available summary statistics and summary statistics from in-house analyses or 
using LD Hub (Zheng et al., 2017). LD Hub datasets from the categories 
Psychiatric, Personality, Autoimmune and Neurological were selected and 
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datasets with the attached warning note ‘Caution: using this data may yield less 
robust results due to minor departure from LD structure’ were excluded from 
the analyses. Where multiple GWAS datasets were available for the same trait, 
the one with the largest sample size and/or European ancestry was retained 
with priority given to European ancestry, for example, for PTSD multiple 
different ancestry groups were available and European was selected.  
Genetic correlation between MCP and between von Korff chronic pain grade (see 
1.1.2 &  2.3.2.2) was also calculated. A secondary GWAS of participants with 
chronic pain all over the body (termed chronic widespread pain, CWP) versus 
10,000 chronic pain-free controls was also carried out (total N = 15,258), and 
these summary statistics were used in LDSR analyses to calculate genetic 
correlation between CWP and MCP.   
P values for heritability are estimated according to formulae given by Altman & 
Bland (Altman & Bland, 2011).  
4.2.4 Phenotypic Correlations 
Phenotypic information on BMI was obtained from baseline measure of BMI (data 
field 21001). For MDD, anxiety, schizophrenia, autism spectrum disorder, 
anorexia nervosa and bipolar disorder, UK Biobank data field 20544 “mental 
health problems ever diagnosed by a professional” (part of the Thoughts and 
Feelings questionnaire in online follow-up) was used to derive a dichotomous 
phenotype value. For subjective well-being the UK Biobank data field 20459 
“general happiness with own health”, a Likert-like self reported measure of 
subjective wellbeing where 1 = extremely happy and 6 = extremely unhappy, 
was used to derive a continuous measure of subjective well-being.  
Phenotypic information for the traits rheumatoid arthritis, asthma, primary 
biliary cirrhosis/cholangitis, inflammatory bowel disease, Crohn’s disease, 
ulcerative colitis and Parkinson disease was derived from the UK Biobank data 
field 20002 “non-cancer illness codes, self-reported”. Phenotypic information for 
PTSD, a psychiatric cross-disorder phenotype, neuroticism, celiac disease, and 
depressive symptoms was not available within datasets associated with UKB 
projects to which access was available to for this PhD project.   
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For all available traits, those who answered, “prefer not to answer”, “do not 
know”, or who did not have complete phenotypic information on both traits to 
be used in the phenotypic correlation coefficient calculation were removed 
before estimation of phenotypic correlation.  
For continuous traits, phenotypic correlation coefficients between the trait and 
MCP were calculated as Pearson’s rho. For dichotomous traits a special case of 
Pearson’s rho, the point biserial correlation coefficient, was calculated to give 
an estimate of phenotypic correlation. The point biserial correlation is 
appropriate for use in estimating correlation when one variable is dichotomous 
and the other continuous (Kornbrot, 2014; Sheskin, 2000). Note that sample size 
varied depending upon availability of variables (phenotypic information) in UKB 
datasets available for use in this PhD project, and due to the fact psychiatric 
trait phenotype information was derived from the Thoughts and Feelings online 
follow-up data which was only completed by a subset of the UK Biobank sample 
(max N = 157, 366) (see also 2.3.4).  
4.3 Results 
4.3.1 Description of Participants  
A total of 387, 649 UK Biobank participants with a mean age of ~56 years old and 
53.9% of whom were female were included in the MCP GWAS analysis (Table 4.1). 
MCP total N (%) male N (%) female N (%) age (mean) 
0 218622 (56.4) 105474 (48.2) 113148 (51.8) 56.71 
1 92718 (23.92) 42734 (46.1) 49984 (53.9) 57.03 
2 44612 (11.51) 18612 (41.7) 26000 (58.3) 57.29 
3 20147 (5.2) 7771 (38.6) 12376 (61.4) 57.65 
4 8289 (2.14) 2970 (35.8) 5319 (64.2) 57.48 
5 2503 (0.65) 780 (31.2) 1723 (68.8) 56.53 
6 652 (0.17) 181 (27.8) 471 (72.2) 56.2 
7 106 (0.03) 34 (32.1) 72 (67.9) 56.17 
total 387649 178556 (46.1) 209093 (53.9) 56.91 
Table 4. 1: Age, sex and MCP phenotype value of UK Biobank participants included in the MCP GWAS.  
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MCP = MCP phenotype value (0 = no chronic pain). 
4.3.2 Common genetic variants and genes associated with MCP 
MCP was found to have a moderate SNP-heritability value (h2SNP = 10.2%). 
Genome-wide association analyses showed 76 SNPs were associated with MCP at 
a genome-wide significance p value threshold of 5 x 10-8, spread across 39 
genomic risk loci (Table 4.2). 143 genes were also found to be significantly 
associated with MCP in gene-level analyses (Appendix 1).  
Genomic Risk 
Locus 
rsID (Lead SNP) Chr Pos GWAS p 
1 rs10888692 1 50991473 5.30E-09 
2 rs197422 1 112317512 2.00E-09 
3 rs59898460 1 150493004 9.20E-12 
4 rs12071912 1 243241614 5.30E-09 
5 rs4852567 2 80703379 4.30E-08 
6 rs7628207 3 49754970 8.40E-10 
7 rs28428925 3 107294634 1.40E-09 
8 rs6770476 3 136073920 9.40E-09 
9 rs34811474 4 25408838 2.70E-11 
10 rs13135092 4 103198082 1.50E-13 
11 rs13136239 4 140908755 3.60E-08 
12 rs6869446 5 65570607 9.50E-09 
13 rs1976423 5 104042643 8.20E-09 
14 rs17474406 5 122732342 2.40E-08 
15 rs1946247 5 160836620 4.90E-08 
16 rs11751591 6 33794215 2.70E-10 
17 rs6907508 6 34592090 1.10E-08 
18 rs6926377 6 145105354 7.90E-09 
19 rs10259354 7 3487414 3.00E-08 
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20 rs7798894 7 21552995 1.60E-08 
21 rs6966540 7 95727967 3.30E-08 
22 rs12537376 7 114025053 1.70E-09 
23 rs11786084 8 142651709 2.30E-08 
24 rs10992729 9 96181075 1.10E-09 
25 rs6478241 9 119252629 3.10E-09 
26 9:140251458_G_A 9 140251458 5.30E-14 
27 rs2183271 10 21957229 3.10E-08 
28 rs11599236 10 106454672 3.30E-08 
29 rs12765185 10 134977077 3.90E-08 
30 rs61883178 11 16317779 2.00E-10 
31 rs1443914 13 53917230 2.80E-11 
32 rs12435797 14 73797669 3.70E-08 
33 rs2006281 14 104327732 3.40E-08 
34 rs2386584 15 91539572 2.80E-11 
35 rs285026 16 77100089 1.90E-08 
36 rs11871043 17 43172849 1.70E-09 
37 rs11079993 17 50301552 5.70E-12 
38 rs62098013 18 50863861 4.00E-11 
39 rs2424248 20 19650324 3.70E-10 
Table 4. 2: Genomic Risk Loci. 








Figure 4. 1 : MCP GWAS Manhattan plot 
-log10P-value = transformed p values (-log base 10) for SNP-trait association. The red dotted line indicates 
the significance threshold (~7 i.e. p < 5 x 10-8). 
 
Genes associated with MCP were also found to be significantly enriched in 
biological pathways through MAGMA gene set analyses (see 2.3.1.1). These 
MsigDB (Molecular Signatures Database) (Liberzon et al., 2015) C2 (curated gene 
set) canonical pathways were DCC-mediated attractive signalling, PLC-β-
mediated events, BCR signalling and α6β4 and α6β1 integrin signalling (Appendix 1 
Table A1.3). Function of these genes is also summarised in 4.4.3.3. 
4.3.3 Genetic Correlations 
MCP was significantly genetically correlated with a range of psychiatric disorders 
and phenotypes, notably MDD, depressive symptoms, anxiety, PTSD, and 
schizophrenia (Table 4.3, Figure 4.1). MCP was not found to be significantly 
genetically correlated with inflammatory bowel diseases (Crohn’s disease, 
ulcerative colitis, inflammatory bowel disease) or other autoimmune diseases 
Celiac disease and systemic lupus erythematosus. The only psychiatric 
phenotype examined which was not significantly genetically correlated with MCP 
was bipolar disorder. Rheumatoid arthritis, an autoimmune disease associated 
with significant chronic pain (Walsh & McWilliams, 2014), was significantly 
genetically correlated with MCP, but with an rg value of only 16% (Table 4.3). In 
contrast genetic overlap between MCP and MDD, depressive symptoms, and 
neuroticism ranged from 40-59% (Table 4.3). 
There were no genome-wide significant SNP associations in the second chronic 
widespread pain (CWP) GWAS, likely due to the fact the sample size is too small 
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for significant power, but the summary statistics could still be taken forward for 
LDSR analysis – this is another route to assessing the relationship between 
chronic widespread pain and MCP, in contrast to the polygenic risk score 
analyses described in Chapter 5. 
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Trait rg se z h2 h2 p (FDR) source PMID Category p p (FDR) 
MDD 0.53 0.03 18.92 0.077 1.25 x 10-47 PGC 29700475 psychiatric 7.68 x 10-
80 
1.69 x 10-78 
Depressive 
symptoms 
0.59 0.03 17.16 0.047 6.87 x 10-29 ld_hub 27089181 psychiatric 5.63 x 10-
66 
6.19 x 10-65 
BMI 0.31 0.02 15.69 0.138 5.42 x 10-59 GIANT 
consortium 
25673413 anthropometric 1.90 x 10-
55 
1.39 x 10-54 
Neuroticism 0.4 0.03 11.9 0.089 3.66 x 10-26 ld_hub 27089181 personality 1.24 x 10-
32 
6.82 x 10-32 
Subjective well 
being 
-0.36 0.04 -8.94 0.025 2.77 x 10-32 ld_hub 27089181 psychiatric 3.78 x 10-
19 
1.66 x 10-18 
Low Relative 
Amplitude 
-0.3 0.05 -6.37 0.053 3.03 x 10-13 In-house 
analysis 
30120083 circadian 1.91 x 10-
10 
7.00 x 10-10 
Rheumatoid 
Arthritis 
0.16 0.03 4.7 0.160 7.41 x 10-8 ld_hub 24390342 autoimmune 2.64 x 10-
6 
8.30 x 10-6 
Anxiety (Case-
Control) 
0.49 0.11 4.53 0.081 0.00405 PGC 26754954 psychiatric 5.91 x 10-
6 
1.63 x 10-5 
Schizophrenia 0.1 0.03 4.08 0.443 6.56 x 10-79 PGC 25056061 psychiatric 4.50 x 10-
5 
1.10 x 10-4 
Asthma 0.22 0.06 3.63 0.123 3.53 x 10-6 ld_hub 17611496 autoimmune 3.00 x 10-
4 




0.13 0.04 3.54 0.172 7.89 x 10-36 ld_hub 23453885 psychiatric 4.00 x 10-
4 
8.00 x 10-4 
PTSD (European 
Ancestry) 




-0.1 0.04 -2.22 0.451 9.38 x 10-17 ld_hub NA psychiatric 0.026 0.0443 
Primary biliary 
cirrhosis 
0.1 0.04 2.17 0.376 1.11 x 10-8 ld_hub 26394269 autoimmune 0.03 0.047 
Anorexia 
Nervosa 





0.05 0.03 1.75 0.333 9.17 x 10-21 ld_hub 26192919 autoimmune 0.08 0.1101 
Celiac disease -0.07 0.05 -1.49 0.314 2.50 x 10-10 ld_hub 20190752 autoimmune 0.136 0.1756 
Crohn’s disease 0.04 0.03 1.35 0.504 2.65 x 10-17 ld_hub 26192919 autoimmune 0.179 0.2125 
Systemic lupus 
erythematosus 
0.06 0.04 1.33 0.390 9.77 x 10-9 ld_hub 26502338 autoimmune 0.184 0.2125 
Ulcerative 
colitis 
0.04 0.04 1.08 0.257 1.19 x 10-14 ld_hub 26192919 autoimmune 0.281 0.3094 





0.0 0.04 0.05 0.409 0.000761 ld_hub 19915575 neurological 0.961 0.9612 
Table 4. 3: Genetic correlation results.  
rg = genetic correlation coefficient value, se = standard error of correlation value, z = z value, h2 = SNP-
heritability value, h2 p (FDR) = p value (FDR-corrected) for SNP-heritability, source = source of GWAS 
summary statistics, PMID = PubMed ID of associated paper (if applicable), p = p value for genetic 





























Trait rg rp p N 
MDD 0.53 0.15 < 2 x 10-16 155570 
Depressive symptoms 0.59 NA NA NA 
BMI 0.31 0.148 < 2 x 10-16 491364 
Neuroticism 0.4 NA NA NA 
Subjective well being -0.36 0.26 < 2 x 10-16 155653 
Low Relative Amplitude -0.3 -3.13 x 10-4 0.925 91077 
Rheumatoid Arthritis 0.16 0.055 < 2 x 10-16 155570 
Anxiety (Case-Control) 0.49 0.1039 < 2 x 10-16 155570 
Schizophrenia 0.1 -0.0032 0.212 155570 
Asthma 0.22 0.06 < 2 x 10-16 155570 
PGC cross-disorder analysis 0.13 NA NA NA 
PTSD (European Ancestry) 0.41 NA NA NA 
Autism spectrum disorder -0.1 0.0075 0.0033 155570 
Primary biliary cirrhosis 0.1 0.007 0.0032 155570 
Anorexia Nervosa -0.06 0.018 4.35 x 10-13 155570 
Inflammatory Bowel Disease (European 
Ancestry) 
0.05 0.007 0.0045 155570 
Celiac disease -0.07 NA NA NA 
Crohn’s disease 0.04 0.018 1.04 x 10-12 155570 
Systemic lupus erythematosus 0.06 0.02 1.73 x 10-18 155570 
Ulcerative colitis 0.04 0.014 1.44 x 10-8 155570 
Bipolar disorder -0.02 0.015 9.02 x 10-9 155570 
Parkinson’s disease 0.0 0.013 3.71 x 10-7 155570 
Table 4. 4 : Phenotypic correlations between MCP and traits of interest 
rp = phenotypic correlation coefficient (Pearson’s rho/ point biserial correlation coefficient), rg = genetic 
correlation coefficient for comparison, p = p value associated with phenotypic correlation coefficient, N = 
sample size for phenotypic correlation estimation. 
The genetic correlation between von Korff chronic pain grade and MCP was large 
and significant at rg = -0.78 (p = 3.46 x 10-13), but negative (Figure 4.1). The 
genetic correlation between chronic widespread pain and MCP was significant 




Figure 4. 2: Genetic correlations between MCP and a range of traits.  
GIP1 = genetically independent phenotype 1 (see Appendix 3). CWP = chronic widespread pain. Error bars 
indicate 95% confidence interval (estimated as +/- 2 x standard error of the genetic correlation value rg). 
 
Overall, psychiatric phenotypes, particularly MDD and depressive symptoms, 
shared the largest and most statistically significant proportions of common 
genetic variation with MCP. Many conditions commonly associated with 
significant chronic pain, including inflammatory bowel diseases and systemic 
lupus erythematosus, showed no genetic overlap with MCP. 
 
4.4 Discussion 
4.4.1 Genetic Correlations with MCP and Traits of Interest 
A range of traits of interest, either found previously to be associated with 
chronic pain in the literature, or with potential involvement of or association 
with chronic pain but with inconclusive evidence from past epidemiological 
studies, were chosen for LD-score regression analysis (see 1.1.5). 
4.4.1.1 Psychiatric Traits 
The psychiatric phenotype most significantly genetically correlated with MCP 
was MDD (rg = 0.53) while the largest significant genetic correlation coefficient 
was for MCP and depressive symptoms (rg = 0.59). This matches closely with a 
genetic correlation value for chronic pain grade and MDD found by McIntosh et al 
via a mixed-modelling approach (rho = 0.53). MCP was also positively genetically 
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correlated with neuroticism (rg = 0.40), anxiety (rg = 0.49), schizophrenia (rg = 
0.10), cross-disorder psychiatric phenotype (rg = 0.13) and PTSD (rg = 0.41). 
Significant negative genetic correlation was found between MCP and anorexia 
nervosa, autism spectrum disorder, and between MCP and subjective well-being. 
There was no significant genetic correlation between MCP and bipolar disorder. 
The genetic overlap between schizophrenia and MCP is somewhat in contrast to 
findings indicating people with schizophrenia tend to show less sensitivity to 
ongoing or chronic pain compared to the general population (1.1.5), and may 
indicate that these differences could be due to environmental factors, including 
difficulties in reporting pain for people with schizophrenia. A lack of significant 
genetic correlation between bipolar disorder and MCP may also indicate non-
genetic factors drive the overlap in bipolar disorder and chronic pain. The 
genetic overlap between MCP and psychiatric disorders and traits, particularly 
MDD and depressive symptoms, emphasises the psychological and affective 
component to chronic pain.  
4.4.1.2 Autoimmune Traits 
Autoimmune disorders and disorders with a significant autoimmune component 
such as rheumatoid arthritis, asthma and primary biliary cholangitis showed 
positive genetic correlation with MCP. However, gastrointestinal autoimmune 
disorders ulcerative colitis and Crohn’s Disease did not. This suggests that 
distinct genetic variation and mechanisms underlie chronic pain associated with 
these disorders compared to those outwith the digestive system. Pain related to 
inflammatory bowel diseases may represent something less ‘chronic’ and more 
‘on-going acute’, as stricture, abscesses and partial or complete obstruction of 
the small bowel result in pain (Docherty et al., 2011). Structural and functional 
brain changes associated with the transition to chronic pain may also play a less 
central role in gastrointestinal autoimmune disorder-associated pain, due to 
potential for the enteric nervous system to act independently from the CNS, and 
the role of the gut-brain axis in chronic abdominal pain (Carabotti et al., 2015; 
Cryan & Dinan, 2012). In addition, Crohn’s disease is associated with pain not 
only viscerally and in relation to disease exacerbation, strictures and abscesses, 
but also with pain in the joints (arthritis) and back, which for some individuals 
never goes away even with remission or successful management of active 
Crohn’s disease (Norton et al., 2017). A GWAS of Crohn’s or other inflammatory 
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bowel disease may therefore not capture genetic variation involved in pain and 
chronic pain, but instead significantly associated variation is related to disease 
activity and inflammation more specific to the digestive system.  
There was no significant genetic correlation between MCP and systemic lupus 
erythematosus (SLE). This may be, again, because pain associated with SLE is 
complex and multifactorial, and can vary between individuals with the same SLE 
diagnosis (Waldheim et al., 2018). SLE involves multiple body systems – specific 
types of arthritis can be involved, neuropathic pain or headache syndromes are 
often experienced, and SLE is also associated with pericarditis and Raynaud’s 
(Fava & Petri, 2019). Pain therefore likely depends at least in part on organ 
system and active disease, and SNPs associated with SLE will not necessarily be 
associated with chronic pain. Similarly to other conditions (Crohn’s, 
osteoarthritis, rheumatoid arthritis), pain in SLE has been found not to “track 
with disease activity” (Fava & Petri, 2019). 
4.4.1.3 Parkinson’s Disease  
Chronic pain is often reported in those with neurological diseases (Borsook, 
2012), including Parkinson’s disease (Ford, 2012; Simuni & Sethi, 2008), reaching 
prevalence of 60% in certain patient populations. However, no significant 
genetic correlation was found between Parkinson’s disease and MCP (p = 0.96), 
suggesting other factors associated with Parkinson’s disease may contribute to 
chronic pain, as opposed to shared genetic contributions to risk for both 
disorders. Some of the pain experienced by those with Parkinson’s disease may 
also be distinct from an unexplained chronic pain or widespread chronic pain, 
and may be related to muscle rigidity, dystonia, reduced movement in the joints, 
changes in posture and associated radicular pain due to trapped nerves – this 
pain could be viewed as chronic in the sense that potentially causal contributory 
factors are chronic in nature but may be distinct from chronic pain without 
comorbid Parkinson’s disease. Again, GWAS of Parkinson’s disease may reveal 
SNPs associated with disease activity and progression, rather than with chronic 
pain experienced as part of Parkinson’s disease. 
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4.4.1.4 Neurodevelopmental, Circadian and Anthropometric Traits 
Significant negative genetic correlation was found between autism spectrum 
disorder and MCP. This negative genetic correlation between autism spectrum 
disorder and MCP may suggest differences observed between autistic people and 
the general population in terms of integrating bodily signals (interoception) lead 
to reduced experience of or reporting of chronic pain. Alternatively, increased 
prevalence of autism spectrum disorder diagnosis in men (Halladay et al., 2015), 
who tend to have chronic pain at reduced rates compared to women (see 1.2.2), 
may drive this negative genetic correlation value. 
Significant negative genetic correlation was found for low relative amplitude and 
MCP, which is unexpected: low relative amplitude is a circadian rhythmicity and 
health phenotype that indicates poor circadian regulation, which is associated 
with a range of poor health outcomes. A PRS for low relative amplitude was 
significantly associated with mood instability, MDD and neuroticism (Ferguson et 
al., 2018). The fact that shared common genetic variation between MCP and low 
relative amplitude is associated with opposing directions of effect in these two 
disorders may indicate that the association between poor sleep and circadian 
rhythm and chronic pain is instead driven by other lifestyle factors, rather than 
shared genetic factors predisposing to increased risk for both chronic pain and 
low relative amplitude. There may also be a significant underrepresentation of 
people with chronic illness and chronic pain amongst the sub-sample of UK 
Biobank (N = 71, 500) who took part in activity monitoring, introducing potential 
bias into SNP effect value estimates. 
Significant positive genetic correlation was found between BMI and MCP, 
indicating that a moderate proportion of variants are shared between MCP and 
BMI, and contribute to an increase in both BMI and chronic pain. This is in line 
with work linking increased BMI (obesity) and adiposity to immune activation and 
chronic inflammation, which play a key role in pain perception and development 
of chronic pain.  
4.4.1.5 Chronic Widespread Pain 
Chronic widespread pain and MCP were strongly positively correlated, but the 
genetic correlation value was significantly different to 1– this may be due to 
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small sample size of the CWP GWAS or may mean that these are subtly different 
phenotypes with a large genetic overlap. For example, Nicholl et al found that 
multisite pain was associated with MDD and bipolar disorder severity except at 
the ‘extreme’ – chronic pain ‘all over the body’ (= chronic widespread pain) was 
less strongly associated with MDD and bipolar disorder severity in comparison to 
chronic pain at 4-7 body sites. Other work also suggests that chronic widespread 
pain represents a distinct phenotype in comparison to chronic pain in general 
(Gerhardt et al., 2016b; Mansfield et al., 2017). However, it may be the true 
‘clinical reality’ that there are no natural or logical cut-off points for localised 
versus widespread chronic pain (Kamaleri et al., 2008). Traits with lower genetic 
correlation values are commonly used as proxies for one another e.g. 
educational attainment as proxy for intelligence (rg ~ 70%) (Savage et al., 2018), 
or current age as a proxy for life span (rg ~40-70%) (K. M. Wright et al., 2019).  It 
may therefore be acceptable to say rg = 0.83 means that these GWASs capture 
genetic variation associated with the same underlying construct, and this 
definition of chronic widespread pain (chronic pain all over the body for 3+ 
months) could be added as the maximum trait value of MCP.  
4.4.1.6 Chronic Pain Grade 
Genetic correlation coefficient value between MCP and CPG was significant and 
large, but negative. This suggests most shared SNPs between the two conditions 
are associated with opposing direction of effect i.e., most SNPs are associated 
with an increase in trait value in MCP and decrease in trait value in CPG, or vice 
versa. Another important difference in the GWASs of the two chronic pain traits 
is that CPG was adjusted for both body-mass index (BMI) and an employment-
related variable (manual labour). This difference may drive the unexpected 
differences in effect sign for MCP and CPG-associated variants, and a difference 
in trait-associated variants may additionally be generated because BMI is also 
heritable and is genetically correlated (as demonstrated above) with chronic 
pain.  
Adjusting for genetically correlated traits, such as adjusting for BMI in a GWAS of 
chronic pain, can bias results (Aschard et al., 2015; Vansteelandt et al., 2009). If 
the relationship between a genetic variant (SNP), covariate of interest, and 
outcome (i.e. GWAS trait) is as shown in Figure 4.2 A below, then the adjusted 
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GWAS estimate of effect size represents the direct effect (or measures directly 
the magnitude of association) between SNP and outcome trait, and the 
unadjusted GWAS estimate gives a total effect (direct + indirect) of SNP on 
outcome trait – in every other situation or relationship type between SNP, 
covariate and outcome trait (Figure 4.2 B-D) the adjusted estimate may be 
biased (Aschard et al., 2015).  
 
Figure 4. 3: Sources of bias in GWAS.  
Based on Figure 1 (Aschard et al., 2015). Possible relationships between SNP, covariate and outcome 
variable in GWAS. 
Aschard et al suggest that adjustment for environmental or demographic traits 
would not likely introduce bias as they do not have genetic associations – 
however, recent GWASs including of demographic traits such as socioeconomic 
status (Hill et al., 2019) indicate that genetic variation is in fact associated with 
traits previously considered environmental/ demographic and therefore ‘safe’ as 
GWAS covariates. Adjustment for manual labour may therefore also introduce 
bias into GWAS effect size estimates in the Pfizer-23andMe CPG GWAS. 
As a sensitivity analysis, a second MCP GWAS was carried out, identical in every 
way to the main analyses except with adjustment for BMI – the genetic 
correlation results with CPG remained the same, suggesting adjustment for 
manual labour may contribute to the negative correlation value. 
Departure of the genetic correlation value from 1 may also be due to differences 
in the trait concepts of CPG and MCP themselves – CPG takes account of 
disability and the impact of chronic pain on daily life and functioning (Smith et 
al., 1997; Von Korff et al., 1992), whereas MCP simply sums chronic pain sites. It 
has been theorised that phenotypic correlations between traits tend to reflect 
genetic correlations, to the extent that phenotypic correlations can be used as 
proxies of genetic correlation (Cheverud’s conjecture) – if phenotypic correlation 
between CPG and MCP were found to be negative, a negative genetic correlation 
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as found here may not be unexpected after all. This was explored using 
Generation Scotland participant data (see Appendix 2), where it was found that 
phenotypic correlation between CPG and MCP was significant and positive (~0.3). 
This again suggests that there may be potential bias in the GWAS output of the 
23andMe-Pfizer GWAS due to the inclusion of manual labour as a covariate, 
which may be the cause of unexpected negative genetic correlation between 
CPG and MCP. 
4.4.2 Heritability and Polygenicity of Multisite Chronic Pain 
MCP was found to be moderately heritable. This reduction in heritability value 
when comparing SNP-heritability (a narrow-sense heritability) with twin study 
derived estimates of heritability (a broad sense heritability measure) is to be 
expected (see 2.2.1.1). This heritability value is of similar magnitude to recent 
SNP-heritability estimates of MDD (8.9% (Howard et al., 2019)). Results also 
indicated a high degree of polygenicity, shown through MAGMA gene-level 
analysis. 
4.4.3 Genes of Interest Associated with MCP 
Genes found to be associated with MCP through MAGMA gene-level analyses 
suggested CNS involvement in chronic pain, with genes found to be involved in 
processes such as synaptic connectivity (SDK1) (Yamagata & Sanes, 2008) and 
glial-guided neuronal migration (ASTN2) (Wilson et al., 2010). Genes associated 
with MCP were also involved in Notch signalling pathway and implicated in 
neurogenesis and CNS plasticity (NUMB, MAML3) (Ables et al., 2011; Andersson 
et al., 2011; Kitagawa, 2015), in non-UK Biobank studies. Several MCP-associated 
genes were also involved in immune processes, cell cycle regulation, protein 
degradation, and apoptosis. A full list of genes associated with MCP is discussed 
in Appendix 1. 
4.4.3.1 Associations with Other Chronic Pain Conditions 
Five of the 143 genes significantly associated with MCP are also listed in the 
Human Pain Genetics Database (Meloto et al., 2018), an online repository 
documenting genetic contributors to chronic pain and chronic pain conditions. 
These genes, ASTN2, SLC24A3, RABGAP1L, F2 and FHL5 have been previously 
associated with migraine (Anttila et al., 2013; Gormley et al., 2016; Rodriguez-
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Acevedo et al., 2015), a chronic pain condition where large and well-powered 
GWAS have been previously carried out. DCC and SOX5 (which jointly functions 
with SOX6 in chondrogenesis) have been associated with chronic back pain (Suri 
et al., 2018), GABRB3 (encoding one of three beta subunits of the GABA A 
receptor along with GABRB2) has been associated with migraine and fibromyalgia 
(Zorina-Lichtenwalter et al., 2016). AMIGO3, SLC39A8, ECM1, EXD3 and FOXP2 
have been associated with a musculoskeletal pain phenotype (Tsepilov et al., 
2020) (see also Appendix 3) in addition to MCP.  
Genes associated with chronic pain related phenotypes in previous candidate 
gene studies including COMT, OPRM1, GCH1 and BDNF were not found to be 
associated with MCP – this could be due to the pitfalls of candidate gene studies 
generally, and is in keeping with general inconsistency/ lack of replication for 
candidate gene study findings (Mogil, 2012). For example, the association 
between COMT and individual differences in pain perception was originally found 
in studies of healthy individuals or fibromyalgia patients exposed to pain in an 
experimental setting, with relatively small sample sizes N ~ 29-202 (Diatchenko 
et al., 2005; Martínez-Jauand et al., 2013; Zubieta et al., 2003), which were 
likely not powerful enough for discovery of trait-associated common genetic 
variation. In addition, while these studies may indicate pain perception 
differences associated with COMT haplotypes or polymorphisms, pain perception, 
particularly in response to acute pain challenges delivered in an experimental 
setting, may not be equivalent to chronic pain.  
None of the genes involved in CIP, erythromelalgia or PEPD (SCN9A, FAAH, 
NTRK1, PRDM12) were found to be associated with MCP. This suggests that CIP 
and chronic pain (MCP) are distinct, despite the role CIP-associated genes play in 
the perception of pain (as discovered through mutations leading to CIP), this is 
different to chronic pain.  
4.4.3.2 Associations with Other Disorders 
Several MCP-associated genes have been previously implicated in other traits 
and disorders, which was explored by manually searching GeneCards (Stelzer et 
al., 2016) and Online Mendelian Inheritance in Man (OMIM) (McKusick-Nathans 
Institute of Genetic Medicine, Johns Hopkins University) databases with gene 
names as search terms. Disorders such as Brugada Syndrome 9 and Spinal ataxia 
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19 & 22 (KCND3) (Duarri et al., 2012; Giudicessi et al., 2011; Y. C. Lee et al., 
2012), systemic lupus erythematosus (SLE) (Y RNAs) (Kowalski & Krude, 2015), 
Joubert syndrome 31 and short-rib thoracic dysplasia 13 (CEP120) (Roosing et al., 
2016), were found to be associated with genes which were also associated with 
MCP (relevant genes given in parentheses). Genes associated with MCP were also 
found to be associated with Amyotrophic lateral sclerosis (ALS) (FAF1) (Baron et 
al., 2014), Urbach-Wiethe disease (ECM1) (Hamada et al., 2003; Oyama et al., 
2003), cohesinopathies associated with intellectual disability as well as Cornelia 
de Lange Syndrome (STAG1) (Lehalle et al., 2017; Liu & Krantz, 2009), split 
hand/ split foot malformation (DYNC1I1) (S. H. Roberts et al., 1991; Tayebi et 
al., 2014), and a wide range of cancers (PRC1) (J. Li et al., 2018). Schizophrenia 
(GABRB2) (Laroche et al., 2008; T. Li et al., 2013; Lo et al., 2007; Petryshen et 
al., 2005; Sanjuá et al., 2006; Tolosa et al., 2010; Yeung et al., 2018; Yin et al., 
2018), intellectual disability and epilepsy (GABRB2) (Srivastava, Cohen, Pevsner, 
et al., 2014), and neuroleptic-induced tardive dyskinesia (GABRB2) (Inada et al., 
2008) were also found to be associated with MCP-related genes.  
These disorders can be roughly grouped according to pathogenic similarities, 
which short-rib thoracis dysplasias, electrodactyly and Urbach-Wiethe disease 
involving musculoskeletal and soft tissue malformations. Short-rib thoracic 
dysplasias are a group of autosomal recessive ciliopathies, associated with short 
ribs, abnormalities of the hip joint, and potential involvement of other organs 
and tissues (Schmidts et al., 2013). Split hand/ split foot malformation 
(electrodactyly) can be caused by many different mutations, and can be 
inherited singly or as a symptom of a congenital syndrome, with failure to 
maintain signalling from and typical development of the median apical 
ectodermal ridge (AER) (a structure at the distal end of limb buds coordinating 
limb development) identified as a main mechanism of pathogenesis (Tayebi et 
al., 2014). Urbach-Wiethe disease is a rare, autosomal recessive disorder 
characterised deposits of collagen in skin and soft tissues. Complications due to 
these collagen deposists can manifest as papules around the eyes and fingers, 
and calcification of brain tissue (most often basal ganglia) that can lead to 
seizures and cognitive changes (Parida et al., 2015). 
Several genes associated with MCP were also found to be associated in 
neurodegenerative disorders with motor function involvement. Spinal ataxias 19 
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& 22 are rare, progressive, degenerative nervous system diseases associated with 
cerebellar atrophy and a range of motor coordination, balance and speech 
related symptoms (Duarri et al., 2012). Joubert syndrome is another condition 
affecting the cerebellum, and is also associated with motor and cognitive 
symptoms (Roosing et al., 2016; Uniprot). ALS is a neurodegenerative disorder 
affecting motor function, with extra-motor symptoms in up to half of cases such 
as changes in behaviour, executive dysfunction and problems with language 
(Masrori & Van Damme, 2020).  
GABRB2, encodes the GABAA beta-2 subunit protein, a component of ionotropic 
(neurotransmitter-binding) GABAA receptors which form the major inhibitory 
system in the brain (Jacob et al., 2008). Dysregulation of this system has been 
suggested to play a key role in schizophrenia pathogenesis (Lichtshtein et al., 
1978), and variants in this gene have since been associated with schizophrenia 
(Laroche et al., 2008; Lo et al., 2007; Yeung et al., 2018).   
Brugada Syndrome 9 is a type of rare heart arrythmia disorder, associated with 
increased risk of sudden death (Gourraud et al., 2016). Pathology may be a 
result of sodium channel defects and either concurrent gain of function or loss of 
function in cardiac potassium or calcium channels, respectively, or of purely 
sodium-channel related defects (Gourraud et al., 2016).   
SLE is an autoimmune disorder associated with significant chronic pain and 
potential involvement of a range of tissues and organs (Fava & Petri, 2019, see 
also 1.1.5). Y-RNAs are generally involved in maintenance of typical cell function, 
and form a part of autoantigen complexes found in serum from individuals with 
SLE (Driedonks & Nolte-T’Hoen, 2019). Extracellular vesicle exchange (involving 
these circulating RNAs) is generally important in immune-related processes 
including inflammation, immune suppression, and tumour micro environment 
establishment (Driedonks & Nolte-T’Hoen, 2019). Another gene involved in 
immune processes is PRC1, which encodes an evolutionarily conserved Polycomb 
group (PcG) protein. PRC1 has been shown to be involved in cancer metastasis 
through immunosuppressive activities (Su et al., 2019), and this protein is also 
involved in epigenetic regulation of gene expression and resultant cell fate 
decisions (Schuettengruber et al., 2017).  
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Cohesinopathies are caused by mutations in genes coding for components of the 
cohesion complex, which guides sister chromatid segregation during cell division 
(Piché et al., 2019). A wide range of symptoms across a variety of associated 
disorders are associated with malfunctioning of the cohesion complex, including 
intellectual and growth delays.  
Overall, it is difficult to extrapolate from these genes shared between MCP and 
other disorders in terms of any causal roles these genes may play in either 
disorder, or in relation to whether this genetic overlap drives any increased 
chronic pain seen in these disorders (if present). Conclusions as to the 
mechanisms of chronic pain development also cannot be drawn based on the 
putative roles these genes play in each disorder. As an extreme generalisation, 
genes associated with both MCP and the disorders discussed in this section seem 
to suggest involvement of the CNS, particularly the cerebellum, the immune 
system, and structural changes in organs and tissues. Dysfunction in the 
inhibitory system of the brain could also be associated with chronic pain.   
4.4.3.3 Function of Genes Associated with MCP 
Many genes associated with MCP are implicated in CNS development and 
functioning. For example, several genes associated with MCP were linked to 
synapse development and plasticity (CTNNA2, CEP120, KNDC1, CA10, FOXP2, 
NRXN1, SLC4A10, LANCL1, SEMA3F) development of the nervous system (e.g. 
AMIGO3, NCAM1), development of astrocytes (UTRN), and peripheral nerve 
myelination (DAG1) (Appendix 1 Table A1.2). 
Several genes associated with MCP through MAGMA analyses have been linked to 
regulation of cell cycle progression, including DNA replication regulation and 
apoptotic processes. These included STAG1, involved in organisation of sister 
chromatids, genes associated with regulation of the cell cycle (e.g., ANAPC4, 
PRC1, BOLL) and several genes involved in apoptotic processes (e.g., FAM120A, 
MON1B, SEMA3F) (Appendix 1 Table A1.2). 
Genes associated with MCP were also found to be involved in a range of immune-
related processes, including neutrophil activation (UTRN), T-cell activation (FYN, 




Other genes associated with MCP were involved in a wide range of processes 
including DNA replication regulation (PURG), angiogenesis both specific to the 
brain (BAI2) and generally (F2), protein transport (e.g., SORT1, TM9SF4) 
degradation (UBA7, PSMA5), and repair (PCMT1). Several genes associated with 
MCP are implicated in regulation of gene transcription (e.g., SMARCC1, ASXL3, 
AGO2) and pre-mRNA processing (PRPF3, PTBP1) and mRNA processing (e.g., 
SNRPC). Other processes associated with genes found to be associated with MCP 
included cell development/ differentiation (e.g., FYN, LEMD2), and 
mitochondrial metabolism (e.g., UQCC2) and protein synthesis (e.g., DHX30). 
MCP-associated genes were also linked to roles in cell adhesion, migration, and 
outgrowth (e.g., LAMB2, RHOA, AMIGO3) (Appendix 1 Table A1.2),  
4.4.3.4 Pathways Enriched for MCP-Associated Genes 
PLC-β-mediated events include immune signalling cascades (Bueno et al., 2006) 
and synapse formation (Hwang et al., 2005; Südhof, 2018), and disruption is 
associated with a wide range of conditions including schizophrenia, epilepsy, 
cancers and autoimmune disease (Yang et al., 2013). BCR signalling coordinates 
B cell development, and is key for various immune processes (Kurosaki, 2000; Liu 
et al., 2020). Integrin signalling generally mediates cell-cell adhesion, regulation 
of gene expression and cell growth, with α6β1 and α6β4 involved in maintaining 
tissue integrity in muscle, skin and kidney (Anderson et al., 2014).  
DCC-mediated attractive signalling is involved in cell migration and motility, 
including processes such as neuronal haptotaxis (Meijers et al., 2020) and axon 
guidance (Torres-Berrío et al., 2020), in addition to its role in colorectal and 
other cancers as a (malfunctioning) tumour suppressor gene (Mehlen & Fearon, 
2004). The protein product of DCC functions as a receptor, binding Netrin ligands 
(secreted ligands involved in regulation of axon guidance and migration in 
addition to roles during development of a wide range of other tissues (Larrieu-
Lahargue et al., 2012)) – this signalling and its role as a cue for axon guidance is 
highly evolutionarily conserved (reviewed by Boyer & Gupton, 2018). The role of 
DCC in neuronal migration is key for brain, particularly cortical, development 
through coordination of newly born cortical neurons. Commissural axons (axons 
directed towards the ventral midline of the CNS) that express Dcc proteins on 
their surface are attracted to Netrin sources, and are repelled in the additional 
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presence of uncoordinated 5 (UNC5) (reviewed by Meijers et al., 2020). Dcc-
Netrin binding has also been found in mouse studies to specifically repel 
GABAergic neurons from the ventricular zone of the ganglionic eminence (a 
temporary structure involved in cell and axon migration during foetal 
development) (Yamagishi et al., 2021). DCC may also play a role in synaptic 
plasticity the adult brain, with studies in rodents showing that deletion of this 
protein in neurons in the adult forebrain led to loss of long-term potentiation 
and negative impact on spatial and recognition memory (Horn et al., 2013), and 
a putative DCC ligand found to be highly expressed in neurogenic brain regions 
(Yamagishi et al., 2015). Emerging work in humans and rodents also links DCC to 
corpus callosum development through regulation of development of astroglia 
(Morcom et al., 2021). 
DCC has also been associated with psychiatric phenotypes including mood 
instability (Ward et al., 2019), self-injurious behaviour (Campos et al., 2020), 
suicidality (Strawbridge et al., 2019), insomnia (Byrne et al., 2013), depression 
(Li et al., 2020), and to complex brain-related traits such as putamen volume 
(Satizabal et al., 2019) and intelligence (Savage et al., 2018).  
Overall, results indicate MCP is a moderately heritable, polygenic trait, 
significantly genetically correlated with a range of traits and disorders – most 
markedly other chronic pain phenotypes and mood disorder phenotypes. Genetic 
correlation results in particular emphasise that GWAS findings from studies of 
chronic pain-associated conditions, rather than chronic pain itself, may capture 
genetic variation associated with disease specific processes rather than pain (as 
indicated by low/ moderate genetic correlation and in some cases no significant 
genetic correlation between MCP and conditions associated with significant 
chronic pain). Findings also suggest a key role for both nervous system and 
immune-related changes in the development and maintenance of chronic pain 
and implicate pathways such as DCC-mediated attractive signalling which have 
previously been found to be linked to nervous system development, cell 
proliferation, and a wide range of psychiatric phenotypes.  
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Chapter 5 Validation of Multisite Chronic Pain Phenotype 
5.1 Introduction  
Analyses were carried out to validate the MCP phenotype using PRSs, both in an 
independent general-population cohort, and in a subset of UK Biobank. This 
chapter specifically addresses objectives 1: to uncover common genetic 
variation associated with chronic pain phenotypes, and 2: To investigate genetic 
correlation and pleiotropy between MDD and chronic pain. 
Both utility and validity of trait PRSs can be assessed by testing for association 
between the trait investigated in the original GWAS, and PRS in an independent 
cohort. In this chapter, this was achieved through constructing a MCP PRS for a 
subset of Generation Scotland participants and testing for association between 
PRS and an MCP-like phenotype within Generation Scotland, and for association 
between MCP PRS and CPG, a well-validated chronic pain phenotype.  
PRS analyses can also be used to explore whether common genetic variation is 
shared between two different disorders or traits of interest. This type of PRS 
analysis was undertaken here to examine the relationship between MCP and CWP 
in UK Biobank a chronic pain phenotype that is potentially genetically distinct 
from localised chronic pain and from MCP (Kamaleri et al., 2008; Phillips & 
Clauw, 2011).  
In addition, outlined in Chapter 1, chronic pain is more common in women than 
men. This could be due to a range of genetic and lifestyle factors. Therefore, it 
is of interest to investigate potential genetics-by-sex interactions in chronic pain, 
also achievable through PRS analyses. 
5.2 Methods 
5.2.1 Chronic Pain Phenotyping in Generation Scotland and UKB 
Chronic pain phenotyping is similar between Generation Scotland (Smith et al., 
2013) and UK Biobank (Sudlow et al., 2015) (see also 2.3.3), but with a few key 
differences, such as specific body sites used in the questionnaire (Table 5.1). An 
MCP phenotype was derived in both cohorts, but it was not possible for this 
phenotype to be identical, due to these differences in the types of questions on 
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pain that were asked in each of the two studies. CPG score can also be 
calculated for Generation Scotland participants. In general Generation Scotland 
participants were asked a greater range of questions on their pain, including 
questions on social and work-related impact of pain (a total of 24 pain-related 
question items are present in Generation Scotland, compared to effectively two 
in UK Biobank). 
 
Generation Scotland UK Biobank 
Back Back 
Neck or Shoulder Neck or Shoulder 
Headache, facial or dental pain Headache 
Stomachache/ abdominal Stomach/ abdominal 




All over the body 
Table 5. 1: Pain site options in Generation Scotland versus UK Biobank 
5.2.1.1 Chronic pain grade 
CPG (2.3.3.2) phenotype value (0-4) was calculated for each Generation 
Scotland participant included in PRS analyses (N = 6, 080 total). This sample 
consists of a subset of Generation Scotland participants who were not related to 
one another (Generation Scotland was developed using a family-based 
recruitment structure, see Chapter 2.3.2.3) and who had complete information 
on CPG phenotype, genotyping data, age, sex, and multidimensional scaling 
components (MDS) available. The subset of unrelated participants was created 
by using the GCTA (J. Yang, Lee, et al., 2011) ‘--grm-cutoff’ option to derive a 
set of individuals related at < 0.025 genetic covariance from the Generation 
Scotland GRM. Overlapping participants between Generation Scotland and UK 
Biobank were also removed from this subset. 
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CPG Mean age N male (%) N total  
0 49.44 1692 (64.75) 3708  
1 52.92 579 (22.16) 1260 
2 51.97 224 (8.57) 711 
3 52.72 60 (2.30) 198 
4 55.05 58 (2.22) 203 
total 50.75 2613 (42.98) 6080 
Table 5. 2: Age and sex of participants included in CPG regression analyses. 
5.2.1.2 Multisite chronic pain 
A chronic pain phenotype similar to UK Biobank MCP was derived in Generation 
Scotland (see 2.3.3.2.2)) and was calculated for unrelated Generation Scotland 
participants with complete genotype data and information on age, sex and MDS 
components. As before, any participants in Generation Scotland who were also 
participants in UK Biobank were also removed. 
MCP Mean age N male (% male) N total 
0 49.41 1801 (63.46) 3898 
1 53.01 513 (18.08) 1169 
2 53.53 329 (11.59) 801 
3 55.38 120 (4.23) 418 
4 53.67 45 (1.59) 170 
5 52.91 25 (0.88) 74 
6 52.68 5 (0.18) 25 
total 51.09 2838 (43.28) 6558 
Table 5. 3: Age and sex of participants included in MCP regression analyses.  
5.2.2 Validation of MCP Polygenic Risk Score in Generation Scotland 
5.2.2.1 Polygenic Risk Scoring in Generation Scotland 
A MCP PRS value was calculated for unrelated Generation Scotland participants, 
who had not participated in UK Biobank, and whose genetic data passed quality 
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control checks. This was carried out using PRSice (Euesden et al., 2015) (see also 
2.2.6)– the target phenotype was MCP derived in Generation Scotland as 
explained above. The best PRS was calculated by PRSice as one consisting of 
SNPs associated with MCP at a GWAS p < 0.4, and this PRS was standardised by 
PRS z value throughout. A weighted PRS is unit-less, and using a standardised 
score in this way aids interpretation of regression output i.e., for every 1-SD PRS 
increase, MCP phenotype value increased by X. 
5.2.2.2 Regression Analyses 
The relationship between MCP PRS and MCP phenotype in unrelated Generation 
Scotland participants with complete data on PRS, age, sex, MCP phenotype value 
and Multidimensional Scaling (MDS) components 1-4 (N = 6, 558) was then 
examined via linear regression (adjusting for age, sex and MDS components). 
MDS components are included to account for population stratification between 
UK Biobank and Generation Scotland (see Chapter 2.2.1.2 & Chapter 2.2.6). Four 
regression models in total were run (model formulae and sample size 
summarised Table 5.4). 
Model Formula N 
Initial MCP~ Age + Sex + PRS + C1 + C2 + C3 + C4 6558 
Sex Interaction MCP~ Age + Sex*PRS + C1 + C2 + C3 + C4 6568 
Sex-stratified: Male MCP~ Age + PRS + C1 + C2 + C3 + C4 2838 
Sex-stratified: Female MCP~ Age + PRS + C1 + C2 + C3 + C4 3720 
Table 5. 4: Summary of regression models with MCP as outcome.  
C1-4 = MDS components 1-4, MCP = Multisite Chronic Pain trait value (0-6), PRS = Polygenic Risk Score  
The relationship between MCP PRS and CPG phenotype in unrelated GS 
participants with complete data on PRS, age, sex, CPG phenotype value and 
Multidimensional Scaling (MDS) components 1-4 (N = 6, 080) was then examined 
via linear regression. (adjusting for age, sex and MDS components). Four 
regression models in total were run (model formulae and sample size 
summarised Table 5.5). 
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Model Formula N 
Initial CPG~ Age + Sex + PRS + C1 + C2 + C3 + C4 6080 
Sex Interaction CPG~ Age + Sex*PRS + C1 + C2 + C3 + C4 6080 
Sex-stratified: Male CPG~ Age + PRS + C1 + C2 + C3 + C4 2613 
Sex-stratified: Female CPG~ Age + PRS + C1 + C2 + C3 + C4 3467 
Table 5. 5: Summary of regression models and sample sizes.  
C1-4 = MDS components 1-4, CPG = Chronic Pain Grade, PRS = Polygenic Risk Score 
5.2.3 Multisite Chronic Pain and Chronic Widespread Pain in UK Biobank: PRS 
Analysis 
An MCP PRS was calculated for individuals who reported chronic pain all over the 
body in UK Biobank (excluded from previous GWAS analyses described in Chapter 
5, N = 6, 815) and in 10, 000 randomly selected UKB participants who reported 
no chronic pain at any site or all over the body (also excluded from previous MCP 
GWAS analyses). The PRS was calculated using SNPs associated with MCP at p < 
0.01, weighting by MCP GWAS effect size (GWAS beta) for each SNP. PRS score 
was standardised by standard deviation (SD) to give a z-PRS. A weighted PRS is 
unit-less, and using a standardised score in this way aids interpretation of 
regression output i.e., for every 1-SD PRS increase, CPG score increased by X.  
5.2.3.1 Regression Analyses 
The association between MCP PRS and CWP status was investigated using logistic 
regression, adjusting for age, sex, genotyping array and the first eight UK 
Biobank genetic PCs (to account for potential population stratification when 
comparing the two subsets of UK Biobank participants). 
5.3 Results 
5.3.1 MCP PRS Validation in Generation Scotland 
PRS analyses undertaken to validate the MCP phenotype showed that MCP PRS 
was significantly (p < 0.05) associated with both MCP and CPG in Generation 
Scotland (Table 5.6: p = 8 x 10-32, Table 5.7: 2.87 x 10-23, respectively). Every 1-
SD increase in PRS value was associated with a 0.17-site increase in MCP 
phenotype value, and with a 0.13 increase in CPG phenotype value.  
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Estimate SE t p 
(Intercept) 0.31 0.07 4.23 2.40 x 10-5 
PRS 0.17 0.01 11.80 8.08 x 10-32 
age 0.01 0.00 11.76 1.30 x 10-31 
sexM -0.25 0.03 -8.60 9.81 x 10-18 
C1 -14.75 10.17 -1.45 0.15 
C2 -25.06 11.34 -2.21 0.03 
C3 -4.94 1.85 -2.67 0.01 
C4 3.32 2.49 1.33 0.18 
Table 5. 6: Results of the regression of MCP polygenic risk score on MCP in Generation Scotland, adjusted 
for age, sex and multidimensional scaling components 1-4..  
Estimate = regression coefficient value, SE = standard error of regression coefficient value, t = t-statistic 
value, p = p value. Default level for factor variable ‘Sex’ is set to female (F). PRS refers to standardised (z) 
PRS.  
 
Estimate SE t p 
(Intercept) 0.32 0.07 4.82 1.45 x 10-6 
PRS 0.13 0.01 9.98 2.87 x 10-23 
age 0.01 0.00 9.48 3.57 x 10-21 
sexM -0.21 0.03 -8.14 4.72 x 10-16 
C1 -5.89 9.13 -0.65 0.52 
C2 -20.28 10.12 -2.00 0.05 
C3 -3.07 1.64 -1.87 0.06 
C4 2.08 2.21 0.94 0.35 
Table 5. 7: Results of the regression of MCP polygenic risk score on chronic pain grade in Generation 
Scotland, adjusted for age, sex and multidimensional scaling components 1-4.  
Estimate = regression coefficient value, SE = standard error of regression coefficient value, t = t-statistic 




5.3.2 Sex-Specific Associations between PRS and MCP in Generation Scotland 
There was a significant interaction between sex and PRS (Table 5.11: p = 0.002), 
and in sex-stratified regression analyses the association between PRS and MCP 
phenotype value was markedly higher in females than in males (Table 5.11: 0.21 
vs 0.12, respectively). This significance survives Bonferroni correction of 
significance threshold (all p values for PRS terms in models << pbonf = 0.0125). 
 
 
Estimate SE t p 
(Intercept) 0.31 0.07 4.19 2.82 x 10-5 
PRS 0.21 0.02 11.01 5.96 x 10-28 
sexM -0.25 0.03 -8.67 5.36 x 10-18 
age 0.01 0.00 11.77 1.16 x 10-31 
C1 -14.43 10.17 -1.42 0.156 
C2 -24.71 11.33 -2.18 0.029 
C3 -4.90 1.85 -2.65 0.008 
C4 3.15 2.49 1.26 0.206 
PRS: sexM -0.09 0.03 -3.12 0.002 
Table 5. 8: Results for the regression of MCP polygenic risk score on MCP in Generation Scotland with 
inclusion of an interaction term (sex x PRS).  
Estimate = regression coefficient value, SE = standard error of regression coefficient value, t = t-statistic 
















Estimate SE t p 
(Intercept) 0.26 0.10 2.61 0.0092 
PRS 0.12 0.02 5.87 5.00 x 10-9 
age 0.01 0.00 7.06 2.02 x 10-12 
C1 -30.96 14.08 -2.20 0.028 
C2 -32.63 15.62 -2.09 0.037 
C3 -2.36 2.51 -0.94 0.347 
C4 1.02 3.45 0.30 0.767 
Table 5. 9: Results for the regression of MCP polygenic risk score on MCP in Generation Scotland in males 
only.  
Estimate = regression coefficient value, SE = standard error of regression coefficient value, t = t-statistic 





















Estimate SE t p 
(Intercept) 0.15 0.10 1.42 0.15 
PRS 0.21 0.02 10.29 1.67 x 10-24 
age 0.01 0.00 9.50 3.79 x 10-21 
C1 -2.50 14.28 -0.18 0.86 
C2 -18.92 15.98 -1.18 0.24 
C3 -6.94 2.64 -2.63 0.01 
C4 4.85 3.50 1.38 0.17 
Table 5. 10: Results for the regression of MCP polygenic risk score on MCP in Generation Scotland in 
females only.  
Estimate = regression coefficient value, SE = standard error of regression coefficient value, t = t-statistic 
value, p = p value. PRS refers to standardised (z) PRS. 
Model PRS PRS*Sex Significant 
Initial 0.17 NA Yes 
Sex Interaction 0.21 -0.09 Yes, Yes 
Sex-stratified: Male 0.12 NA Yes 
Sex-stratified: Female 0.21 NA Yes 
Table 5. 11 Summary of all four model key results.  
PRS = coefficient value for PRS term in regression models, PRS*Sex = coefficient value for sex-PRS 
interaction term (where applicable). Significant = p value for coefficient < 0.0125 (Bonferroni-corrected by 
number of regression models run in total (4)). PRS refers to standardised (z) PRS. 
 
5.3.3 MCP and Chronic Widespread Pain in UK Biobank 
PRS analyses carried out to assess the relationship between CWP and MCP, as 
well as to partially validate the MCP phenotype, indicated that genetic risk for 
MCP (MCP PRS) was significantly associated with having chronic widespread pain, 
with every 1-standard deviation (SD) increased in PRS associated with a 63% 
increase in the odds of having chronic widespread pain (Table 5.12: OR = 1.63, p 




Term Estimate SE (Estimate) Z P OR 
(Intercept) -61.418 2.763 -22.23 1.90 x 10-109 2.12 x 10-27 
Age 0.016 0.002 7.45 9.25 x 10-14 1.02 
Sex -0.488 0.035 -14.01 5.56 x 10-45 0.61 
PRS 0.488 0.022 22.24 1.45 x 10-109 1.63 
Table 5. 12: Results of the regression of MCP polygenic risk score on chronic widespread pain in UK Biobank.  
Regression beta coefficient values (Estimate), odds ratios (OR), and P values. The reference level for ‘sex’ 
is set to female, PRS = z-polygenic risk score. 
 
5.4 Discussion 
5.4.1 Multisite Chronic Pain and Chronic Widespread Pain 
Clinical syndromes involving chronic pain all over the body such as fibromyalgia, 
and chronic widespread pain itself, may represent the upper end of a spectrum 
of centralisation of pain, or the extreme of a chronic pain state (Phillips & Clauw, 
2011). It has also been suggested that there are not “natural cut-off points” 
when it comes to chronic widespread pain versus localised chronic pain 
(Kamaleri et al., 2008). In support of this, MCP PRS was significantly associated 
with chronic widespread pain, indicating that chronic widespread pain be the 
upper end of a spectrum of increasingly widespread chronic pain, as previously 
suggested (Kamaleri et al., 2008; Phillips & Clauw, 2011), and that there are 
likely to be genetic variants that predispose both to MCP and to CWP. 
5.4.2 Validation of MCP PRS in an Independent Cohort 
Polygenic risk for MCP was significantly associated with both increasing MCP trait 
value and increasing chronic pain grade trait value in an independent cohort. 
This indicates that SNP associations discovered in UK Biobank are not limited to 
this specific cohort, and instead capture variation in chronic pain more generally. 
In addition, the significant association of MCP PRS with CPG is encouraging as 
CPG represents a validated chronic pain phenotype, again indicating that the 
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GWAS of MCP in UK Biobank was capturing genetic variation contributing 
generally to chronic pain. 
5.4.3 Sex Differences in PRS Associations 
An MCP PRS was associated with MCP in Generation Scotland in both men and 
women, but the size of the association was greater in women (β = 0.21, if a 95% 
CI is taken to be 0.21 +/- 0.04 this is significantly larger than the size of the 
male PRS-MCP association β = 0.12). There was also significant PRS-by-sex 
interaction. These results may indicate a genetic contribution to sex differences 
in prevalence of chronic pain, and were further examined in the published 
journal article associated with analyses in this chapter (Johnston et al., 2021).   
Sex as a biological variable has a range of effects on how the genome functions 
and therefore on resulting phenotypic trait values (Bernabeu et al., 2021; 
Khramtsova et al., 2019; Rawlik et al., 2016). These effects can be mediated by 
sex differences in DNA methylation (Ge et al., 2017; Gilks et al., 2014; Hall et 
al., 2014; McCormick et al., 2017; Rahmioglu et al., 2015), sex differences in 
gene expression (Quinn & Cidlowski, 2016; X. Xu et al., 2012) and in eQTL 
effects (Kukurba et al., 2016; Yao et al., 2013), and varying levels and actions of 
hormones (Gomez-Santos et al., 2011; Kósa et al., 2009). Sex-specific pleiotropy, 
whereby genetic variants are associated with multiple traits but these 
relationships differ according to sex, can also contribute to sex differences in 
complex traits (Mitra et al., 2016; Rahmioglu et al., 2015), including chronic 
pain. Environmental factors strongly correlated with sex can also contribute to 
sex differences in complex trait phenotypic values. 
Sex-differential gene expression has been observed in populations of sensory 
neurons (Mecklenburg et al., 2020) including within the dorsal root ganglion (K. 
Stephens et al., 2018) and tibial nerve (Ray et al., 2019).  
In rodents, it has been found that different immune cells mediate mechanical 
pain hypersensitivity depending on sex, and that this relationship is affected by 
the action of testosterone (Mapplebeck et al., 2016; Sorge et al., 2015; Sorge & 
Totsch, 2017). In humans, improvement in chronic pain symptoms associated 
with some chronic pain conditions (particularly autoimmune conditions such as 
rheumatoid arthritis and MS) has been observed during pregnancy (Adams 
Waldorf & Nelson, 2008; Krause & Makol, 2016; Ray-Griffith et al., 2018; Varytė 
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et al., 2020). Again, this relationship is thought to be associated with varying sex 
hormone levels and their downstream effects on immune cell populations such 
as T helper cells (Craft et al., 2004; Pozzilli & Pugliatti, 2015). The relationship 
between pain perception and varying sex hormone levels during the human 
menstrual cycle, and between pain symptoms in chronic pain conditions and the 
menstrual cycle, is not fully understood (reviewed by Iacovides et al., 2015). 
A range of diverse non-genetic (environmental) factors associated with female 
gender may also contribute to differences in chronic pain prevalence between 
sexes. Pain and chronic pain are more common in people reporting intimate 
partner/ domestic violence (Alhalal et al., 2018; Craner et al., 2020; Wuest et 
al., 2008), who also tend to be women (World Health Organization, 2021). 
Willingness to seek medical treatment, which is generally higher in women than 
men (Höhn et al., 2020; Thompson et al., 2016), may also contribute to higher 
prevalence estimates for chronic pain in women, as women are more likely to 
seek treatment for pain (K. D. S. Ferreira & Speciali, 2015)– however some 
evidence is mixed (Hunt et al., 2011) and this relationship may depend on pain 
type and be generally variable. Women may also be more likely to use 
maladaptive coping strategies for chronic pain (El-Shormilisy et al., 2015), 
potentially increasing any time period spent in pain and contributing to higher 
chronic pain prevalence. Adverse childhood experiences (ACEs) such as parental 
conflict, poverty, and psychological, physical or sexual abuse are also associated 
with higher rates of chronic pain in adulthood (Edwards et al., 2016; Groenewald 
et al., 2020), and some types of ACEs have been found to be more commonly 
experienced by women (Bellis et al., 2014; CDC, 2019), and in other cases 
greater variation and complexity in ACEs has been reported by women compared 
to men (Haahr-Pedersen et al., 2020). 
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Chapter 6: Using Genetics to Assess Causal Relationships 
in Pain and MDD 
6.1 Introduction 
Analyses undertaken in this chapter address the over-arching aim of this PhD 
project: to investigate causal relationships between MDD and chronic pain. 
Although the relationship between MDD and chronic pain in terms of comorbidity 
and genetic overlap is well documented, it is unclear as to whether a causal 
aspect to the relationship between MDD and chronic pain exists (see 1.3.2). In 
the absence of longitudinal data collection (that is specifically designed to 
control for many potential confounding factors in any underlying causal 
relationship between MDD and chronic pain, e.g., BMI, socioeconomic 
deprivation), it can be difficult to examine causality. One potential method to 
determine causality in exposures where randomised control trials (RCTs) are 
inappropriate for ethical, feasibility and financial reasons, and where 
longitudinal data is scarce or non-existent, is Mendelian Randomisation (MR) 
(reviewed by (Zheng, Baird, et al., 2017), see also 2.2.7). Using MR can mean 
that bias in causal estimates due to both reverse causality and confounding are 
in theory avoided.  
The first section of this chapter (6.2.1), compares three different MR methods; 
Inverse-Variance Weighted (IVW), MR-Egger, and MR with Robust Adjusted Profile 
Score (MR-RAPS). Subsequent analyses focus solely on MR-RAPS (6.2.2) – this is 
because MR-RAPS is likely to be the most appropriate method when some degree 
of horizontal pleiotropy is almost certain to exist between the two traits. This is 
the case with depression and chronic pain, shown both by analyses in this thesis 
(Chapters 3, 4 and 5) showing significant genetic correlation between the two 
conditions, and in prior literature (see 1.1.5, 1.3.1). Differences in MR 
approaches and respective advantages and limitations are discussed in further 
detail in 2.2.7.  
The next section of this chapter (6.2.3) examines the relationship between SNP 
genotype rs1186556 and chronic pain, and between SNP genotype and depression, 
in UK Biobank. Rs1186556 was found to be pleiotropic in cFDR analyses of MDD 
and CPG (Chapter 3), and mapped to LRFN5, a locus previously linked to 
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neuroinflammation and involved in neuronal development and synapse formation 
(3.3.5). 
6.2 Methods 
6.2.1 MR: Causal Relationship between Chronic Pain Grade and MDD 
6.2.1.1 GWAS Datasets & Data Preparation 
GWAS summary statistics from the 23andMe-Pfizer CPG GWAS were used. This 
GWAS was carried out on 23, 301 unrelated individuals of European descent (see 
2.3.2.2 and 2.3.3.2.1). Harmonisation was carried out (see 2.2.7.5), with an r2 
threshold of 0.01 chosen throughout. LD between instruments was checked using 
PLINK command --r2 --ld-window-r2 0.01, checking against UK Biobank 
genotyping data as a reference. This command delivers a list of pairwise 
correlation values (measured in r2) between instrument SNPs, for any value of r2 > 
0.01. This stringent threshold was used to make MR-RAPS (Zhao et al., 2020) 
valid. Where LD was found (r2 > 0.01), the SNP with the lowest GWAS p value 
amongst the inter-correlated group was reserved. These reserved SNPs plus the 
SNPs that were not found to be in LD comprised the list of instruments for MR. 
SNPs associated with the exposure (here, CPG) at p < 10-5 and satisfying the 
other criteria were taken forward into the MR analysis. Note that this p value 
threshold is one order of magnitude more conservative than recommended for 
MR-RAPS (where recommended threshold is p < 10-4), to account for the fact that 
CPG-associated SNP effect sizes were calculated in a sample that was not 
independent of the source GWAS for the exposure trait (CPG). After the above 
steps were completed, 25 SNPs were taken forward to assess the causal effect of 
CPG on MDD. 
MR-Egger, IVW and MR-RAPS were carried out, and Q and I2GX values were 
calculated. 
A large GWAS meta-analysis was carried out by Wray et al (Wray et al., 2018), 
and data from UK Biobank and 23andMe participants were removed from those 
results, to give GWAS summary statistics for a cohort consisting of 43, 028 and 
87, 522 MDD cases and controls, respectively. Harmonisation and pruning steps 
were carried out as described in the preceding section, leaving 44 independent 
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SNPs associated with MDD at p < 10-5 to be used as instruments to assess the 
causal effect of MDD on CPG. 
6.2.1.2 Mendelian Randomisation Analysis  
MR-Egger (2.2.7.3), IVW (2.2.7.2) and MR-RAPS (2.2.7.4) were carried out using 
summary statistic datasets prepared as described in previous sections, first to 
estimate the causal effect of CPG on MDD, then to estimate the causal effect of 
MDD on CPG. Q and IGX2 values were calculated to assess pleiotropy in SNP 
instruments. 
IVW MR involves fixed-effect meta-analysis of the Wald ratio causal effect 
estimates for each SNP. MR-Egger analysis provides a causal estimate through 
treating each instrument (SNP) as a study in a meta-analysis, where the overall 
effect estimate (causal effect estimate) is given by the slope of the MR-Egger 
regression – in contrast to IVW analysis the intercept of this regression is not 
constrained to pass through the origin. Directional horizontal pleiotropy was also 
tested for through testing whether the intercept of this regression was 
significantly different to zero. Both IVW and MR-Egger MR analyses were carried 
out using code written in R (versions 3.5.3 – 3.6.0), partially based on code 
templates distributed as part of the 2018 Mendelian Randomisation workshop 
(University of Bristol).  
MR-RAPS was carried out using the package ‘mr-raps’ in R (version 3.6.0) (Zhao 
et al., 2020).  
6.2.2 MR: Causal relationships between Multisite Chronic Pain and MDD 
6.2.2.1 GWAS Datasets & Data Preparation 
Summary statistics for the GWAS carried out in Chapter 4 in UKB on MCP were 
used to derive instruments for MCP, a second chronic pain phenotype distinct 
from CPG. After harmonisation and pruning steps were completed as above, this 
resulted in 200 independent SNP instruments associated with MCP at p < 10-5 for 
use in investigating potential causal effects of MCP on MDD.  
Wray et al summary statistics were used and pruning and harmonisation steps 
followed as previously outlined. This resulted in 99 independent SNPs associated 
with MDD at p < 10-5 to be used as instruments in estimating the causal effect of 
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MDD on MCP. Note that the number of instruments for MDD varies between the 
MCP<->MDD and CPG<->MDD analyses as pruning and harmonisation is carried out 
with respect to the outcome variable GWAS data in each case. 
6.2.2.2 Mendelian Randomisation Analysis 
MR-RAPS (2.2.7.4) analyses were carried out, first to estimate the causal effect 
of MCP on MDD, then to estimate the causal effect of MDD on MCP.  
 
6.3 Results 
6.3.1 Causal Relationships between Chronic Pain Grade and MDD 
MR analyses investigating a potentially causal effect of CPG on MDD found no 
significant causal effect after FDR correction for multiple testing (Table 6.1, p 
value = 0.08). With respect to MR-Egger, where the causal effect was non-
significant even prior to FDR correction, this may be due to causal dilution 
caused by violation of the NOME (No Measurement Error) assumption, as 
indicated by the I2GX value of < 0.9.  
 





IVW 0.068 0.03 2.218 0.036 0.054 21.75 0.594 0 0 NA NA NA 
MR-
Egger 










0.035 0.054 NA NA NA NA NA simple L2 
Table 6. 1: MR results with chronic pain grade as the exposure and MDD as the outcome across all three 
methods.  
β = causal estimate, SE = standard error of causal estimate, β/ SE = z value, p = p value, p (FDR) = FDR-
adjusted p value, Q = Cochran’s Q value, p (Q) = p value for Cochran’s Q, I2 = heterogeneity estimate (IVW), 
τ2 = among-study variance (heterogeneity estimate, IVW), I2gx = heterogeneity indicator (MR-Egger).  
No significant directional or balanced horizontal pleiotropy was detected in 
these analyses, as indicated by the non-significant intercept value in MR-Egger 
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(Table 6.1 p = 0.7), and the non-significant Q value for IVW MR (Table 6.1 p = 
0.59), respectively. This is corroborated in MR-RAPS analysis, as no significant 
over-dispersion (indicating widespread horizontal pleiotropy amongst 
instruments) or idiosyncratic pleiotropy (horizontal pleiotropy in a small subset 
of instruments) was detected – simple, non-robust (L2 loss function) regression 
was best-fitting.  
In MR analyses investigating potential causal effect of MDD on CPG, again no 
significant causal effect was found across any of the four MR methods. IVW 
results indicated no horizontal pleiotropy among instruments (Table 6.2 p (Q) > 
0.05), and MR-Egger intercept results suggest no direction pleiotropy (Table 6.2 
p > 0.05), but MR-Egger results suggest significant violation of the NOME 
assumption (Table 6.2 I2GX <<0.9). The fact that the best-fitting MR-RAPS model 
was one with a Huber loss function indicates idiosyncratic pleiotropy among 
instruments – a small subset of instruments for MDD were horizontally pleiotropic.  
 







0.03 -0.74 0.46 0.69 45.9 0.35 6.3 0.003 NA NA NA 






0.004 -1.86 0.07 NA NA NA NA NA NA NA NA 
MR-RAPS -
0.012 
0.032 -0.375 0.712 0.712 NA NA NA NA NA simple, 
robust 
Huber 
Table 6. 2: MR results with MDD as the exposure and chronic pain grade as the outcome across all three 
methods.  
β = causal estimate, SE = standard error of causal estimate, β/ SE = z value, p = p value, p (FDR) = FDR-
adjusted p value, Q = Cochran’s Q value, p (Q) = p value for Cochran’s Q, I2 = heterogeneity estimate (IVW), 
τ2 = among-study variance (heterogeneity estimate, IVW), I2gx = heterogeneity indicator (MR-Egger). 
6.3.2 Causal Relationships between Multisite Chronic Pain and MDD 
MR-RAPS analysis was performed to investigate causal relationships between 
MDD and MCP, first with MDD as the exposure and MCP as the outcome. QQ plots, 
leave-one out versus t-value plots and Anderson-Darling/ Shapiro-Wilk test p 
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values indicated that models without dispersion were best-fitting (Table 6.3 
rows 1-3, pAD > 0.05, pSW > 0.05). Effects of outliers (idiosyncratic pleiotropy) 
are not ameliorated in models with dispersion despite robust regression (Figure 
6.1: D, E, F right-hand panels). The best-fitting model with greatest 
amelioration of pleiotropy was one without over-dispersion and with a Tukey loss 






β SE (β) p (β) p (AD) p (SW) τ p (τ) C.F 
FALSE L2 0.0117 0.0052 0.0241 0.9375 5.34E-01 NA NA A 
FALSE Huber 0.0153 0.0054 0.0042 0.9285 5.23E-01 NA NA B 
FALSE Tukey 0.0185 0.0054 0.0006 0.9230 5.18E-01 NA NA C 
TRUE L2 -0.0096 0.0132 0.4671 0.0080 1.76E-03 1.61E-04 0.0470 D 
TRUE Huber -0.0056 0.0126 0.6556 0.0087 2.11E-03 1.30E-04 0.0677 E 
TRUE Tukey -0.0065 0.0137 0.6330 0.0055 9.03E-04 1.67E-04 0.0627 F 
Table 6. 3: MR results for MR-RAPS analysis with MDD as the exposure and MCP as the outcome.  
β refers to the causal effect, SE (β) and p (β) to the standard error and p value of β, p (AD) to the 
Anderson-Darling test of normality p value, p (SW) to the Shapiro-Wilk test of normality p value, τ to the 
over-dispersion statistic size and p (τ) to the p value. C.F = corresponding QQ plot panel for the model. p 
(τ) was calculated from the tau estimate and its standard error (Altman & Bland, 2011). The row of the 




Figure 6. 1. Diagnostic plots of MR-RAPS analysis with MDD as exposure 
Quantile-quantile plots (left-hand panels, ‘normal Q-Q plot’) and leave-one-out β versus t-value plots 
(right-hand panels) for each of the six models fitted during MR-RAPS analyses (A-F) are shown. 
Beta.hat.loo = leave-one-out β value estimate, abs(b_exp/se_exp) = absolute β value divided by standard 
error (t value). Each point represents a SNP instrument.  
These results indicate idiosyncratic pleiotropy (pleiotropy in some but not all 
instruments). The causal effect of MDD on MCP is positive and significant at beta 
= 0.019 and p = 0.0006, but the diagnostic plots show a ‘swapping’ of sign for 
the causal estimate (Figure 6.1), suggesting that there is not a truly significant 
causal effect of MDD on MCP.  
MR-RAPS analyses were then carried out with MCP as the exposure and MDD as 
the outcome. Models with dispersion are a better fit than those without (Figure 
6.2: A, B, C vs D, E, F, Table 6.4: rows 4-6, pAD > 0.05, pSW > 0.05, pτ << 0.05). 
This indicates that effectively all instruments are horizontally pleiotropic 
(affecting MDD through pathways other than via MCP). The causal effect of MCP 








β SE (β) p (β) p (AD) p (SW) τ p (τ) C.F 
FALSE L2 0.1714 0.0605 0.0046 0.4256 0.0853 NA NA A 
FALSE Huber 0.1815 0.0621 0.0034 0.4247 0.0835 NA NA B 
FALSE Tukey 0.2097 0.0621 0.0007 0.4221 0.0784 NA NA C 
TRUE L2 0.1201 0.0790 0.1286 0.8374 0.2853 9.81E-05 2.43E-03 D 
TRUE Huber 0.1446 0.0801 0.0712 0.8289 0.2724 9.18E-05 5.13E-03 E 
TRUE Tukey 0.1578 0.0795 0.0471 0.8236 0.2641 8.77E-05 7.09E-03 F 
Table 6. 4: MR results for MR-RAPS analysis with MCP as the exposure and MDD as the outcome.  
β refers to the causal effect, SE (β) and p (β) to the standard error and p value of β, p (AD) to the 
Anderson-Darling test of normality p value, p (SW) to the Shapiro-Wilk test of normality p value, τ to the 
over-dispersion statistic size and p (τ) to the p value. p (τ) was calculated from the τ estimate and its 
standard error (Altman & Bland, 2011)The row of the table corresponding to the regression model found to 





Figure 6. 2: Diagnostic plots of MR-RAPS analysis with MCP as exposure and MDD as the outcome. 
Quantile-quantile plots (left-hand panels, ‘normal Q-Q plot’) and leave-one-out β versus t-value plots 
(right-hand panels) for each of the six models fitted during MR-RAPS analyses (A-F) are shown. 
Beta.hat.loo = leave-one-out β value estimate, abs(b_exp/se_exp) = absolute β value divided by standard 
error (t value). Each point represents a SNP instrument. 
Overall, the results of this analysis suggest a causal effect of MCP on MDD. 
6.4 Discussion 
6.4.1 Causal relationship between MCP and MDD 
Several MR analyses indicated no causal effect of CPG on MDD or vice versa, but 
MR-RAPS suggested MCP has a causal effect on MDD.  
The finding of no causal effect of CPG on MDD could be due to the comparatively 
smaller sample size of the 23andMe-Pfizer CPG GWAS, an order of magnitude 
smaller than the MCP GWAS, reducing power. It is also possible that potential 
bias introduced into the CPG GWAS output through adjustment for traits which 
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are likely to be genetically correlated with CPG (BMI and manual labour) may 
affect causal analyses (see 4.4.1.6).  
Differences between CPG and MCP as traits may also contribute to potential 
differences in observed causal estimates. Although the environment has a large 
influence on MCP (heritability, i.e., additive genetic component of trait 
variation, is only ~10%), environmental components of chronic pain experience 
are perhaps more explicitly measured with CPG. For example, interference in 
daily activities (e.g., item 4, how many days in the last 6 months have you been 
kept from your usual activities because of this pain?), is assessed as part of CPG. 
The individual’s interaction with their environment and the relationship between 
this interaction and any chronic pain is, in contrast, not directly measured or 
used to calculate the number of chronic pain sites on the body (i.e., MCP).  
MR-RAPS results for the causal effect of MCP on MDD also showed that 
effectively all instruments were horizontally pleiotropic – their effect on MDD is 
not exclusively through MCP and is instead dispersed or diluted out through other 
MCP-correlated traits. This emphasises that despite evidence of a significant 
causal role of chronic pain in MDD, many interrelated factors are involved in the 
relationship between MDD and chronic pain, and the relationship between the 
two phenotypes is complex. However, lack of significant causal effect of MDD on 
MCP can be interpreted as evidence that despite high comorbidity and genetic 
overlap, MDD does not directly cause chronic pain.  
Heterogeneity in MDD may mean that, although unexplained physical symptoms 
including chronic pain and headaches are experienced by some people with an 
MDD diagnosis, any potential causal effect of some specific subtypes of 
depression on MCP is obscured as the MDD GWAS included MDD cases overall, 
many of whom likely experience no chronic pain or unexplained physical 
symptoms. It is perhaps then even more significant that significant (if small) 
causal effect of MCP on MDD was found, given that MCP is also a heterogeneous 
trait. The translational impact of the results of these analyses is, however, 
minimal. MR studies of modifiable exposures or medications can have a direct 
translational impact as the causal effect of discrete, actionable changes (e.g. 
smoking cessation or taking a medication) can be ascertained – for example the 
impact of PSCK9 inhibitors on risk for type 2 diabetes was investigated in this 
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manner and has potential direct clinical implications (Schmidt et al., 2017). In 
contrast, in this section the causal impact of chronic pain (a heterogeneous, 
complex-trait exposure that is perhaps not modifiable in the way lifestyle 
factors such as cigarette smoking are) on MDD (and vice versa) is estimated.  
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Chapter 7: General Discussion 
This chapter is designed to bring together an overview of results from each of 
the previous chapters, along with discussion of strengths, limitations, and future 
directions of work carried out in this thesis. The over-arching aim of this thesis 
was to investigate causal relationships between major depression and chronic 
pain. Three main research objectives were addressed to achieve this aim; to 
uncover common genetic variation associated with chronic pain phenotypes, to 
investigate genetic correlation and pleiotropy between MDD and chronic pain, 
and finally to test for clinical heterogeneity between MDD and chronic pain.  
Novel common genetic variation associated with chronic pain phenotypes 
Chronic Pain Grade (CPG) was discovered first through leveraging genetic 
overlap with MDD (Chapter 3), then through genome wide association analysis 
with a novel chronic pain phenotype (Multisite Chronic Pain, MCP) (Chapter 4). 
Eleven novel SNPs were found to be associated with CPG, and 76 with MCP. MCP 
was found to be a moderately heritable, polygenic trait, with associated genes 
suggesting a strong central nervous system component to MCP development.  
Genetic correlation and pleiotropy was examined through analyses in Chapter 3 
which identified pleiotropic loci of interest (associated with effects in both MDD 
and chronic pain), and through estimating genetic correlation between MCP and 
MDD (Chapter 4). Analyses in Chapter 3 also tested for clinical heterogeneity in 
MDD with respect to CPG and vice versa, using GWAS summary statistics for each 
trait. LRFN5, a gene involved in cell-cell adhesion in the CNS and previously 
implicated in neuroinflammation and major depression, was found to be 
pleiotropic with respect to MDD and CPG. Significant genetic correlation was 
observed between MCP and a range of traits and disorders, most notably mood 
and psychiatric traits, with low-moderate or non-significant genetic overlap 
observed between MCP and conditions involving significant chronic pain (e.g., 
IBDs and rheumatoid arthritis). No significant evidence for clinical heterogeneity 
in MDD or in CPG was found in UK Biobank.  
Analyses undertaken in Chapter 5 examined whether genetic risk for MCP was 
associated with CPG, and with chronic widespread pain, where it was found that 
genetic risk for MCP was significantly associated with both CPG and chronic 
widespread pain, and with MCP in an independent cohort. Finally, GWAS 
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summary statistics were taken forward for causal analyses in Chapter 6, where a 
significant causal effect of MCP on MDD was observed.  
7.1 History of Pain Theories 
Understanding pain and chronic pain has been a key philosophical as well as 
scientific question throughout human history. Ancient theories on pain include 
those formulated by Plato, such as intensity theory (Zeyl & Sattler, 2019), i.e. 
that pain is an “emotion” and occurs when a stimulus is sufficiently intense and 
long-lasting. In the 1600s Descartes posited Cartesian dualism, suggesting pain is 
a result of physical injury or of psychological (emotional) injury, but never both 
and neither can influence the other. However, he described the mind (‘soul’) 
and body as intertwined and connected the concept of pain to a soul, with the 
soul of pain in the pineal gland. Descartes also described ‘fibres’ that could 
transmit pain messages to the brain (Benini & Deleo, 1999; Moayedi & Davis, 
2013). Later, in the 1800s Bell outlined specificity theory, assigning types of 
sensations to particular pathways, and also described brain as a complex 
structure with different components (Bell & Shaw, 1868;Bell, 1811) 
Also during this period Muller suggested that different sensations, including pain, 
are due to activity at different receptors (reviewed by Perl, 2007). The work of 
von Frey also assigned different sensations to separate and specific receptors, 
with four separate modalities of somatosensory system activity (pain, cold, heat 
and touch) – different small areas of skin were linked to different types of 
sensation, and Von Frey observed relationships between types of neural 
structure (histologically defined) and these small skin areas (specificity theory) 
(reviewed by Moayedi & Davis, 2013; Rey, 1995). However, contrasting theories 
around the same time such as those of Erb argued that pain was a result of a 
stimulus being sufficiently intense to evoke painful sensation through activity at 
receptors that usually were involved in other, non-painful sensation (i.e. the 
opposite of specificity theory/ intensity theory as suggested by Plato, and in 
opposition to Muller) (reviewed by Moayedi & Davis, 2013; Perl, 2007). In the 
1900s ‘pattern theory’ attributed to Nafe stated that there are no separate or 
specific receptors, and instead different types of sensations lead to different 
sequences or patterns of signals being transmitted to the brain.  
The first theory to incorporate endogenous (non-peripheral) modulation of pain 
signals was that of Wall & Melzack in 1965: gate control theory. Here, stimuli 
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have to pass through 3 locations in the spinal cord before reaching the brain, 
with the substantia gelatinosa in the dorsal horn acting as a gate that modulates 
these signals – if a signal reaches significant intensity, this is transmitted to the 
brain (the gate ‘opens’), with additional control mechanism in cortical regions of 
the brain. This theory incorporated psychological and cognitive aspects in pain in 
addition to explaining clinical observations of non-noxious activity (e.g. rubbing 
an injured area) attenuating the level of pain felt, and the wide variation seen 
in the relationships between stimuli and resultant pain (Katz & Rosenbloom, 
2015; Melzack & Wall, 1965; Mendell, 2014).  
Later, in 1990, Melzack also described the idea of a neuromatrix, whereby the 
CNS is responsible for producing painful sensation, not the periphery (though the 
periphery can influence this sensation, in line with previous gate-control ideas) 
(Melzack, 1990, 2001). The ‘neuromatrix’ consists of multiple CNS locations that 
work in concert to produce a “neurosignature”, leading to pain. Peripheral 
information can influence this neurosignature but cannot lead to production of a 
neurosignature in isolation: this theory recognised influence of cognitive and 
emotional (but not social) factors in pain, and the fact that pain (particularly 
chronic pain syndromes) can be experienced in the absence of, or related only to 
minimal, direct sensory input. In this context mechanistic descriptors of pain 
(nociceptive, neuropathic, nociplastic, see also 1.1.1) may therefore describe 
ways in which the neurosignature is modulated, rather than discrete and causal 
descriptions for pain experiences.  
The biopsychosocial model of disease (Bevers et al., 2016) as applied to chronic 
pain (Fillingim, 2015, 2017, see also 1.1.4), can be thought of as uniting these 
three broad categories of theories on pain (specificity theory, intensity theory, 
and ideas of pain as a kind of emotion), and additionally emphasises 
multifactorial contributions, including environmental (e.g. social) factor 
contributions, to chronic pain development.  
Results of analyses in this thesis are in line with these theories – derivation of a 
broad chronic pain trait (MCP) where sensory input associated with inflammation 
or injury is not directly measured as a component of the phenotype ties in with 
ideas of the neuromatrix (with a neurosignature and chronic pain modulated by 
but not wholly produced by nociceptive or other peripheral input). Furthermore, 
several disease traits which commonly involve significant chronic pain were not 
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genetically correlated with MCP, including Crohn’s disease, lupus and 
rheumatoid arthritis (4.4.1.2). This suggests GWAS in these traits does not 
capture underlying mechanisms of chronic pain development, but rather genetic 
variation associated with more specific disease characteristics (which have a 
variable relationship with pain experienced). However, it should be noted that 
comparatively smaller sample sizes of some GWAS datasets (e.g., 5, 956 Crohn’s 
disease cases and 21, 770 controls) (Liu et al., 2015) may mean power to detect 
significant genetic correlation is reduced. This smaller sample size is directly 
related in many cases to lower prevalence of many chronic pain conditions – 
again taking Crohn’s disease as an example, prevalence in cases per 100,000 
people in Europe is estimated to be 1.5-213 (Burisch et al., 2013), whereas for 
MDD (where highly significant genetic correlation with MCP was observed and the 
GWAS sample size was much larger) this figure is ~12,000 (see 1.2.2). It may also 
be the case that genetic correlation on a more local level is present but not 
detectable between MCP and chronic pain conditions (see 7.6.3). Additionally, 
phenotyping chronic pain in addition to chronic pain-associated condition status 
may be more informative in finding genetic predictors of chronic pain, as across 
a range of conditions disease severity, disease activity and tissue damage are not 
necessarily reflected in severity of pain experienced. 
Several MCP-associated genes (particularly DCC) are involved in neuronal 
migration (see 4.4.3), outlined as a key component of the formation and 
alteration of the neuromatrix across the life course (Melzack, 1990). Pathways 
enriched for MCP-associated genes (see 4.4.3) included DCC-mediated attractive 
signalling, involved in cell motility and migration including in neural cell 
haptotaxis and synapse formation, and PLC-β-mediated signalling, also involved 
in synapse formation.  
Results of GWAS analyses also indicate that chronic pain follows the 
biopsychosocial model of disease: ~10% of trait variation is attributed to 
common genetic (SNP) variation, with therefore ~90% attributed potentially to 
non-genetic (environmental) factors in addition to other types of genetic 
variation not assayed in GWAS. Genetic correlations between MCP and other 
traits of interest indicated significant and large overlap in psychiatric traits, 
such as MDD and depressive symptoms, emphasising an affective component of 
chronic pain in addition to biological and social components. Considering chronic 
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pain as a disease or trait in this way is also in line with recent definitions of 
Chronic Primary Pain for the ICD-11 (see 1.1.1). 
7.2 Evolutionary Perspectives of Pain 
Acute pain is considered to be adaptive, as it warns against damage and danger 
(De C Williams, 2019) – in humans one demonstration of this is severe injury and 
even limb loss in individuals with congenital insensitivity to pain (see also 1.3.4). 
If chronic pain is related to a high enough degree to acute pain, this may explain 
why chronic pain as a trait is maintained in the population – as an unavoidable 
side effect of acute pain where any deleterious effect is outweighed by the 
adaptive benefit of acute pain. However, the relationship between acute and 
chronic pain is less straightforward, and most likely not strong enough to explain 
maintenance of chronic pain. This is demonstrated by the fact that severe and 
debilitating chronic pain can result from initial injuries where the experience of 
acute pain is minimal e.g. CRPS (C. Chang et al., 2019; F. & Chandan G., 2014), 
and that chronic pain is thought to be often absent in wild non-human animals 
(though this may be due to the fact this phenomenon is under-studied) (De C 
Williams, 2019).  
Other traits apart from acute pain may be both highly correlated with chronic 
pain and highly adaptive, driving the maintenance of chronic pain as a trait in 
the population in the face of natural selection. For example, neural plasticity is 
thought to be involved in chronic pain development, but is also an adaptive (or 
rather essential) trait in general brain development and function (Mateos-
Aparicio & Rodríguez-Moreno, 2019)– the selective disadvantage conferred by 
chronic pain would not outweigh the adaptive role of neural plasticity. It could 
also be the case that chronic pain itself is adaptive and so maintained through 
positive selection – studies in laboratory animals have shown advantages for 
predator avoidance associated with nociceptive sensitisation after injury (Crook 
et al., 2014; Lister et al., 2020).  
At the genetic rather than trait level, many hundreds of genetic variants 
contribute a small amount to variation in complex traits (see 1.3.3.1), and 
pleiotropy is widespread – results of analyses in this thesis indicate that chronic 
pain (MCP) is a highly polygenic complex trait (4.3.2, 4.3.3, 4.4.2), and 
pleiotropic variants were found specifically to contribute to both MDD and 
chronic pain (3.4.2). The vast majority of MCP-associated variants are therefore 
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likely to be selectively neutral (have a small effect size, and circulate in the 
population as common SNPs), or exert effects (however small) on traits that are 
adaptive, and so are maintained in the population.  
Another important point to note is that traits persist in a population not 
necessarily because they are adaptive (or strongly associated with an adaptive 
trait) at all: they are just not sufficiently deleterious to be removed by purifying 
selection. It is also important to note that maladaptive in a clinical sense is not 
the same as maladaptive in evolutionary terms. Traits may be selectively neutral, 
particularly traits like chronic pain where trait onset is often established after 
the reproductive period (Macfarlane, 2016), does not have severe enough fitness 
effects (in terms of negative impact on reproduction) to be subject to negative 
selection, or both. Additionally, natural selection, particularly if not extremely 
strong purifying selection, acts over long, multigenerational timespans. It may 
be the case that chronic pain played an adaptive role in the context of more 
ancient human environments (Walters, 2019), and this has recently stopped 
being the case – again lack of evidence of chronic pain in wild animals (but 
presence in domesticated animals) could be taken to support this theory (De C 
Williams, 2019).  
7.3 Multisite Chronic Pain in UK Biobank  
7.3.1 Comparing MCP and Other Chronic Pain Phenotypes 
Studying chronic pain as a disease entity or phenotype in its own right may 
present a more tractable way to uncover genetic factors involved in 
development of and vulnerability to chronic pain. An attempt to do this was 
made through derivation of the MCP phenotype in UK Biobank. 
MCP was found to be a moderately heritable, polygenic complex trait, similar to 
MDD. Genes associated supported a view of chronic pain as a disorder with a 
significant central nervous system component, implicating neuroinflammation 
and neuronal plasticity. Interestingly, so-called ‘classic’ chronic pain genes such 
as COMT was not found to be associated with MCP. Similarly to early candidate 
gene studies of MDD, this may be due to COMT’s association with individual 
variation in pain perception being specific to those cohorts, or an artefact of 
reduced power (associated with small sample sizes and with methodological 
issues in candidate gene analysis). It may be the case that more general genetic 
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factors influencing chronic pain susceptibility or development are likely to be 
found in GWAS presented in this thesis, and that GWASs of chronic pain 
conditions are more likely to show genetic variation associated with more 
specific disease or condition-associated processes.  
The relationship between MCP and other more ‘general’ i.e., non-disease or 
chronic pain condition-associated chronic pain traits was also explored. Chronic 
widespread pain could be considered the ‘upper end’ or more extreme 
presentation chronic pain (Kamaleri et al., 2008; Phillips & Clauw, 2011), and 
this was supported by genetic correlation results between MCP and ‘chronic pain 
all over the body’, rg = 0.83. MCP-PRS was also significantly associated with MCP 
in an independent cohort (Generation Scotland), and with having CWP in UK 
Biobank. In addition to demonstrating genetic overlap with these different 
chronic pain phenotypes, these results further support view of MCP as a useful 
chronic pain phenotype and suggest associations between this phenotype and 
common genetic variation are not specific to UK Biobank. CPG and MCP were 
also found to be phenotypically correlated in an independent cohort, further 
legitimising MCP as a chronic pain phenotype. Finally, extremely high genetic 
correlation was seen between a chronic pain phenotype derived in a data-driven 
manner by Tsepilov et al in UK Biobank, and MCP (Appendix 3). This suggests the 
assumptions made in defining MCP as a trait (namely equivalence between 
genetic predictors of musculoskeletal and non-musculoskeletal chronic pain 
(Tsepilov et al., 2020)) are in fact acceptable, and again indicating MCP 
represents a valid broad chronic pain phenotype derived from a basic pain 
questionnaire. 
Key differences between MCP and CPG include that a larger sample size was 
possible for the MCP GWAS, and there was no adjustment for correlated traits. 
This increased power to find trait-associated genetic variants. Environmental 
aspects of chronic pain experience may be more explicitly captured in CPG 
compared to in measuring number of chronic pain sites (as is done with MCP) – 
this aspect may explain differences in MCP vs CPG such as the unexpected 
negative genetic correlation between the two traits. This could also have an 
impact on causal estimates between CPG and MDD. 
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7.3.2 Broad MDD Phenotyping Parallels 
MCP can be considered a broad chronic pain phenotype, as more detailed 
information on pain (such as impact on daily functioning or on mood) was not 
collected at baseline by the original pain questionnaire, and GWAS of MCP does 
not consider or adjust for participants having chronic pain conditions, or for 
related traits of interest such as BMI.  
Similar ‘broad’ phenotyping has been shown to be useful for investigating the 
genetics of depression and MDD (1.3.5), meaning questionnaire ascertained 
probable MDD or other depression phenotypes share significant enough genetic 
overlap with ‘narrow’ (detailed or specific clinician diagnosed) MDD phenotypes 
to be informative. However, fully dissecting the heterogeneity of MDD, and of 
chronic pain, will require both broad and narrow phenotyping approaches (which 
can be non-mutually exclusive, as suggested for the field of MDD genetics 
research) (Cai et al., 2020). There is opportunity to carry out both approaches 
on a large scale in UK Biobank with the release of the new chronic pain 
questionnaire data, a more in-depth follow-up assessment of pain experience 
(see 7.5.2).  
MDD and chronic pain share overlapping symptom profiles, can respond to the 
same pharmacological and psychological treatments, and are significantly 
genetically correlated. Although this means the two conditions are more likely to 
be misclassified (misdiagnosed) as one another, BUHMBOX analyses indicated 
that the two conditions are distinct with respect to one another, and the 
relationship between them represents true, biological pleiotropy. In addition to 
this finding being of general interest, this also aids in interpretation of causal 
analyses results – if misclassification is the underlying reason for genetic 
correlation, the question being asked in MR inadvertently becomes “does X cause 
X” to some degree, rather than “does X cause Y”. 
 
7.5 Causal Effect of Chronic Pain on MDD  
Results indicate a significant causal effect of chronic pain on MDD, but not the 
reverse. Attempts at triangulation were made via use of different Mendelian 
randomisation approaches. MR-RAPS indicated that effectively all instruments 
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were horizontally pleiotropic (associated with MDD through pathways other than 
via MCP).  The size of the causal effect is relatively small (beta = 0.16) – again 
suggesting involvement of non-additive-genetic factors and gene-by-environment 
interactions may be involved in the high degree of comorbidity between 
depression and chronic pain.  
The potential introduction of bias in effect sizes through adjustment for manual 
labour in the 23andMe-Pfizer chronic pain grade GWAS could also have affected 
MR results. Sensitivity analyses to check for this kind of bias were not possible as 
summary statistics for an unadjusted CPG GWAS do not exist (see also Appendix 
2).  
MR-RAPS results show that something specific to chronic pain is causal for MDD, 
and not just non-genetic factors closely associated with chronic pain. Results of 
these causal analyses indicate that chronic pain itself contributes to 
development of MDD. Although studies on causal relationships between pain and 
depression often show mixed results (see 1.3.2), including that depression has a 
causal effect on chronic pain, MR-RAPS results here indicated that MDD did not 
cause chronic pain, suggesting chronic pain subsequent to depression is not a 
direct result of the depression itself. Causal analyses also suggest multifactorial 
pathways leading to MDD from pain, detected as widespread horizontal 
pleiotropy – chronic pain itself has an independent, causal effect, but many 
other factors (genetic and environmental) are likely involved.  
7.6 Strengths & Limitations 
A main limitation to analyses in this thesis, and to GWAS analyses in general 
(Mills & Rahal, 2019, 2020), is that cohorts primarily consist of white European-
ancestry participants (e.g. GS: SFHS: 99% white). While this is approximately 
representative of a Scottish population (Smith et al., 2006, 2013), this 
demographic make-up is non-representative in terms of ethnicity of global or 
even UK-wide populations, and SNP-trait associations may not be generalisable 
to populations with different ancestry, including admixed samples. In addition, 
ethnicity itself also acts to confound associations between SNPs and traits of 
interest – if magnitude of trait values or disease prevalence vary between ethnic 
groups, this may generate spurious SNP-trait associations (Medina-Gomez et al., 
2015). This confounding occurs even though race or ethnicity as biological 
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constructs cannot be quantified in a meaningful way. In other words this 
confounding is epidemiological rather than genetic, and is different from 
population structure (“AAPA Statement on Biological Aspects of Race,” 1996; 
Blackburn, 2000; Yudell et al., 2016).  
Another potential limitation is that extensive heterogeneity in MCP as a trait 
construct is not fully explored in, and is beyond the scope of, this thesis. As 
discussed above and in the previous section7.3.2, despite advances made in MDD 
research using broad phenotyping, more detailed phenotyping is also of value, 
and examining both detailed and broad chronic pain phenotypes in a non-
mutually exclusive fashion would be of interest. Heterogeneity in terms of 
clinical heterogeneity in chronic pain is only examined with respect to MDD and 
vice versa (a methodological constraint with BUHMBOX analysis). With respect to 
causal analyses, again as chronic pain measured as MCP is a broad trait construct, 
this is not really modifiable in the way e.g., cigarette smoking is, meaning MR 
results are difficult to interpret or involve in e.g., treatment guidelines in 
chronic pain. 
As previously discussed, (4.4.1.6, see also Appendix 2), use of summary statistics 
adjusted for traits that are genetically correlated with the main trait of interest, 
such as manual labour and BMI in the case of CPG, has the potential to bias 
GWAS results and subsequent analyses involving GWAS outputs. This is a 
possibility with 23andMe-Pfizer CPG GWAS outputs, and may have affected 
genetic correlation and causal analyses.  
A key strength is that analyses undertaken in this thesis represent the largest 
GWAS of a chronic pain trait to date, giving insight into potential mechanisms of 
chronic pain development. A novel chronic pain trait based on recent re-
definition of chronic pain emphasising its independence from nociception and 
detectable biological causes, was derived, providing genetic research in keeping 
with shifting paradigms in defining chronic pain. This way of exploring chronic 
pain as a ‘broad’, complex trait phenotype is similar to recent study of broad 
MDD phenotypes and represents a potentially powerful route to understanding 
genetic contribution to chronic pain. This view of chronic pain is also in line with 
theories on chronic pain as a complex trait following the biopsychosocial model 
of disease. In addition, analyses in this thesis employ a varied range of statistical 
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genetics techniques to answer research objectives, examining common genetic 
variation, genetic correlation, and pleiotropy from multiple angles – several 
techniques (BUHMBOX, cFDR, MR-RAPS) have never before been applied in 
research into MDD and chronic pain. 
7.6 Future Directions 
7.6.1 Representative Cohorts 
Recent advances for successful GWAS analysis in ancestrally diverse populations 
(Peterson et al., 2019), including in admixed populations, such as Tractor 
(Atkinson et al., 2021) could be used to investigate genetic variation 
contributing to chronic pain, including in the entirety of UK Biobank (as opposed 
to the white British sub-sample), addressing a key limitation of ancestrally 
homogenous cohort use. Tractor is a statistical framework and associated 
software package that allows for the inclusion of admixed individuals in GWAS, 
achieved through leveraging local ancestry in contrast to traditional GWAS where 
population stratification is adjusted for using e.g. genetic principal components, 
which represent a broader estimate of admixture (Atkinson et al., 2021).  
The model used within Tractor allows for inclusion of terms that estimate SNP-
trait association within different ancestry categories (Equation 7.1), where b 
values are effect estimates, X1 represents the number of haplotypes of the index 
ancestry at the locus in question for each individual, X2 is the number of copies 
of the risk allele coming from the first ancestry, X3 is the copies coming from the 
second ancestry, and X4 – Xk are additional covariates such as age, sex, and an 
estimate of global (rather than local) ancestry (Atkinson et al., 2021). 
𝐿𝑜𝑔𝑖𝑡[𝑌] = 𝑏0 + 𝑏1𝑋1 + 𝑏2𝑋2 + 𝑏3𝑋3 … + 𝑏𝑘𝑋𝑘 
Equation 7. 1: Tractor association model 
Tractor analysis can therefore boost SNP discovery power and have a 
downstream effect on utility of PRS in less ancestrally homogenous populations. 
This would be achieved by allowing calculation of ancestry-specific SNP effect 
sizes which then contribute to weighting in PRS calculation. Another potential 
benefit of the inclusion of mixed-ancestry participants in GWAS is the ability to 
use admixture based fine-mapping approaches for discovery of causal variants. 
Fine-mapping refers to analysis of trait-associated genetic loci, found through 
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GWAS, in order to determine which genetic variants within these regions are 
putative causal variants for the trait (Schaid et al., 2018). One fine-mapping 
approach is use of admixture (trans-ethnic fine-mapping) whereby meta-analysis 
is carried out across GWASs of the same trait across ancestrally diverse 
populations. This allows for pinpointing putative causal variants as patterns of 
LD vary between populations – signals that persist despite variation in LD block 
structure indicate potential causal variants (Y. R. Li & Keating, 2014). Tractor 
analysis specifically can also improve location of causal variants within GWAS 
results due to improved power to find causal variants in non-European 
populations (Atkinson et al., 2021). In addition to application of newer GWAS 
methods for diverse and admixed populations being applied to the full UK 
Biobank sample, more ethnically and ancestrally diverse cohorts such as All of Us 
(All of Us Research Program Investigators, 2019), could also be used in GWAS 
analyses of chronic pain conditions and chronic pain phenotypes. All of Us is a 
large general-population biobank research program funded by the National 
Institutes of Health (NIH) in the USA, with recruitment ongoing and a 
commitment to recruiting a diverse participant pool. The program aims to 
recruit 1 million participants and to contain genotyping data in addition to 
information on a wide range of traits and conditions of public health interest. 
7.6.2 New Pain Data for UK Biobank 
Other emerging datasets could also be used to further investigate the genetics of 
MCP, in addition to allowing for derivation of more detailed chronic pain 
phenotypes. In particular, the recent release of the new UK Biobank pain 
questionnaire data (UKB Data Showcase category 154: Experience of Pain) gives 
the opportunity to derive narrower chronic pain phenotypes, due to comparative 
increased detail of questioning compared to the baseline UK Biobank pain 
questionnaire. Whereas the baseline UK Biobank touchscreen questionnaire on 
pain effectively contained just two questions, on pain site and the duration of 
pain at that site, the new UK Biobank pain questionnaire, an online follow-up 
questionnaire completed by ~167,000 participants, contains ten sections. 
Questions asked of participants include ones on the location (an extended 
number of site options in comparison to the baseline pain questionnaire), nature, 
and impact of pain, in addition to sections separately asking about medical 
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conditions, depression, fatigue, and health outcomes that may be relevant to 
pain. Separate sections also exist on neuropathic pain and headache.  
The new UK Biobank pain questionnaire also provides opportunity for potentially 
very large longitudinal studies of pain and depression – baseline pain data were 
collected at recruitment from 2006-2010, whereas the new pain questionnaire 
was sent to participants initially in 2017 (UK Biobank, 2020). With more detailed 
information on timing, duration, and associated symptoms and pain, genetic 
similarity, and differences between chronic pain with certain characteristics 
could also be explored. However, there may be issues with trying to carry out 
longitudinal studies as data collection (for the new pain questionnaire) was 
carried out in instances that were relatively far apart in time, and on a subset of 
participants rather than the entire UK Biobank sample of 0.5 million (Caruana et 
al., 2015). Another potentially interesting analysis would be comparison of 
‘depression-in-pain’, derived from mood information in the new UKB pain 
questionnaire, versus MDD with and without comorbid chronic pain.  
Outside of UK Biobank, output from analyses of conditions associated with 
chronic pain, such as Ehlers-Danlos syndrome (Forghani, 2019), which have 
previously not been investigated at scale and/or using GWAS are expected in 
coming years. The relationship between these phenotypes and MCP in terms of 
genetic overlap and causal effect would also be of interest.  
7.6.3 Alternative Approaches to Pleiotropy  
As previously discussed, the clinical heterogeneity of chronic pain, and of MCP 
specifically, cannot be fully explored using just BUHMBOX. This method can only 
examine clinical heterogeneity in a trait with respect to a second, defined trait 
or condition – there is no scope for an agnostic investigation of clinical 
heterogeneity. Additional data-driven approaches, such as cluster analysis as 
previously used to explore clinical heterogeneity in a range of traits and diseases 
(Guo et al., 2017; Mu et al., 2017; Nagel et al., 2018) could be used to 
characterise heterogeneity within the broad MCP trait construct, particularly in 
conjunction with new pain questionnaire data.  
Emerging methods could also be used to interrogate location-specific pleiotropy 
in MDD and chronic pain and act as an extension of cFDR analyses. An example of 
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such a method is LAVA (Local Analysis of coVariant Association) a recently 
developed framework for calculating local genetic correlation (Werme et al., 
2021). Most current genetic correlation analysis methods, including LDSR, 
measure a global average of rg across the genome – this may not allow detection 
of heterogeneous genetic correlation relationships where rg varies between 
genomic regions and where global rg is non-significant, and does not give an idea 
of specific pleiotropic loci of interest. In contrast, LAVA allows for estimating 
location-specific rg, and similarly to cFDR analyses undertaken in this thesis, 
could be used to investigate shared loci in MCP and MDD. 
7.6.4 Whole-Exome Data and Chronic Pain 
Whole-exome data, recently released for UK Biobank, could also be used to 
explore exome regions associated with chronic pain. As previously discussed, 
(1.3.3.1, 2.2.1.1), rare variants are excluded from GWAS analyses, but studying 
their association with traits of interest is possible through aggregating them at 
the gene or exon level. The exome refers to sections of the genome containing 
protein coding sections (exons), which comprise a small fraction of the total 
genome (Dunham et al., 2012) but are where most rare variants of large effect 
are thought to reside. Although most of the genetic variation associated with 
complex traits such as MCP and chronic pain in general is likely to be common 
and of small effect (i.e., SNP) (1.3.3.1), rarer variants of large effect in exons 
could also contribute to trait variation (2.2.1.1). 
Whole-exome association studies, whereby larger-effect and rarer genetic 
variation is tested for association with traits or conditions of interest, have been 
used in a clinical setting to determine genetic causes or contributory factors to a 
range of genetic disorders, including both single-gene and complex disorders 
(Rabbani et al., 2014; Retterer et al., 2016; Srivastava, Cohen, Vernon, et al., 
2014). These include heterogeneous monogenic disorders such as hearing loss, 
movement disorders (study N ranging from 9-270) and rare subtypes of diabetes 
(N = 1) (reviewed by Rabbani et al., 2014), and determination of specific 
pathological phenotype such as abnormality of the nervous system or 
mitochondrial dysfunction (with successful diagnoses in ~30% of N = 3, 040 cases) 
(Retterer et al., 2016).  
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In addition to these applications, whole-exome association studies have the 
potential to shed light on rare genetic variation contributing to common, 
complex traits using large cohorts (Cirulli et al., 2020; Povysil et al., 2019). The 
missing heritability (see also 2.2.1.1) in complex traits could be partially 
explained by the contribution of rare variants to phenotypic variance remaining 
unmeasured (Eyre-Walker, 2010) (as these variants are present at much lower 
allele frequency in the population due to negative selection pressures, and so 
are unmeasured as part of GWAS). Rare variants have been found to contribute 
to complex traits such as height (Marouli et al., 2017), autism spectrum disorder 
(De Rubeis et al., 2014; Wilfert et al., 2021), and schizophrenia (Fromer et al., 
2014; S. M. Purcell et al., 2014), in studies with sample sizes ranging from 600 to 
450,000, indicating exome data available in the UK Biobank (N ~ 50,000 with an 
eventual goal of sequencing the exomes of 450,000 participants) could also be 
used to investigate rare variant associations with complex traits such as chronic 
pain.  
With respect to chronic pain more specifically, in their large-scale analyses of 
UK Biobank exome data Cirulli et al found rare variants within the genes TET3, 
PTPRR, PHLDB1, TSPYl4, IQCM, ACTN2 to be associated at a suggestive level (p < 
10-3) with back pain for 3+ months (Ncase = 6819, Ncontrol =2981), within MMS19 
with hip pain for 3+ months (Ncase = 3378, Ncontrol =953), within TNS3, ZNF347, 
HEATR6, RBL1 and FAM17A1 with stomach or abdominal pain for 3+ months (Ncase 
= 1631, Ncontrol =1401), and within PRG4, NLRC5, ITGAE, PLEKHA6 and EIF2AK4 
with knee pain for 3+ months (Ncase = 6798, Ncontrol = 1710). Rare variants were 
also found to be associated (p < 10-3) with neck/shoulder pain for 3+ months, 
implicating genes LARP7, LRRC7, OTOG, MEI1, GDF1, RSPH1 and ZNF462 (Ncase = 
6009, Ncontrol =2656). Although for the most part these associations are suggestive 
(p > 10-6), they again suggest exome association studies could be of interest in 
the study of chronic pain. 
7.6.5 Genomic Structural Equation Modelling Approaches 
A potentially powerful way to investigate genetic variation contributing to 
chronic pain development and maintenance, in contrast to deriving a ‘general’ 
or broad chronic pain trait such as MCP, could be to use various applications of 
GenomicSEM (Grotzinger et al., 2019). GenomicSEM (genomic structural equation 
modelling), is a flexible framework that allows for studying multivariate genetic 
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architecture of groups of related traits through fitting network models, taking 
GWAS summary statistics as input.  
GenomicSEM applications of interest for the study of chronic pain include 
common factor GWAS approaches. Existing GWAS output for chronic pain 
conditions could be used in this way to find common genetic variation shared 
across chronic pain conditions e.g., from large-scale GWASs of Crohn’s disease, 
rheumatoid arthritis, and lupus. This is a similar approach to recent work 
attempting to uncover variation associated with a ‘p factor’ associated with 
psychiatric traits (Grotzinger et al., 2019). It would also be of interest to 
compare the output of this analysis with that of the MCP GWAS, to further 
explore the extent to which MCP represents genetic variation associated more 
generally with chronic pain.  
Another genomicSEM application of interest could be ‘GWAS by subtraction’ 
(Demange et al., 2021). GWAS by subtraction involves ‘subtracting’ the genetic 
influence on a trait from each SNPs association with a second trait – the 
remaining SNP-trait association values represent a new GWAS of an unmeasured 
trait of interest. These kinds of analyses could be used to highlight genetic 
variation captured by chronic pain condition GWASs that is independent of 
chronic pain itself, and which may be more specific to disease processes. For 
example, if the genetic influence on MCP were subtracted from that on e.g., 
rheumatoid arthritis, remaining SNP-arthritis association may highlight loci with 
a more specific role in disease progression. A separate and potentially useful 
way to use GWAS by subtraction could also be ‘unadjustment’ of GWAS where 
adjustment for particular covariates has likely introduced bias into estimation of 
SNP-trait associations e.g., subtraction of the relationship a SNP has with manual 
labour from its relationship with CPG-adjusted-for-manual-labour, if original CPG 
datasets and raw data are not available for reanalysis for legal and data 
protection reasons.  
Exploratory factor analysis (EFA) could also be used in conjunction with existing 
chronic pain condition GWAS outputs, and MCP GWAS output, to explore the 
relationship between MCP and chronic pain conditions generally, and to further 
characterise heterogeneity in the MCP trait construct e.g., do certain kinds of 
chronic pain condition cluster with MCP more so than others? EFA could also 
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present a way to investigate the genetic contributions to broad factors 
associated with chronic pain and affective spectrum disorders.  
Affective spectrum disorders is an umbrella term describing a group of mood 
conditions including MDD, GAD, and PTSD among others, which are also 
commonly comorbid with chronic pain generally in addition to chronic pain 
conditions including fibromyalgia, migraine and IBS (Gardner & Boles, 2011; 
Hudson & Pope, 1994). As significant genetic overlap between chronic pain and 
mood disorders, including MDD but also phenotypes such as neuroticism and 
PTSD, has been demonstrated (4.3.3), it would be interesting to further explore 
the affective spectrum disorder group using GWAS outputs and genomicSEM. 
7.6.4 Affective Dysregulation and Pain 
Another potentially interesting area linking chronic pain and psychopathology 
may be aspects of emotional self-regulation. As previously mentioned, 
comorbidity in chronic pain and multiple affective spectrum disorders suggests 
affect and emotion play a key role in the development of physical and 
psychiatric distress. Results both from the literature and from analyses 
undertaken in this thesis, demonstrating significant genetic correlation between 
MCP and mood disorders and mood-related phenotypes in particular (1.1.5, 
4.3.3), are in agreement with this. 
Although a negative genetic correlation was seen between MCP and autism 
spectrum disorder, the relationship between neurodevelopmental disorders such 
as autism spectrum disorder and chronic pain warrants further investigation. In 
addition to physical comorbidities in autism spectrum disorder that potentially 
contribute to chronic pain (1.1.5), certain emotion-related personality 
constructs associated with autism spectrum disorders, such as alexithymia, could 
be involved. Alexithymia refers to difficulty identifying and expressing emotions 
and was originally described in studies of patients with a range of psychosomatic 
conditions (Goerlich, 2018; Poquérusse et al., 2018). Alexithymia involves 
confusing bodily sensation and emotion – many people scoring highly on 
alexithymia scales may only be able to describe emotion in terms of bodily 
sensation. Although alexithymia shows high degree of overlap with autism 
spectrum disorder it is not universal or a core component (Kinnaird et al., 2019): 
alexithymic traits are also common in people with neurodegenerative disease, 
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depression, and eating disorders, and in neurotypical relatives of autistic people 
(De Berardis et al., 2017; Martino et al., 2020; Poquérusse et al., 2018). 
Alexithymia is also thought to contribute to emotional dysregulation, and has 
been found to be more common in those with chronic pain (Aaron et al., 2019).  
7.7 Overall Conclusions  
In addressing the objective of uncovering common genetic variation associated 
with chronic pain phenotypes, it was demonstrated that examining chronic pain 
as a broad phenotype is a powerful way to look at chronic pain.  
The objective of investigating pleiotropy and genetic correlation was achieved 
through use of well-powered MCP GWAS results. Significant genetic overlap was 
found between MCP and a range of traits of interest, including MDD (rg = 0.53). 
This overlap highlighted an affective component to chronic pain and indicated 
that genetic variation associated with chronic pain conditions like IBDs may not 
be associated with pain or pain experience, but instead with disease processes 
more specifically – this is in line with recent work highlighting the value of 
studying chronic pain as a disease rather than a symptom (see 1.1.1).  
The comorbidity between chronic pain and psychiatric, mood and 
neurodevelopmental phenotypes has been documented to varying degrees, but 
in some cases, results are mixed and/ or may only hold in specific non-general-
population cohorts (see 1.1.5). The genetic correlation between MDD and 
chronic pain (MCP) was quantified in analyses in this thesis (4.3.3), and results 
specifically informed subsequent causality analyses. Horizontal pleiotropy in MR 
as indicated in genetic correlation and cFDR results, for example, has the 
potential to bias causal estimates. Clinical heterogeneity can also be thought of 
as a type of pleiotropy. Therefore, further characterising pleiotropy with respect 
to MDD and chronic pain was also a key part of this thesis and of investigating 
causal relationships between MDD and chronic pain. This was achieved through 
BUHMBOX analyses, and through use of MR methods that quantified and adjusted 
for horizontal pleiotropy amongst SNP instruments. A significant causal effect 
roughly equivalent to each +1 increase in MCP trait value resulting in 17% 
increase in the odds of having MDD (OR = 1.17) was found.  
Mixed results are also seen in studies of causal relationships between MDD and 
chronic pain. Genetic correlation and MR analyses in this thesis contribute to 
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answering both of these outstanding questions, quantifying genetic overlap and 
size and direction of the causal effect of chronic pain on MDD 
Genes found to be associated with MCP (N = 143, see 4.4.3, Appendix 1) 
highlighted neural system development and functioning, immune processes, and 
cell cycle regulation as broad functional categories important for chronic pain 
development and maintenance. This is in agreement with past studies indicating 
the importance of neural plasticity in chronic pain development, and indicating 
changes in brain structure and function associated with chronic pain 
development and maintenance (see 1.1.4).  
Overall, results of analyses completed as part of this thesis emphasise the 
existence of genetic variation shared across chronic pain conditions regardless of 
putative cause or mechanistic description. Large-scale investigations of a broad 
chronic pain trait were shown to be a powerful way to explore this genetic 
variation. Viewing chronic pain a complex disease trait that follows the 
biopsychosocial model of disease draws on both historical theories of pain and 
chronic pain development, and is also in line with recent work of IASP taskforces 





Appendix 1: Genes Associated with Multisite Chronic Pain 
A total of 143 genes were found to be significantly associated with MCP using 
MAGMA gene level analyses (see 2.3.1.1). Significance thresholds for association 
are Bonferroni-adjusted (0.05 divided by number of genes tested (18, 670)) = 
2.67 x 10-6. Genes of interest associated with MCP, their association with other 
traits and disorders, and functional roles are also discussed in the published 
article that resulted from these analyses (Johnston et al., 2019). 
As 143 genes total were found to be significantly associated with MCP, it was not 
feasible to discuss them in the same level of detail as with DCC (see 4.4.3.4). 
DCC is described as it was the most significantly associated gene of the 143, has 
also been implicated in other psychiatric and brain-structure related phenotypes, 
and the pathway showing most significant enrichment of MCP-associated genes 
was found to be DCC-mediated attractive signalling. 
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CHR NSNPS ZSTAT P SYMBOL 
1 34 5.3574 4.22 x 10-8 BAI2 
1 30 4.9792 3.19 x 10-7 PABPC4 
1 417 4.6593 1.59 x 10-6 DNAJC6 
1 32 4.7804 8.75x 10-7 TRMT13 
1 119 4.5989 2.12x 10-6 SORT1 
1 41 4.7137 1.22x 10-6 PSMA5 
1 236 4.8592 5.89x 10-7 FAM212B 
1 8 4.6565 1.61x 10-6 C1orf51 
1 50 6.1047 5.15x 10-10 MRPS21 
1 77 5.7623 4.15x 10-9 PRPF3 
1 311 5.6039 1.05x 10-8 RPRD2 
1 57 6.1773 3.26x 10-10 TARS2 
1 12 6.3192 1.31x 10-10 ECM1 
1 192 4.6001 2.11x 10-6 GATAD2B 
1 12 4.577 2.36 x 10-6 CRTC2 
1 214 4.8049 7.74 x 10-7 NUP210L 
1 1673 5.1844 1.08 x 10-7 RABGAP1L 
1 373 5.1296 1.45 x 10-7 FAM129A 
1 157 5.3923 3.48 x 10-8 CEP170 
1 411 5.0361 2.38 x 10-7 SDCCAG8 
1 1883 4.6993 1.31 x 10-6 KIF26B 
2 3196 5.0683 2.01 x 10-7 NRXN1 
2 21 4.6699 1.51 x 10-6 VAMP5 
2 1078 5.086 1.83 x 10-7 SLC4A10 
2 153 4.6202 1.92 x 10-6 RFTN2 
2 94 4.5783 2.34 x 10-6 AC011997.1 
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2 67 4.6412 1.73 x 10-6 BOLL 
2 103 5.3326 4.84 x 10-8 LANCL1 
2 448 5.8441 2.55 x 10-9 CPS1 
2 4060 5.7201 5.32 x 10-9 ERBB4 
2 659 5.1788 1.12 x 10-7 SPHKAP 
3 208 4.8881 5.09 x 10-7 SMARCC1 
3 35 4.9732 3.29 x 10-7 DHX30 
3 12 4.8195 7.20 x 10-7 LAMB2 
3 3 4.7316 1.11 x 10-6 CCDC71 
3 19 5.1965 1.02 x 10-7 C3orf84 
3 70 5.1723 1.16 x 10-7 CCDC36 
3 4 4.8776 5.37 x 10-7 RP11-3B7.1 
3 86 5.2367 8.17 x 10-8 RHOA 
3 7 5.8232 2.89 x 10-9 TCTA 
3 97 4.9452 3.80 x 10-7 DAG1 
3 150 5.9396 1.43 x 10-9 BSN 
3 7 5.3003 5.78 x 10-8 MST1 
3 47 5.9543 1.31 x 10-9 RNF123 
3 3 5.7329 4.94 x 10-9 AMIGO3 
3 3 5.7329 4.94 x 10-9 GMPPB 
3 88 5.4909 2.00 x 10-8 IP6K1 
3 16 5.6163 9.75 x 10-9 CDHR4 
3 7 4.8532 6.07 x 10-7 UBA7 
3 38 5.3125 5.41 x 10-8 TRAIP 
3 16 5.6583 7.64 x 10-9 CAMKV 
3 25 4.9781 3.21 x 10-7 MST1R 
3 12 4.892 4.99 x 10-7 CTD-2330K9.3 
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3 27 6.3576 1.02 x 10-10 MON1A 
3 238 5.6467 8.18 x 10-9 RBM6 
3 26 6.0831 5.89 x 10-10 RBM5 
3 58 5.992 1.04 x 10-9 SEMA3F 
3 2 4.6616 1.57 x 10-6 GNAT1 
3 226 4.9441 3.82 x 10-7 EIF4E3 
3 4594 5.784 3.65 x 10-9 ROBO2 
3 491 5.8122 3.08 x 10-9 BBX 
3 50 5.7467 4.55 x 10-9 MSL2 
3 119 4.8309 6.80 x 10-7 PCCB 
3 590 5.5475 1.45 x 10-8 STAG1 
3 21 4.9664 3.41 x 10-7 PSMD2 
4 215 4.6644 1.55 x 10-6 GRK4 
4 987 7.3313 1.14 x 10-13 MAML3 
5 620 5.0251 2.52 x 10-7 FAM172A 
5 616 6.6132 1.88 x 10-11 GABRB2 
5 2066 4.7086 1.25 x 10-6 TENM2 
5 60 4.632 1.81 x 10-6 NPM1 
6 61 5.8246 2.86 x 10-9 UQCC2 
6 100 5.988 1.06 x 10-9 IP6K3 
6 64 4.5588 2.57 x 10-6 LEMD2 
6 140 4.6315 1.82 x 10-6 PACSIN1 
6 200 5.839 2.63 x 10-9 C6orf106 
6 45 5.6501 8.02 x 10-9 SNRPC 
6 233 5.5866 1.16 x 10-8 UHRF1BP1 
6 156 4.6163 1.95 x 10-6 PXT1 
6 132 4.848 6.24 x 10-7 FHL5 
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6 140 5.5273 1.63 x 10-8 LIN28B 
6 544 6.0603 6.79 x 10-10 FYN 
6 1493 5.0295 2.46 x 10-7 LAMA2 
6 20 4.8934 4.95 x 10-7 GINM1 
6 109 4.8721 5.52 x 10-7 KATNA1 
6 89 4.6412 1.73 x 10-6 LATS1 
6 44 4.7059 1.26 x 10-6 NUP43 
6 154 4.6245 1.88 x 10-6 PCMT1 
7 3444 7.3968 6.97 x 10-14 SDK1 
7 245 5.4101 3.15 x 10-8 SP4 
7 381 5.3545 4.29 x 10-8 GRM3 
7 242 5.9014 1.80 x 10-9 SLC25A13 
7 792 6.6565 1.40 x 10-11 FOXP2 
8 52 4.9155 4.43 x 10-7 PURG 
8 291 4.6758 1.46 x 10-6 AGO2 
8 514 4.8893 5.06 x 10-7 PTK2 
9 301 6.1799 3.21 x 10-10 FAM120A 
9 399 5.3574 4.22 x 10-8 PHF2 
9 2845 6.4635 5.12 x 10-11 ASTN2 
9 103 4.5993 2.12 x 10-6 GOLGA1 
9 297 4.8088 7.59 x 10-7 SCAI 
9 94 5.409 3.17 x 10-8 DNM1 
9 262 6.3722 9.31 x 10-11 EXD3 
10 847 4.6285 1.84 x 10-6 NEBL 
10 160 6.0382 7.79 x 10-10 MLLT10 
10 74 4.575 2.38 x 10-6 ZRANB1 
10 364 5.3329 4.83 x 10-8 JAKMIP3 
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11 49 4.639 1.75 x 10-6 F2 
11 139 4.7341 1.10 x 10-6 CKAP5 
11 36 5.074 1.95 x 10-7 TSKU 
11 835 4.8551 6.02 x 10-7 NCAM1 
12 430 4.9129 4.49 x 10-7 RERG 
12 604 4.6857 1.40 x 10-6 PTPRO 
12 32 4.868 5.64 x 10-7 ERBB3 
13 65 4.7009 1.30 x 10-6 OLFM4 
13 83 5.0493 2.22 x 10-7 EFNB2 
14 385 4.6906 1.36 x 10-6 NUMB 
14 39 4.6872 1.38 x 10-6 ZFYVE21 
14 232 4.997 2.91 x 10-7 PPP1R13B 
15 68 5.9866 1.07 x 10-9 VPS33B 
16 8933 4.7735 9.05 x 10-7 RBFOX1 
16 31 4.862 5.81 x 10-7 MARVELD3 
16 68 4.9134 4.48 x 10-7 ATXN1L 
16 155 4.9441 3.82 x 10-7 IST1 
16 62 5.0294 2.46 x 10-7 ZNF821 
17 83 5.5391 1.52 x 10-8 DCAKD 
17 154 5.8159 3.01 x 10-9 NMT1 
17 12 4.7923 8.24 x 10-7 HEXIM2 
18 344 5.3098 5.49 x 10-8 ASXL3 
18 4053 8.2342 9.04 x 10-17 DCC 
18 637 4.5548 2.62 x 10-6 TCF4 
19 46 4.7804 8.75 x 10-7 PTBP1 
19 93 4.7278 1.14 x 10-6 SLC44A2 
19 46 5.1026 1.67 x 10-7 ILF3 
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19 46 5.6931 6.24 x 10-9 ATP13A1 
19 30 4.9853 3.09 x 10-7 ZNF101 
20 1440 5.3386 4.68 x 10-8 SLC24A3 
20 99 5.0374 2.36 x 10-7 TM9SF4 
20 67 4.9893 3.03 x 10-7 KIF3B 
20 86 4.9567 3.59 x 10-7 ASXL1 
20 201 5.4406 2.66 x 10-8 C20orf112 
20 348 4.562 2.53 x 10-6 ZBTB46 
22 357 4.972 3.31 x 10-7 TCF20 
Table A1. 1: Genes found to be significantly (p < 2.67 x 10-6) associated with MCP in MAGMA gene-level 
analyses.  
CHR = chromosome, NSNPS = number of SNPs in the GWAS data that were annotated to the gene, ZSTAT = 








General Function Description  Gene Symbol(s) Reference(s) 
Nervous system development & 
function 
Astrocyte development UTRN (Sogos et al., 2002) 
Neuronal cell function DYNC1I1 (Goldstein & Yang, 2000) 
SOX6 (Kurtsdotter et al., 2017) 
Presynaptic cytoskeleton organisation BSN (Frank et al., 2010) 
establishment of nervous system 
connectivity  
TENM2 (Rebolledo-Jaramillo & Ziegler, 2018) 
neurite formation, neuron morphogenesis PACSIN1 (Mondal et al., 2020) 
Glutamatergic neurotransmission & memory GRM3 (De Quervain & Papassotiropoulos, 2006) 
Nervous system development NCAM1 (Paratcha et al., 2003) 
EFNB2 (Cramer & Miko, 2016) 
ATXN1L (Didonna et al., 2020) 
TCF4 (Mesman et al., 2020) 
BBX (T. L. Chen et al., 2014) 
PTK2 (X. R. Ren et al., 2004) 
ERBB3 (Britsch et al., 1998) 
SORT1 (Nykjaer et al., 2004) 
FYN (Yaka et al., 2002; Zamoyska et al., 2003) 
RHOA (K. Y. Wu et al., 2005) 
DAG1 (K. M. Wright et al., 2012) 
AMIGO3 (Kuja-Panula et al., 2003) 
ROBO2 (T. Kidd et al., 1998) 
Synapse development and plasticity  CTNNA2 (Zhong et al., 2016) 
CEP120 (Guerrier & Polleux, 2007) 
KNDC1 (Hayashi et al., 2017) 
CA10 (Sterky et al., 2017) 
FOXP2 (Vernes et al., 2011) 
NRXN1 (Araç et al., 2007; Missler et al., 2003) 
SLC4A10 (Gurnett et al., 2008) 
LANCL1 (W. Zhang et al., 2009) 
SEMA3F (Nakayama et al., 2018) 
LAMB2 (Hunter et al., 1989; Nishimune et al., 2004) 
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Peripheral nerve myelination DAG1 (Masaki & Matsumura, 2010; Saito et al., 2003) 
Cell cycle progression DNA proof-reading EXD3 (Bębenek & Ziuzia-Graczyk, 2018) 
Regulation ANAPC4 (J. M. Peters, 2006) 
PRC1 (J. Li et al., 2018; Shrestha et al., 2012; C. Zhu & 
Jiang, 2005) 
BOLL (Kang et al., 2015) 
LATS1 (Furth & Aylon, 2017) 
Sister chromatid organisation STAG1 (van der Lelij et al., 2017) 
LEMD2 (von Appen et al., 2020) 
KATNA1 (McNally et al., 2000) 
CKAP5 (Schneider et al., 2017) 
KIF3B (Zhou et al., 2019) 
Apoptosis FAM120A (Tanaka et al., 2009) 
MON1B (Kinchen & Ravichandran, 2010) 
FAM129A (H. Ji et al., 2012) 
DHX30 (Bosco et al., 2020) 
FAF1 (Menges et al., 2009) 
SEMA3F (Nakayama et al., 2018) 
PTK2 (Kurenova et al., 2004) 
PTPRO (Motiwala et al., 2004) 
OLFM4 (Anholt, 2014) 
PPP1R13B (Samuels-Lev et al., 2001) 
Synapsis CCDC36 (Stanzione et al., 2017) 
Cell proliferation NPM1 (Okuda et al., 2000) 
PTK2 (X. R. Ren et al., 2004) 
F2 (Danckwardt et al., 2006) 
ERBB3 (Holbro et al., 2003) 
KIF3B (Zhou et al., 2019) 
Cytokinesis  IST1 (Renvoise et al., 2010) 
DNA replication regulation PURG (Johnson et al., 2013) 
Immune-related Neutrophil activation UTRN (Cerecedo et al., 2010) 
T cell activation PABPC4 (H. Yang et al., 1995) 
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FYN (Sharma et al., 2016; Zamoyska et al., 2003) 
B-cell antigen receptor-mediated signalling  RFTN2 (Saeki et al., 2003) 
innate immune signalling TRAIP (M. Zhang et al., 2012) 
MST1R (Sakamoto et al., 1997) 
ILF3 (Pfeifer et al., 2008) 
VPS33B (Akbar et al., 2016) 
OLFM4 (Wenli Liu, Yan, et al., 2010) 
immune surveillance  NCAM1 (Van Acker et al., 2017) 
Other Brain-specific inhibition of angiogenesis BAI2 (Okajima et al., 2010) 
Angiogenesis F2 (Danckwardt et al., 2006) 
Thrombosis SLC44A2 (Bennett et al., 2020) 
Heat shock protein DNAJC6 (Alderson et al., 2016) 
tRNA processing  TRMT13 (Towns & Begley, 2012) 
TARS2 (Lightowlers et al., 2015) 
Protein transport RABGAP1L (T. Itoh et al., 2006) 
NUP43 (Cronshaw et al., 2002) 
VPS33B (Ambrosio & Di Pietro, 2019) 
TM9SF4 (Vernay et al., 2018) 
protein degradation PSMA5 (Tomko & Hochstrasser, 2013) 
UBA7 (H. Li et al., 2018) 
PSMD2 (Rock et al., 1994) 
Inhibitor of serine/threonine-protein kinase PAK4  (Vadlamudi & Kumar, 2003) 
FAM212B (Y. Y. Liu et al., 2019) 
mitochondrial protein synthesis MRPS21 (Kenmochi et al., 2001) 
DHX30 (Bosco et al., 2020) 
protein repair PCMT1 (DeVry & Clarke, 1999; Tsai & Clarke, 1994) 
mitochondrial metabolism  PCCB (Chapman et al., 2018; Ugarte et al., 1999) 
UQCC2 (Tucker et al., 2013) 
SLC25A13 (Convertini et al., 2019) 
pre-mRNA processing PRPF3 (Heng et al., 1998; Martínez-Gimeno et al., 2003) 
PTBP1 (Vuong et al., 2016) 
Regulation of gene transcription CRTC2 (Cheng & Saltiel, 2006) 
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SMARCC1 (He et al., 2020) 
GATAD2B (Willemsen et al., 2013) 
MLLT10 (Ogoh et al., 2017) 
HEXIM2 (Yik et al., 2005) 
ASXL3 (Katoh & Katoh, 2004) 
ZNF101 (Bellefroid et al., 1993) 
TCF20 (Sanz et al., 1995) 
MSL2 (L. Wu et al., 2011) 
AGO2 (Hansen et al., 2011) 
Adipogenesis ASXL1 (Park et al., 2011) 
mRNA processing EIF4E3 (Joshi et al., 2004) 
SNRPC (Du & Rosbash, 2002) 
ILF3 (Pfeifer et al., 2008) 
Cell development/ differentiation UHRF1BP1 (El Baroudi et al., 2017; Unoki et al., 2004) 
LEMD2 (M. D. Huber et al., 2009) 
Organelle transport KIF26B (Miki et al., 2001) 
Myogenesis VAMP5 (Zeng et al., 1998) 
UQCC2 (Feichtinger et al., 2017) 
Urea cycle CPS1 (Martínez et al., 2010) 
Cell adhesion, migration, outgrowth RHOA (Valderrama et al., 2006) 
DAG1 (Morikawa et al., 2017) 
MST1R (Ghigna et al., 2005) 
LAMA2 (Vuolteenaho et al., 1994) 
SCAI (Brandt et al., 2009) 
OLFM4 (Wenli Liu, Lee, et al., 2010) 
EFNB2 (F. Zhu et al., 2020) 
ZFYVE21 (Nagano et al., 2010) 
PTK2 (Chan et al., 2009; Hsia et al., 2003) 
Membrane trafficking MON1A (Bagley et al., 2012) 
Cardiac myofibril assembly NEBL (Moncman & Wang, 2002) 
Manganese transport ATP13A1 (Anagianni & Tuschl, 2019; Farley, 2012) 




DNA damage response signalling SDCCAG8 (Chaki et al., 2012) 
Table A1. 2: Function of genes associated with MCP.  
This table (Table A1.2) is designed to give a brief overview of gene function 
(note also that some of these categories are non-mutually exclusive). For 
example, PAK4 (RAC1 Activated Kinase 4) is listed under its main associated 
function (as an inhibitor of serine/threonine-protein kinase), but the protein 
encoded by this gene is also implicated in cell motility, proliferation, and 
angiogenesis. The full picture of gene function, gene interaction, and potential 
health and disease related effects associated with every gene found to be 
associated with MCP is in many cases not fully known and is beyond the scope of 
this thesis. 
GeneSet p value genes 
REACTOME_DCC_MEDIATED_ATTRACTIVE_SIGNALING 5.10 x 10-5 DCC, NCK1 
REACTOME_PLC_BETA_MEDIATED_EVENTS 9.85 x 10-5 PRKAR2A, GNAT1, ITPR3 
SIG_BCR_SIGNALING_PATHWAY 1.41 x 10-4 PPP1R13B, DAG1, ITPR3 
PID_A6B1_A6B4_INTEGRIN_PATHWAY 1.41 x 10-4 LAMB2, MST1, MST1R 
Table A1. 3: MAGMA gene set analysis results (for curated gene sets i.e., MSigDB C2).  
GeneSet = Canonical MSigDB pathway enriched for MCP-associated genes. p value = p value for MAGMA 
gene set analysis test. Genes = MCP-associated genes.  
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Appendix 2: Phenotypic Correlation between Multisite 
Chronic Pain and Chronic Pain Grade in Generation 
Scotland  
 
Cheverud’s conjecture posits that phenotypic and genetic correlations are likely 
to be similar in both direction and size, and phenotypic correlations can 
therefore be used as proxies for genetic correlations between traits (Cheverud, 
1988; Sodini et al., 2018). Evidence to support Cheverud’s conjecture has been 
found in plants, animals, and recently in humans across a large number of traits 
using UK Biobank (Sodini et al., 2018). 
Despite differences between the two phenotypes, MCP and CPG, such as 
assessment of disability due to pain in CPG and not MCP, intuitively one could 
expect that MCP and CPG are likely to be positively genetically and 
phenotypically correlated, at least to some degree. Therefore, the negative 
genetic correlation was described as unexpected. Potential reasons for this 
negative genetic correlation are discussed in 4.4.1.6, but an alternate 
explanation is that a negative genetic correlation may, counterintuitively, be 
expected between CPG and MCP, if there were a negative phenotypic correlation 
between these phenotypes. To investigate this possibility, phenotypic 
correlations were calculated between MCP and CPG in a cohort where both 
phenotypes can be derived (Generation Scotland).  
Both Pearson’s rho and Kendall’s tau were calculated, and p value significance 
thresholds Bonferroni adjusted (0.05/2). CPG can be treated as a continuous 
variable, and indeed was in previous PRS analyses in this thesis, and in 23andMe-
Pfizer GWAS, but is technically an ordinal construct hence calculation of 
Kendall’s tau as sensitivity analysis. N = 7, 574 GS participants had complete 
phenotype data for both CPG and MCP (mean age 50.9 years, 37% male), and 
their data were used in this analysis. Defining CPG and the Generation Scotland 




Test Correlation coefficient value (CI) p value Type 
Pearson 0.317 (0.296-0.337) < 2.2 x 10-16 Parametric 
Kendall 0.246 (NA) < 2.2 x 10-16 Non-Parametric 
Table A2. 1: Phenotypic correlation between CPG and MCP.  
CI = confidence interval (where applicable).  
Results suggest genetic correlation should be expected to be positive between 
CPG and MCP – as discussed in 4.4.1.6, it is therefore likely that the covariates 
adjusted for in the 23andMe-Pfizer GWAS may be involved in the unexpectedly 
negative genetic correlation between the two phenotypes. i.e., the “true” 
underlying relationship is that, on average, allelic effects for pleiotropic variants 
are in the same direction in CPG and MCP but adjusting for manual labour in 
particular in the 23andMe-Pfizer GWAS has obscured that in subsequent genetic 
correlation analyses. 
Aschard et al also provide derivation of a Wald test for specific use to test for 
bias in GWAS caused by adjustment for covariates – as there is not an unadjusted 
GWAS of CPG available for comparison, these analyses could not be carried out, 
but would be of interest for formally testing whether adjustment for manual 





Appendix 3: Genetic Correlation between Tsepilov et al 
Phenotype GIP1 (Genetically Independent Phenotype 1) 
and Multisite Chronic Pain 
 
Tsepilov et al generated several genetically independent phenotypes (GIPs) 
related to musculoskeletal chronic pain at four bodily locations in UK Biobank 
(Tsepilov et al., 2020). GIP1 represents the “leading” GIP and explains 78.4% of 
the genetic variance in the musculoskeletal chronic pain traits and is genetically 
correlated with many psychiatric traits to a similar degree as MCP. GIP1 is also 
described as the most stable and most heritable of the GIPs derived and 
investigated. GIP1 shows enrichment with multiple nervous-system related terms, 
and GWAS of GIP1 indicates some overlapping genes that were also found to be 
associated with MCP.  
Tsepilov et al argue that a GWAS of MCP relies on the assumption that there is 
equivalence between genetic predictors of musculoskeletal pain conditions and 
non-musculoskeletal pain conditions, an assumption that may be too strong. 
However, similarities between the trait construct GIP1, explaining the majority 
of genetic variance in the examined musculoskeletal pain traits in UKB, and MCP, 
indicates that it may be an acceptable assumption that genetic predictors are 
shared between diverse types of pain conditions. It is also of note that the first 
GIP for a wider range of transformed pain traits (i.e., all but one of the pain site 
options in UKB, some which are not likely to be musculoskeletal e.g., stomach/ 
abdominal pain) is almost genetically equivalent to ‘musculoskeletal’ GIP1 rg = 
0.99.  
To investigate the genetic overlap between MCP and GIP1, LDSR was carried out 
using GIP1 GWAS summary statistics downloaded from 
https://zenodo.org/record/3797553 [13/12/2020] and the summary statistics 
from the MCP GWAS (Chapter 4) 
Trait 1 Trait 2 rg se z p 
MCP GIP1 0.9753 0.003 327.0843 <<0.001 
Table A3. 1: Genetic correlation results.  
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rg = genetic correlation coefficient, se = standard error of genetic correlation coefficient.  
Results indicate that GIP1 and MCP are highly genetically correlated (rg = 0.98). 
This is significantly lower than rg = 1 (0.98 + 2 x SE < 1), but as discussed 
previously (4.4.1.5) genetic correlation values of this magnitude can indicate 
that these phenotypes are measuring the same underlying trait construct. 
Differences between MCP and GIP1 in terms of associated genes and other 
downstream results in the GIP1 GWAS analysis could therefore be due to 
differences in power (N for the Tsepilov et al discovery cohort is roughly 100,000 
fewer participants than the MCP GWAS sample size). Although ~20% of genetic 
variance in musculoskeletal traits is not explained by GIP1, the large genetic 
overlap between MCP and GIP1 indicates that genetic predictors of a 
biopsychological component to chronic pain may be shared across a diverse set 
of chronic pain conditions. Furthermore, this remaining proportion of genetic 
variance not attributed to GIP1 may in fact be related to disease and tissue-
specific elements of chronic pain conditions, rather than being informative on 
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